Peplife 2.0 - Browse by Length

Browsing by Length

Browse Results:

Filter by Year
From
Upto

ID	PMID	YEAR	Sequence	Name	Length	N-ter MOD	C-ter MOD	Linear/Cyclic	Chirality	Chem-MOD	Origin	Nature	Incubation Time	Concentration	Half Life	Protease	Assay	Test Sample	Vivo/Vitro	Reference	Patent No.	Activity
1037	20844765	2010	RRWQWRMKKLG	Lfc7	11	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	>30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=15Î¼M for E.coli
1038	20844765	2010	RRWQWRMKKLG	Lfc7	11	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	>30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=7.5Î¼M for S. aureus
1039	20844765	2010	RRWQWRMKKLG	Lfc7	11	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	>30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=0.9Î¼M for B. subtilis
1043	20844765	2010	RRWQWRMKKLG	Lfc8	11	Free	Free	Cyclic (head-to-tail backbone cyclization)	L	None	Synthetic	Antimicrobial	9 hours	5 µM	110	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=3.8 Î¼M for E.coli
1044	20844765	2010	RRWQWRMKKLG	Lfc8	11	Free	Free	Cyclic (head-to-tail backbone cyclization)	L	None	Synthetic	Antimicrobial	9 hours	5 µM	110	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=15Î¼M for S. Aureus
1045	20844765	2010	RRWQWRMKKLG	Lfc8	11	Free	Free	Cyclic (head-to-tail backbone cyclization)	L	None	Synthetic	Antimicrobial	9 hours	5 µM	110	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99 ‰¤ 0.45Î¼M for B. subtilis
1046	20844765	2010	CRRWQWRMKKLGC	Lfc9	13	Free	Amidation	Cyclic (C1-C13)	L	None	Synthetic	Antimicrobial	9 hours	5 µM	110	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=1.9 Î¼M for E.coli
1047	20844765	2010	CRRWQWRMKKLGC	Lfc9	13	Free	Amidation	Cyclic (C1-C13)	L	None	Synthetic	Antimicrobial	9 hours	5 µM	110	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99 ‰¤ 0.45Î¼M for S. Aureus
1048	20844765	2010	CRRWQWRMKKLGC	Lfc9	13	Free	Amidation	Cyclic (C1-C13)	L	None	Synthetic	Antimicrobial	9 hours	5 µM	110	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99 ‰¤ 0.45Î¼M for B. subtilis
1056	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1a	18	Acetylation	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	5mg/kg	7.6	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=1.1nM for fVIIa binding assay
1057	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1b	18	Acetylation [(C6H6)2-CO-]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	5mg/kg	15	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=4nM for fVIIa binding assay
1058	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1c	18	Acetylation [(CH3)2-CH-CH2-(C6H6)-CH(CH3)-CO]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	4.9mg/kg	24	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=14.6nM for fVIIa binding assay
1059	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1c	18	Acetylation [(CH3)2-CH-CH2-(C6H6)-CH(CH3)-CO]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	17	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=14.6nM for fVIIa binding assay
1060	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1m	18	Acetylation (Napthalene acyl sulfonamide)	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	30	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=1.0nM for fVIIa binding assay
1061	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 1a	18	Acetylation	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	1.11mg/kg	4.18	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=9.7nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1062	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 1b	18	Acetylation(Naphthalene acylsulfonamide)	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	30	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=24nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1063	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 5a	18	Acetylation [(C6H6)-(C6H12)-(C6H6)]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	222	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=90nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1064	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 5b	18	Acetylation (Naphthalene)	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	34.8	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=9.2nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1065	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 5c	18	Acetylation [(C6H6)(CH2)4CH3]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	79.1	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=22nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1077	2147696	1990	GVQLDLDEAI	Synthetic peptide	10	Free	Free	Linear	L	None	Synthetic peptide (corresponding to amino acids 605-614 of human protein S)	Anticoagulant	Not reported	Not mentioned	80	Rabbit blood proteases	Spectrofluorometry	Intravenously injected in male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared	in vivo	None	None	34% of 125I protein S bound to C4b-binding protein in presence of 150 µM of peptide
1079	2147696	1990	DGEQLADLIV	Control peptide	10	Free	Free	Linear	L	None	Synthetic peptide (amino acids 400-407 of human protein S)	Anticoagulant	Not reported	Not mentioned	15	Rabbit blood proteases	Spectrofluorometry	Intravenously injected in Male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared	in vivo	None	None	No activity found
1113	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3 µg/ml for M. Luteus ATCC 9341
1114	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=4 µg/ml for M. Luteus ATCC 9341
1115	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=7 µg/ml for M. Luteus ATCC 9341
1116	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3 µg/ml for M. Luteus ATCC 9341
1117	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for M. Luteus ATCC 9342
1118	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3 µg/ml for M. Luteus ATCC 9343
1119	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3.12 µg/ml for M. Luteus ATCC 9344
1120	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6 µg/ml for M. Luteus ATCC 9345
1121	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6.25 µg/ml for S. Aureus ATCC 6538
1122	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=9 µg/ml for S. Aureus ATCC 6538
1123	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=19 µg/ml for S. Aureus ATCC 6539
1124	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for S. Aureus ATCC 6540
1125	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for S. Aureus ATCC 6541
1126	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for S. Aureus ATCC 6542
1127	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=9 µg/ml for S. Aureus ATCC 6543
1128	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=11 µg/ml for S. Aureus ATCC 6544
1129	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12228
1130	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12229
1131	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3.12 µg/ml for S. Epidemidis ATCC 12228
1132	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12229
1133	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3.12 µg/ml for S. Epidemidis ATCC 12228
1134	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12229
1135	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=2 µg/ml for S. Epidemidis ATCC 12228
1136	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	Not reported
1137	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for MRSA SR 1550
1138	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=50 µg/ml for MRSA SR 1551
1139	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=100 µg/ml for MRSA SR 1552
1140	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=50 µg/ml for MRSA SR 1553
1141	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=>100 µg/ml for MRSA SR 1554
1142	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=42 µg/ml for MRSA SR 1555
1143	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=38 µg/ml for MRSA SR 1556
1144	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=16 µg/ml for MRSA SR 1557
1145	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for M. smegmatis ATCC 607
1146	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for M. smegmatis ATCC 607
1147	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=>100 µg/ml for M. smegmatis ATCC 607
1148	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for M. smegmatis ATCC 607
1149	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for M. smegmatis ATCC 607
1150	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for M. smegmatis ATCC 612
1151	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for M. smegmatis ATCC 613
1152	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	Not reported
1153	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for E. coli ATCC 2592
1154	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for E. coli ATCC 2592
1155	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=23 µg/ml for E. coli ATCC 2592
1156	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for E. coli ATCC 2592
1157	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=31 µg/ml for E. coli ATCC 2592
1158	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=21 µg/ml for E. coli ATCC 2592
1159	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=19 µg/ml for E. coli ATCC 2592
1160	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=11 µg/ml for E. coli ATCC 2592
1161	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=4 µg/ml for P. aeruginosa ATCC 9027
1162	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for P. aeruginosa ATCC 9027
1163	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=20 µg/ml for P. aeruginosa ATCC 9027
1164	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6.25 µg/ml for P. aeruginosa ATCC 9027
1165	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for P. aeruginosa ATCC 9027
1166	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for P. aeruginosa ATCC 9027
1167	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6.25 µg/ml for P. aeruginosa ATCC 9027
1168	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=5 µg/ml for P. aeruginosa ATCC 9027
1169	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for C. albicans ATCC 36232
1170	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=9 µg/ml for C. albicans ATCC 36232
1171	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=17 µg/ml for C. albicans ATCC 36232
1172	10461747	1998	KKÎ¨[CH2NH]VVFKVKFk	KSL3	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6.25 µg/ml for C. albicans ATCC 36232
1173	10461747	1998	KÎ¨[CH2NH]KÎ¨[CH2NH]VVFKVKFk	KSL4	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	>81	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=31 µg/ml for C. albicans ATCC 36232
1174	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for C. albicans ATCC 36232
1175	10461747	1998	KÎ¨[CH2OCONH]KÎ¨[CH2OCONH]VVFKVKFk	KSL6	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	67	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=11 µg/ml for C. albicans ATCC 36232
1176	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for C. albicans ATCC 36232
1181	10773009	2000	TaLIDNNATEEILY	TX14(A)	14	Free	Free	Linear	Mix	None	Synthetic derivative of prosaposin	Neurotrophic factor	9 minutes	Not mentioned	4.2 ±0.3	Rat serum proteases	Radioactivity measured with a gamma counter	Injected in jugular vein of male Sprague-Dawley rats	in vivo	None	None	ED50=1.00 ±0.11ng/ml
1182	10773009	2000	TaIIDNNKTEKEISY	TX15-2	15	Free	Free	Linear	Mix	None	Synthetic derivative of prosaposin	Neurotrophic factor	9 minutes	Not mentioned	2.5 ±0.3	Rat serum proteases	Radioactivity measured by a gamma counter	Injected in jugular vein of male Sprague-Dawley rats	in vivo	None	None	ED50=1.00 ±0.09ng/ml
1218	20587645	2010	VRRADRAAVPGGGGRG	HM-3	16	Free	Free	Linear	L	None	Derivative of endostatin	Anti-angiogenetic	Not mentioned	Not mentioned	10 to 27	SD rat plasma proteases	RP-HPLC	SD rat plasma	in vitro	http://pubs.rsc.org/En/content/articlepdf/2014/tb/	None	39.68% inhibitory effect on mouse tumors
1219	20587645	2010	VRRADRAAVPGGGGRG	PEG20k-HM-3	16	Methoxy-polyethylene glycol-Succinimidyl Carbonate (SC-mPEG, molecular weight 20 kDa, named SC-mPEG20k )	Free	Linear	L	None	HM-3 analogue	Anti-angiogenetic	Not mentioned	Not mentioned	>132	SD rat plasma proteases	RP-HPLC	SD rat plasma	in vitro	http://pubs.rsc.org/En/content/articlepdf/2014/tb/	None	44.35% inhibitory effect on mouse tumors
1220	20587645	2010	VRRADRAAVPGGGGRG	mPEG-ALD10k-HM-3	16	Methoxy-polyethylene glycolPEG-aldehyde (mPEG-ALD10k )	Free	Linear	L	None	HM-3 analogue	Anti-angiogenetic	Not mentioned	Not mentioned	162.08 ±36.57	Proteases in chorioallantoic membrane of chick embryo	RP-HPLC	Chorioallantoic membrane of chick embryo	in vivo	http://pubs.rsc.org/En/content/articlepdf/2014/tb/	None	Dramatically inhibits angiogenesis on the chorioallantoic membrane of chick embryo
1261	22286034	2012	FVPIFTYGELQRVQQRKES	Motilin(1 €“12)ghrelin(12 €“18)	19	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	3.1 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=8.8x10-10nM for GPR38 agonist activity
1262	22286034	2012	FVPIFTYGELQRVQQRK	Motilin(1 €“12)ghrelin(12 €“16)	17	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	2.4 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.2x10-10nM for GPR38 agonist activity
1269	19159331	2009	GSIGAASMEF	Peptide 1	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	2.7013	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1270	19159331	2009	IGAASMEFCF	Peptide 2	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0629	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1271	19159331	2009	AASMEFCFDV	Peptide 3	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0556	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1272	19159331	2009	SMEFCFDVFK	Peptide 4	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0103	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1273	19159331	2009	EFCFDVFKEL	Peptide 5	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0088	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1274	19159331	2009	CFDVFKELKV	Peptide 6	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0122	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1275	19159331	2009	DVFKELKVHH	Peptide 7	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0101	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1276	19159331	2009	FKELKVHHAN	Peptide 8	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0094	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1277	19159331	2009	ELKVHHANEN	Peptide 9	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1969	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1278	19159331	2009	KVHHANENIF	Peptide 10	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.2897	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1279	19159331	2009	HHANENIFYC	Peptide 11	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0485	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1280	19159331	2009	ANENIFYCPI	Peptide 12	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1557	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1281	19159331	2009	ENIFYCPIAI	Peptide 13	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.089	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1282	19159331	2009	IFYCPIAIMS	Peptide 14	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0469	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1283	19159331	2009	YCPIAIMSAL	Peptide 15	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.2911	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1284	19159331	2009	PIAIMSALAM	Peptide 16	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1596	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1285	19159331	2009	AIMSALAMVY	Peptide 17	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0512	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1286	19159331	2009	MSALAMVYLG	Peptide 18	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0132	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1287	19159331	2009	ALAMVYLGAK	Peptide 19	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0077	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1288	19159331	2009	AMVYLGAKDS	Peptide 20	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0111	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1289	19159331	2009	VYLGAKDSTR	Peptide 21	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0135	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1290	19159331	2009	LGAKDSTRTQ	Peptide 22	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0122	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1291	19159331	2009	AKDSTRTQIN	Peptide 23	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0092	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1292	19159331	2009	DSTRTQINKV	Peptide 24	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.021	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1293	19159331	2009	TRTQINKVVR	Peptide 25	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0027	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1294	19159331	2009	TQINKVVRFD	Peptide 26	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0094	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1295	19159331	2009	INKVVRFDKL	Peptide 27	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0069	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1296	19159331	2009	KVVRFDKLPG	Peptide 28	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0119	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1297	19159331	2009	VRFDKLPGFG	Peptide 29	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1526	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1298	19159331	2009	FDKLPGFGDS	Peptide 30	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	25.2445	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1299	19159331	2009	KLPGFGDSIE	Peptide 31	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	40.1296	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1300	19159331	2009	PGFGDSIEAQ	Peptide 32	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	17.8114	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1301	19159331	2009	FGDSIEAQCG	Peptide 33	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	7.122	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1302	19159331	2009	DSIEAQCGTS	Peptide 34	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	13.4815	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1303	19159331	2009	IEAQCGTSVN	Peptide 35	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	6.4814	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1304	19159331	2009	AQCGTSVNVH	Peptide 36	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	4.3435	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1305	19159331	2009	CGTSVNVHSS	Peptide 37	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.1378	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1306	19159331	2009	TSVNVHSSLR	Peptide 38	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1177	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1307	19159331	2009	VNVHSSLRDI	Peptide 39	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0148	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1308	19159331	2009	VHSSLRDILN	Peptide 40	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0527	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1309	19159331	2009	SSLRDILNQI	Peptide 41	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1504	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1310	19159331	2009	LRDILNQITK	Peptide 42	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0939	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1311	19159331	2009	DILNQITKPN	Peptide 43	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	4.1593	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1312	19159331	2009	LNQITKPNDV	Peptide 44	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	20.6999	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1313	19159331	2009	QITKPNDVYS	Peptide 45	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.2963	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1314	19159331	2009	TKPNDVYSFS	Peptide 46	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.012	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1315	19159331	2009	PNDVYSFSLA	Peptide 47	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0026	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1316	19159331	2009	DVYSFSLASR	Peptide 48	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0037	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1317	19159331	2009	YSFSLASRLY	Peptide 49	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0019	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1318	19159331	2009	FSLASRLYAE	Peptide 50	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0035	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1319	19159331	2009	LASRLYAEER	Peptide 51	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0031	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1320	19159331	2009	SRLYAEERYP	Peptide 52	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0052	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1321	19159331	2009	LYAEERYPIL	Peptide 53	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1052	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1322	19159331	2009	AEERYPILPE	Peptide 54	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	11.4998	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1323	19159331	2009	ERYPILPEYL	Peptide 55	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.466	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1324	19159331	2009	YPILPEYLQC	Peptide 56	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1016	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1325	19159331	2009	ILPEYLQCVK	Peptide 57	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.3817	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1326	19159331	2009	PEYLQCVKEL	Peptide 58	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1101	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1327	19159331	2009	YLQCVKELYR	Peptide 59	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0263	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1328	19159331	2009	QCVKELYRGG	Peptide 60	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0128	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1329	19159331	2009	VKELYRGGLE	Peptide 61	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0225	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1330	19159331	2009	ELYRGGLEPI	Peptide 62	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0244	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1331	19159331	2009	YRGGLEPINF	Peptide 63	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0238	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1332	19159331	2009	GGLEPINFQT	Peptide 64	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0336	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1333	19159331	2009	LEPINFQTAA	Peptide 65	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0242	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1334	19159331	2009	PINFQTAADQ	Peptide 66	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0812	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1335	19159331	2009	NFQTAADQAR	Peptide 67	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1293	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1336	19159331	2009	QTAADQAREL	Peptide 68	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0514	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1337	19159331	2009	AADQARELIN	Peptide 69	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0325	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1338	19159331	2009	DQARELINSW	Peptide 70	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0224	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1339	19159331	2009	ARELINSWVE	Peptide 71	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0156	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1340	19159331	2009	ELINSWVESQ	Peptide 72	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.2344	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1341	19159331	2009	INSWVESQTN	Peptide 73	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	3.3348	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1342	19159331	2009	SWVESQTNGI	Peptide 74	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.7564	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1343	19159331	2009	VESQTNGIIR	Peptide 75	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.3309	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1344	19159331	2009	SQTNGIIRNV	Peptide 76	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0066	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1345	19159331	2009	TNGIIRNVLQ	Peptide 77	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0072	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1346	19159331	2009	GIIRNVLQPS	Peptide 78	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0038	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1347	19159331	2009	IRNVLQPSSV	Peptide 79	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0049	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1348	19159331	2009	NVLQPSSVDS	Peptide 80	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.3384	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1349	19159331	2009	LQPSSVDSQT	Peptide 81	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1866	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1350	19159331	2009	PSSVDSQTAM	Peptide 82	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	4.5647	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1351	19159331	2009	SVDSQTAMVL	Peptide 83	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.2013	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1352	19159331	2009	DSQTAMVLVN	Peptide 84	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0195	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1353	19159331	2009	QTAMVLVNAI	Peptide 85	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0264	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1354	19159331	2009	AMVLVNAIVF	Peptide 86	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0165	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1355	19159331	2009	VLVNAIVFKG	Peptide 87	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0087	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1356	19159331	2009	VNAIVFKGLW	Peptide 88	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0051	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1357	19159331	2009	AIVFKGLWEK	Peptide 89	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0054	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1358	19159331	2009	VFKGLWEKAF	Peptide 90	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0039	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1359	19159331	2009	KGLWEKAFKD	Peptide 91	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0053	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1360	19159331	2009	LWEKAFKDED	Peptide 92	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0131	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1361	19159331	2009	EKAFKDEDTQ	Peptide 93	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0329	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1362	19159331	2009	AFKDEDTQAM	Peptide 94	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	7.6573	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1363	19159331	2009	KDEDTQAMPF	Peptide 95	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.6468	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1364	19159331	2009	EDTQAMPFRV	Peptide 96	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0033	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1365	19159331	2009	TQAMPFRVTE	Peptide 97	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0047	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1366	19159331	2009	AMPFRVTEQE	Peptide 98	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0063	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1367	19159331	2009	PFRVTEQESK	Peptide 99	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.131	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1368	19159331	2009	RVTEQESKPV	Peptide 100	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	2.1948	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1369	19159331	2009	TEQESKPVQM	Peptide 101	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	19.4782	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1370	19159331	2009	QESKPVQMMY	Peptide 102	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	3.8079	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1371	19159331	2009	SKPVQMMYQI	Peptide 103	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.124	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1372	19159331	2009	PVQMMYQIGL	Peptide 104	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.088	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1373	19159331	2009	QMMYQIGLFR	Peptide 105	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.006	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1374	19159331	2009	MYQIGLFRVA	Peptide 106	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0025	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1375	19159331	2009	QIGLFRVASM	Peptide 107	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0015	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1376	19159331	2009	GLFRVASMAS	Peptide 108	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.006	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1377	19159331	2009	FRVASMASEK	Peptide 109	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0082	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1378	19159331	2009	VASMASEKMK	Peptide 110	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1745	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1379	19159331	2009	SMASEKMKIL	Peptide 111	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0072	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1380	19159331	2009	ASEKMKILEL	Peptide 112	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0103	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1381	19159331	2009	EKMKILELPF	Peptide 113	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0135	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1382	19159331	2009	MKILELPFAS	Peptide 114	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0183	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1383	19159331	2009	ILELPFASGT	Peptide 115	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0767	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1384	19159331	2009	ELPFASGTMS	Peptide 116	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0648	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1385	19159331	2009	PFASGTMSML	Peptide 117	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	3.844	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1386	19159331	2009	ASGTMSMLVL	Peptide 118	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1692	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1387	19159331	2009	GTMSMLVLLP	Peptide 119	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0949	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1388	19159331	2009	MSMLVLLPDE	Peptide 120	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0317	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1389	19159331	2009	MLVLLPDEVS	Peptide 121	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.323	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1390	19159331	2009	VLLPDEVSGL	Peptide 122	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	8.3587	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1391	19159331	2009	LPDEVSGLEQ	Peptide 123	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.3722	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1392	19159331	2009	DEVSGLEQLE	Peptide 124	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1719	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1393	19159331	2009	VSGLEQLESI	Peptide 125	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.0014	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1394	19159331	2009	GLEQLESIIN	Peptide 126	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.5162	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1395	19159331	2009	EQLESIINFE	Peptide 127	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0686	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1396	19159331	2009	LESIINFEKL	Peptide 128	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0663	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1397	19159331	2009	SIINFEKLTE	Peptide 129	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0667	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1398	19159331	2009	INFEKLTEWT	Peptide 130	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0541	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1399	19159331	2009	FEKLTEWTSS	Peptide 131	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0563	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1400	19159331	2009	KLTEWTSSNV	Peptide 132	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.4176	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1401	19159331	2009	TEWTSSNVME	Peptide 133	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.5842	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1402	19159331	2009	WTSSNVMEER	Peptide 134	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.9286	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1403	19159331	2009	SSNVMEERKI	Peptide 135	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0399	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1404	19159331	2009	NVMEERKIKV	Peptide 136	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0072	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1405	19159331	2009	MEERKIKVYL	Peptide 137	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0037	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1406	19159331	2009	ERKIKVYLPR	Peptide 138	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0008	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1407	19159331	2009	KIKVYLPRMK	Peptide 139	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0017	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1408	19159331	2009	KVYLPRMKME	Peptide 140	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0044	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1409	19159331	2009	YLPRMKMEEK	Peptide 141	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0088	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1410	19159331	2009	PRMKMEEKYN	Peptide 142	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0056	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1411	19159331	2009	MKMEEKYNLT	Peptide 143	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0367	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1412	19159331	2009	MEEKYNLTSV	Peptide 144	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0093	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1413	19159331	2009	EKYNLTSVLM	Peptide 145	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0124	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1414	19159331	2009	YNLTSVLMAM	Peptide 146	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0294	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1415	19159331	2009	LTSVLMAMGI	Peptide 147	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0787	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1416	19159331	2009	SVLMAMGITD	Peptide 148	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1194	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1417	19159331	2009	LMAMGITDVF	Peptide 149	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.8333	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1418	19159331	2009	AMGITDVFSS	Peptide 150	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0154	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1419	19159331	2009	GITDVFSSSA	Peptide 151	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0178	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1420	19159331	2009	TDVFSSSANL	Peptide 152	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.019	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1421	19159331	2009	VFSSSANLSG	Peptide 153	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1849	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1422	19159331	2009	SSSANLSGIS	Peptide 154	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.7012	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1423	19159331	2009	SANLSGISSA	Peptide 155	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.6149	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1424	19159331	2009	NLSGISSAES	Peptide 156	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.5216	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1425	19159331	2009	SGISSAESLK	Peptide 157	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.5455	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1426	19159331	2009	ISSAESLKIS	Peptide 158	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0401	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1427	19159331	2009	SAESLKISQA	Peptide 159	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0451	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1428	19159331	2009	ESLKISQAVH	Peptide 160	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0465	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1429	19159331	2009	LKISQAVHAA	Peptide 161	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0192	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1430	19159331	2009	ISQAVHAAHA	Peptide 162	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1691	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1431	19159331	2009	QAVHAAHAEI	Peptide 163	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1777	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1432	19159331	2009	VHAAHAEINE	Peptide 164	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1356	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1433	19159331	2009	AAHAEINEAG	Peptide 165	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.7772	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1434	19159331	2009	HAEINEAGRE	Peptide 166	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1388	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1435	19159331	2009	EINEAGREVV	Peptide 167	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1025	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1436	19159331	2009	NEAGREVVGS	Peptide 168	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1284	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1437	19159331	2009	AGREVVGSAE	Peptide 169	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0967	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1438	19159331	2009	REVVGSAEAG	Peptide 170	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.7169	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1439	19159331	2009	VVGSAEAGVD	Peptide 171	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	4.0618	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1440	19159331	2009	GSAEAGVDAA	Peptide 172	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	3.1271	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1441	19159331	2009	AEAGVDAASV	Peptide 173	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0711	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1442	19159331	2009	AGVDAASVSE	Peptide 174	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0548	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1443	19159331	2009	VDAASVSEEF	Peptide 175	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0426	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1444	19159331	2009	AASVSEEFRA	Peptide 176	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0246	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1445	19159331	2009	SVSEEFRADH	Peptide 177	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0788	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1446	19159331	2009	SEEFRADHPF	Peptide 178	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0759	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1447	19159331	2009	EFRADHPFLF	Peptide 179	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0569	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1448	19159331	2009	RADHPFLFCI	Peptide 180	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0056	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1449	19159331	2009	DHPFLFCIKH	Peptide 181	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0042	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1450	19159331	2009	PFLFCIKHIA	Peptide 182	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0046	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1451	19159331	2009	LFCIKHIATN	Peptide 183	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0185	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1452	19159331	2009	CIKHIATNAV	Peptide 184	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0929	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1453	19159331	2009	KHIATNAVLF	Peptide 185	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0719	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1454	19159331	2009	IATNAVLFFG	Peptide 186	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0048	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1455	19159331	2009	TNAVLFFGRC	Peptide 187	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0015	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1456	19159331	2009	AVLFFGRCVS	Peptide 188	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0012	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1457	19159331	2009	VLFFGRCVSP	Peptide 189	10	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0014	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1458	19159331	2009	GSIGAASMEFCFDVFK	Peptide 190	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0097	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1459	19159331	2009	IGAASMEFCFDVFKEL	Peptide 191	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0084	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1460	19159331	2009	AASMEFCFDVFKELKV	Peptide 192	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0068	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1461	19159331	2009	SMEFCFDVFKELKVHH	Peptide 193	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0084	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1462	19159331	2009	EFCFDVFKELKVHHAN	Peptide 194	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0098	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1463	19159331	2009	CFDVFKELKVHHANEN	Peptide 195	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0103	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1464	19159331	2009	DVFKELKVHHANENIF	Peptide 196	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0201	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1465	19159331	2009	FKELKVHHANENIFYC	Peptide 197	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0074	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1466	19159331	2009	ELKVHHANENIFYCPI	Peptide 198	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0851	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1467	19159331	2009	KVHHANENIFYCPIAI	Peptide 199	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0892	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1468	19159331	2009	HHANENIFYCPIAIMS	Peptide 200	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0575	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1469	19159331	2009	ANENIFYCPIAIMSAL	Peptide 201	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0425	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1470	19159331	2009	ENIFYCPIAIMSALAM	Peptide 202	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0327	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1471	19159331	2009	IFYCPIAIMSALAMVY	Peptide 203	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0167	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1472	19159331	2009	YCPIAIMSALAMVYLG	Peptide 204	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0125	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1473	19159331	2009	PIAIMSALAMVYLGAK	Peptide 205	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0077	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1474	19159331	2009	AIMSALAMVYLGAKDS	Peptide 206	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0088	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1475	19159331	2009	MSALAMVYLGAKDSTR	Peptide 207	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0063	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1476	19159331	2009	ALAMVYLGAKDSTRTQ	Peptide 208	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0045	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1477	19159331	2009	AMVYLGAKDSTRTQIN	Peptide 209	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0037	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1478	19159331	2009	VYLGAKDSTRTQINKV	Peptide 210	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.004	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1479	19159331	2009	LGAKDSTRTQINKVVR	Peptide 211	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0033	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1480	19159331	2009	AKDSTRTQINKVVRFD	Peptide 212	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0038	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1481	19159331	2009	DSTRTQINKVVRFDKL	Peptide 213	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0044	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1482	19159331	2009	TRTQINKVVRFDKLPG	Peptide 214	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0045	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1483	19159331	2009	TQINKVVRFDKLPGFG	Peptide 215	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0085	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1484	19159331	2009	INKVVRFDKLPGFGDS	Peptide 216	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0111	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1485	19159331	2009	KVVRFDKLPGFGDSIE	Peptide 217	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0131	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1486	19159331	2009	VRFDKLPGFGDSIEAQ	Peptide 218	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1209	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1487	19159331	2009	FDKLPGFGDSIEAQCG	Peptide 219	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	5.693	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1488	19159331	2009	KLPGFGDSIEAQCGTS	Peptide 220	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	6.4211	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1489	19159331	2009	PGFGDSIEAQCGTSVN	Peptide 221	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	5.0348	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1490	19159331	2009	FGDSIEAQCGTSVNVH	Peptide 222	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	1.3951	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1491	19159331	2009	DSIEAQCGTSVNVHSS	Peptide 223	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.4688	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1492	19159331	2009	IEAQCGTSVNVHSSLR	Peptide 224	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.193	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1493	19159331	2009	AQCGTSVNVHSSLRDI	Peptide 225	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0267	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1494	19159331	2009	CGTSVNVHSSLRDILN	Peptide 226	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0499	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1495	19159331	2009	TSVNVHSSLRDILNQI	Peptide 227	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1029	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1496	19159331	2009	VNVHSSLRDILNQITK	Peptide 228	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0614	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1497	19159331	2009	VHSSLRDILNQITKPN	Peptide 229	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1104	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1498	19159331	2009	SSLRDILNQITKPNDV	Peptide 230	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1963	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1499	19159331	2009	LRDILNQITKPNDVYS	Peptide 231	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0514	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1500	19159331	2009	DILNQITKPNDVYSFS	Peptide 232	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0223	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1501	19159331	2009	LNQITKPNDVYSFSLA	Peptide 233	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0054	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1502	19159331	2009	QITKPNDVYSFSLASR	Peptide 234	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0025	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1503	19159331	2009	TKPNDVYSFSLASRLY	Peptide 235	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0011	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1504	19159331	2009	PNDVYSFSLASRLYAE	Peptide 236	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0014	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1505	19159331	2009	DVYSFSLASRLYAEER	Peptide 237	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0011	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1506	19159331	2009	YSFSLASRLYAEERYP	Peptide 238	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0032	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1507	19159331	2009	FSLASRLYAEERYPIL	Peptide 239	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0031	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1508	19159331	2009	LASRLYAEERYPILPE	Peptide 240	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0023	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1509	19159331	2009	SRLYAEERYPILPEYL	Peptide 241	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0028	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1510	19159331	2009	LYAEERYPILPEYLQC	Peptide 242	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0281	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1511	19159331	2009	AEERYPILPEYLQCVK	Peptide 243	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.2682	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1512	19159331	2009	ERYPILPEYLQCVKEL	Peptide 244	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1018	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1513	19159331	2009	YPILPEYLQCVKELYR	Peptide 245	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0298	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1514	19159331	2009	ILPEYLQCVKELYRGG	Peptide 246	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0143	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1515	19159331	2009	PEYLQCVKELYRGGLE	Peptide 247	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0152	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1516	19159331	2009	YLQCVKELYRGGLEPI	Peptide 248	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0093	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1517	19159331	2009	QCVKELYRGGLEPINF	Peptide 249	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0085	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1518	19159331	2009	VKELYRGGLEPINFQT	Peptide 250	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0052	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1519	19159331	2009	ELYRGGLEPINFQTAA	Peptide 251	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0085	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1520	19159331	2009	YRGGLEPINFQTAADQ	Peptide 252	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.011	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1521	19159331	2009	GGLEPINFQTAADQAR	Peptide 253	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0207	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1522	19159331	2009	LEPINFQTAADQAREL	Peptide 254	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0155	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1523	19159331	2009	PINFQTAADQARELIN	Peptide 255	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0183	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1524	19159331	2009	NFQTAADQARELINSW	Peptide 256	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0247	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1525	19159331	2009	QTAADQARELINSWVE	Peptide 257	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0297	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1526	19159331	2009	AADQARELINSWVESQ	Peptide 258	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0322	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1527	19159331	2009	DQARELINSWVESQTN	Peptide 259	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0223	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1528	19159331	2009	ARELINSWVESQTNGI	Peptide 260	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0078	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1529	19159331	2009	ELINSWVESQTNGIIR	Peptide 261	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1455	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1530	19159331	2009	INSWVESQTNGIIRNV	Peptide 262	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0095	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1531	19159331	2009	SWVESQTNGIIRNVLQ	Peptide 263	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0099	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1532	19159331	2009	VESQTNGIIRNVLQPS	Peptide 264	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0085	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1533	19159331	2009	SQTNGIIRNVLQPSSV	Peptide 265	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0032	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1534	19159331	2009	TNGIIRNVLQPSSVDS	Peptide 266	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0033	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1535	19159331	2009	GIIRNVLQPSSVDSQT	Peptide 267	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.005	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1536	19159331	2009	IRNVLQPSSVDSQTAM	Peptide 268	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0069	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1537	19159331	2009	NVLQPSSVDSQTAMVL	Peptide 269	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1618	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1538	19159331	2009	LQPSSVDSQTAMVLVN	Peptide 270	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0332	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1539	19159331	2009	PSSVDSQTAMVLVNAI	Peptide 271	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0371	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1540	19159331	2009	SVDSQTAMVLVNAIVF	Peptide 272	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0236	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1541	19159331	2009	DSQTAMVLVNAIVFKG	Peptide 273	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.008	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1542	19159331	2009	QTAMVLVNAIVFKGLW	Peptide 274	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0051	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1543	19159331	2009	AMVLVNAIVFKGLWEK	Peptide 275	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0061	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1544	19159331	2009	VLVNAIVFKGLWEKAF	Peptide 276	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.003	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1545	19159331	2009	VNAIVFKGLWEKAFKD	Peptide 277	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0028	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1546	19159331	2009	AIVFKGLWEKAFKDED	Peptide 278	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0037	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1547	19159331	2009	VFKGLWEKAFKDEDTQ	Peptide 279	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0057	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1548	19159331	2009	KGLWEKAFKDEDTQAM	Peptide 280	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0084	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1549	19159331	2009	LWEKAFKDEDTQAMPF	Peptide 281	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0101	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1550	19159331	2009	EKAFKDEDTQAMPFRV	Peptide 282	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0037	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1551	19159331	2009	AFKDEDTQAMPFRVTE	Peptide 283	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0047	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1552	19159331	2009	KDEDTQAMPFRVTEQE	Peptide 284	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0049	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1553	19159331	2009	EDTQAMPFRVTEQESK	Peptide 285	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0041	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1554	19159331	2009	TQAMPFRVTEQESKPV	Peptide 286	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0076	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1555	19159331	2009	AMPFRVTEQESKPVQM	Peptide 287	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.005	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1556	19159331	2009	PFRVTEQESKPVQMMY	Peptide 288	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1097	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1557	19159331	2009	RVTEQESKPVQMMYQI	Peptide 289	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1086	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1558	19159331	2009	TEQESKPVQMMYQIGL	Peptide 290	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0696	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1559	19159331	2009	QESKPVQMMYQIGLFR	Peptide 291	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0055	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1560	19159331	2009	SKPVQMMYQIGLFRVA	Peptide 292	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.002	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1561	19159331	2009	PVQMMYQIGLFRVASM	Peptide 293	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0022	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1562	19159331	2009	QMMYQIGLFRVASMAS	Peptide 294	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0021	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1563	19159331	2009	MYQIGLFRVASMASEK	Peptide 295	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0025	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1564	19159331	2009	QIGLFRVASMASEKMK	Peptide 296	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0021	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1565	19159331	2009	GLFRVASMASEKMKIL	Peptide 297	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0047	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1566	19159331	2009	FRVASMASEKMKILEL	Peptide 298	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0026	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1567	19159331	2009	VASMASEKMKILELPF	Peptide 299	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0075	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1568	19159331	2009	SMASEKMKILELPFAS	Peptide 300	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0073	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1569	19159331	2009	ASEKMKILELPFASGT	Peptide 301	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0034	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1570	19159331	2009	EKMKILELPFASGTMS	Peptide 302	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0134	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1571	19159331	2009	MKILELPFASGTMSML	Peptide 303	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.022	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1572	19159331	2009	ILELPFASGTMSMLVL	Peptide 304	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0507	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1573	19159331	2009	ELPFASGTMSMLVLLP	Peptide 305	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.041	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1574	19159331	2009	PFASGTMSMLVLLPDE	Peptide 306	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0444	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1575	19159331	2009	ASGTMSMLVLLPDEVS	Peptide 307	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0325	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1576	19159331	2009	GTMSMLVLLPDEVSGL	Peptide 308	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0306	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1577	19159331	2009	MSMLVLLPDEVSGLEQ	Peptide 309	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0139	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1578	19159331	2009	MLVLLPDEVSGLEQLE	Peptide 310	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1049	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1579	19159331	2009	VLLPDEVSGLEQLESI	Peptide 311	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.2344	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1580	19159331	2009	LPDEVSGLEQLESIIN	Peptide 312	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1597	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1581	19159331	2009	DEVSGLEQLESIINFE	Peptide 313	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0265	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1582	19159331	2009	VSGLEQLESIINFEKL	Peptide 314	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0393	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1583	19159331	2009	GLEQLESIINFEKLTE	Peptide 315	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0228	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1584	19159331	2009	EQLESIINFEKLTEWT	Peptide 316	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0345	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1585	19159331	2009	LESIINFEKLTEWTSS	Peptide 317	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0424	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1586	19159331	2009	SIINFEKLTEWTSSNV	Peptide 318	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0653	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1587	19159331	2009	INFEKLTEWTSSNVME	Peptide 319	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0497	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1588	19159331	2009	FEKLTEWTSSNVMEER	Peptide 320	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0286	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1589	19159331	2009	KLTEWTSSNVMEERKI	Peptide 321	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0414	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1590	19159331	2009	TEWTSSNVMEERKIKV	Peptide 322	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0139	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1591	19159331	2009	WTSSNVMEERKIKVYL	Peptide 323	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.006	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1592	19159331	2009	SSNVMEERKIKVYLPR	Peptide 324	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0021	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1593	19159331	2009	NVMEERKIKVYLPRMK	Peptide 325	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0021	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1594	19159331	2009	MEERKIKVYLPRMKME	Peptide 326	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0014	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1595	19159331	2009	ERKIKVYLPRMKMEEK	Peptide 327	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0012	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1596	19159331	2009	KIKVYLPRMKMEEKYN	Peptide 328	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0016	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1597	19159331	2009	KVYLPRMKMEEKYNLT	Peptide 329	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.003	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1598	19159331	2009	YLPRMKMEEKYNLTSV	Peptide 330	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0054	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1599	19159331	2009	PRMKMEEKYNLTSVLM	Peptide 331	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0051	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1600	19159331	2009	MKMEEKYNLTSVLMAM	Peptide 332	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0321	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1601	19159331	2009	MEEKYNLTSVLMAMGI	Peptide 333	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0225	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1602	19159331	2009	EKYNLTSVLMAMGITD	Peptide 334	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0211	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1603	19159331	2009	YNLTSVLMAMGITDVF	Peptide 335	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0298	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1604	19159331	2009	LTSVLMAMGITDVFSS	Peptide 336	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.017	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1605	19159331	2009	SVLMAMGITDVFSSSA	Peptide 337	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0276	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1606	19159331	2009	LMAMGITDVFSSSANL	Peptide 338	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0241	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1607	19159331	2009	AMGITDVFSSSANLSG	Peptide 339	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0262	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1608	19159331	2009	GITDVFSSSANLSGIS	Peptide 340	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.024	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1609	19159331	2009	TDVFSSSANLSGISSA	Peptide 341	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0361	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1610	19159331	2009	VFSSSANLSGISSAES	Peptide 342	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.2471	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1611	19159331	2009	SSSANLSGISSAESLK	Peptide 343	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.3682	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1612	19159331	2009	SANLSGISSAESLKIS	Peptide 344	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0601	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1613	19159331	2009	NLSGISSAESLKISQA	Peptide 345	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0601	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1614	19159331	2009	SGISSAESLKISQAVH	Peptide 346	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0526	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1615	19159331	2009	ISSAESLKISQAVHAA	Peptide 347	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0502	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1616	19159331	2009	SAESLKISQAVHAAHA	Peptide 348	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0475	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1617	19159331	2009	ESLKISQAVHAAHAEI	Peptide 349	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0463	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1618	19159331	2009	LKISQAVHAAHAEINE	Peptide 350	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0154	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1619	19159331	2009	ISQAVHAAHAEINEAG	Peptide 351	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1789	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1620	19159331	2009	QAVHAAHAEINEAGRE	Peptide 352	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0901	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1621	19159331	2009	VHAAHAEINEAGREVV	Peptide 353	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0783	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1622	19159331	2009	AAHAEINEAGREVVGS	Peptide 354	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1269	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1623	19159331	2009	HAEINEAGREVVGSAE	Peptide 355	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1531	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1624	19159331	2009	EINEAGREVVGSAEAG	Peptide 356	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.195	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1625	19159331	2009	NEAGREVVGSAEAGVD	Peptide 357	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1676	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1626	19159331	2009	AGREVVGSAEAGVDAA	Peptide 358	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.1212	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1627	19159331	2009	REVVGSAEAGVDAASV	Peptide 359	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0694	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1628	19159331	2009	VVGSAEAGVDAASVSE	Peptide 360	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0475	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1629	19159331	2009	GSAEAGVDAASVSEEF	Peptide 361	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0261	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1630	19159331	2009	AEAGVDAASVSEEFRA	Peptide 362	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0214	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1631	19159331	2009	AGVDAASVSEEFRADH	Peptide 363	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0322	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1632	19159331	2009	VDAASVSEEFRADHPF	Peptide 364	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0389	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1633	19159331	2009	AASVSEEFRADHPFLF	Peptide 365	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0233	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1634	19159331	2009	SVSEEFRADHPFLFCI	Peptide 366	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0029	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1635	19159331	2009	SEEFRADHPFLFCIKH	Peptide 367	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0038	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1636	19159331	2009	EFRADHPFLFCIKHIA	Peptide 368	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0031	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1637	19159331	2009	RADHPFLFCIKHIATN	Peptide 369	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0038	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1638	19159331	2009	DHPFLFCIKHIATNAV	Peptide 370	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0046	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1639	19159331	2009	PFLFCIKHIATNAVLF	Peptide 371	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0055	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1640	19159331	2009	LFCIKHIATNAVLFFG	Peptide 372	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0038	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1641	19159331	2009	CIKHIATNAVLFFGRC	Peptide 373	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0025	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1642	19159331	2009	KHIATNAVLFFGRCVS	Peptide 374	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0008	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1643	19159331	2009	HIATNAVLFFGRCVSP	Peptide 375	16	2,4-dichlorophenoxyacetic acid with (CH2)n-spacers	Biotinylation with PEG spacer	Linear	L	None	Synthetic	Not mentioned	120 minutes	67 pico molar	0.0009	Murine crude intestinal proteases	Proteolysis assay	Murine crude intestinal protease preparetion	in vitro	None	None	Not reported
1657	20585128	2010	RRWRIVVIRVRR	Sub3	12	Free	Amidation	Linear	L	None	Derived from bovine peptide bactenecin	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=1 µg/ml for S. Aureus
1658	20585128	2010	Agp-Agp-W-Agp-IVVI-Agp-V-Agp-Agp	Sub3-Agp	12	Free	Amidation	Linear	L	Agp=Î±amino-3-guanidino-propionic acid	Derivative of Sub3	Antimicrobial	Not reported	150 µg/ml	>480	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=1 µg/ml for S. Aureus
1659	20585128	2010	aRRWRIVVIRVRRh	Sub3-D	14	Free	Amidation	Linear	Mix	None	Derivative of Sub4	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=1 µg/ml for S. Aureus
1660	20585128	2010	a-Agp-Agp-W-Agp-IVVI-Agp-V-Agp-Agp-h	Sub3-DAgp	14	Free	Amidation	Linear	Mix	Agp=Î±amino-3-guanidino-propionic acid	Derivative of Sub5	Antimicrobial	Not reported	150 µg/ml	>480	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=1 µg/ml for S. Aureus
1661	20585128	2010	RRWRIVVIRVRR	Sub3	12	Free	Amidation	Linear	L	None	Derived from bovine peptide bactenecin	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=2 µg/ml for P. Aeruginosa
1662	20585128	2010	Agp-Agp-W-Agp-IVVI-Agp-V-Agp-Agp	Sub3-Agp	12	Free	Amidation	Linear	L	Agp=Î±amino-3-guanidino-propionic acid	Derivative of Sub3	Antimicrobial	Not reported	150 µg/ml	>480	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=2 µg/ml for P. Aeruginosa
1663	20585128	2010	aRRWRIVVIRVRRh	Sub3-D	14	Free	Amidation	Linear	Mix	None	Derivative of Sub4	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=2 µg/ml for P. Aeruginosa
1664	20585128	2010	a-Agp-Agp-W-Agp-IVVI-Agp-V-Agp-Agp-h	Sub3-DAgp	14	Free	Amidation	Linear	Mix	Agp=Î±amino-3-guanidino-propionic acid	Derivative of Sub5	Antimicrobial	Not reported	150 µg/ml	>480	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=2 µg/ml for P. Aeruginosa
1665	2533571	1989	TSEKSQTPLVTL	Des-enkephalin-Î³-endorphin	12	Free	Free	Linear	L	None	Endorphin derivative	Neuropeptide	Not reported	0.1mM	4.5	Proteases in SVK14 keratinocytes	HPLC/liquid scintillation counting	SVK14 keratinocytes	in vitro	3582424	None	Not reported
1666	2533571	1989	TSEKSQTPLVTL	Des-enkephalin-Î³-endorphin	12	Free	Free	Linear	L	None	Endorphin derivative	Neuropeptide	Not reported	0.1mM	4.1	Proteases in fibroblasts	HPLC/liquid scintillation counting	Human fibroblasts	in vitro	3582424	None	Not reported
1667	2533571	1989	TSEKSQTPLVTL	Des-enkephalin-Î³-endorphin	12	Free	Free	Linear	L	None	Endorphin derivative	Neuropeptide	Not reported	0.1mM	4.4	Proteases in human fresh whole skin	HPLC/liquid scintillation counting	Human fresh whole skin	in vitro	3582424	None	Not reported
1668	2533571	1989	TSEKSQTPLVTL	Des-enkephalin-Î³-endorphin	12	Free	Free	Linear	L	None	Endorphin derivative	Neuropeptide	Not reported	0.1mM	4.6	Proteases in human fresh epidermis	HPLC/liquid scintillation counting	Human fresh epidermis	in vitro	3582424	None	Not reported
1669	2533571	1989	TSEKSQTPLVTL	Des-enkephalin-Î³-endorphin	12	Free	Free	Linear	L	None	Endorphin derivative	Neuropeptide	Not reported	0.1mM	4.5	Proteases in human fresh dermis	HPLC/liquid scintillation counting	Human fresh dermis	in vitro	3582424	None	Not reported
1688	3080478	1985	SSLKQYWSSLKQSFS	C0-LAP	15	Free	Free	Linear	L	None	Lipid associated peptide -20	Not mentioned	Not reported	300 µl	~300	Not mentioned	Serum decay experiment	Blood sample of female Sprague-Dawley rat	in vivo	6774331	None	Not mentioned
1689	3080478	1985	SSLKQYWSSLKQSFS	C4-LAP	15	Saturated acyl chain of 4 carbons	Free	Linear	L	None	Lipid associated peptide -20	Not mentioned	Not reported	300 µl	~340	Not mentioned	Serum decay experiment	Blood sample of female Sprague-Dawley rat	in vivo	6774331	None	Not mentioned
1690	3080478	1985	SSLKQYWSSLKQSFS	C8-LAP	15	Saturated acyl chain of 8 carbons	Free	Linear	L	None	Lipid associated peptide -20	Not mentioned	Not reported	300 µl	~410	Not mentioned	Serum decay experiment	Blood sample of female Sprague-Dawley rat	in vivo	6774331	None	Not mentioned
1691	3080478	1985	SSLKQYWSSLKQSFS	C12-LAP	15	Saturated acyl chain of 12 carbons	Free	Linear	L	None	Lipid associated peptide -20	Not mentioned	Not reported	300 µl	~410	Not mentioned	Serum decay experiment	Blood sample of female Sprague-Dawley rat	in vivo	6774331	None	Not mentioned
1692	3080478	1985	SSLKQYWSSLKQSFS	C16-LAP	15	Saturated acyl chain of 16 carbons	Free	Linear	L	None	Lipid associated peptide -20	Not mentioned	Not reported	300 µl	513 ±12	Not mentioned	Serum decay experiment	Blood sample of female Sprague-Dawley rat	in vivo	6774331	None	Not mentioned
1694	6086405	1984	Glp-PPGGSKVILF	Hydra head activator	11	Free	Free	Linear	L	Glp-Pyroglutamic acid	Hydra but also found in rat intestine,human and bovine hypothalamus	In hydra-stimulatory effects on growth and differentition,in human-in digestion control process	2 hour	20-100 fmol/ml	7	Not mentioned	Radioimmunoassay	Human plasma	in vitro	None	None	Not mentioned
1695	6117506	1981	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Ovine	Local transmitters either paracrine or neurocrine	5 days	100ng	1.0 ±0.2	Not mentioned	Radioimmunoassay	Blood plasma sample from five mongrel dogs	in vivo	4682131	None	Not mentioned
1706	10647619	2000	GPRPP-Aba-GGaG	TP 850	10	Free	Free	Linear	Mix	4-aminobutyric acid (Aba)	Modified fibrin Î± chain N-terminal peptide	Blood Coagulation	Not reported	11 to 25 iu of oxytocin	4	Blood proteases	Radiolabelling and HPLC	Intravenous injection,Blood sample of rabbit	in vivo	None	None	Platelet aggregation inhibition, IC50=236Î¼m for dog and IC50=167Î¼m for rabbit.
1709	12119302	2002	RLIEDICLPRWGCLWEDD	SA21	18	Acetylation	Amidation	Linear	L	None	Synthetic (Phage display library)	Not mentioned	Not reported	106 cpm/200Î¼l/mouse	2.3	Blood proteases	ESI-LC ˆ’MS/MS	Rabbit blood sample	in vivo	None	None	Dissociation equilibrium constant of peptide for albumin,Kd=320 ±22
1710	12119302	2002	ALCDNPRIDRWYCQFVEG	1a	18	Acetylation	Amidation	Linear	L	None	Synthetic	Coagulation factor VIIa peptide exosite inhibitor	Not reported	106 cpm/200Î¼l/mouse	7.6	Blood proteases	ESI-LC ˆ’MS/MS	Rabbit blood sample	in vivo	None	None	Not mentioned
1767	16892368	2006	WDREINNYTSLIH	C46	13	Glycosylation	Amidation	Linear	L	None	Derived from T20	HIV-1 fusion inhibitory peptide	Not reported	40 ng peptide/200 mL plasma	4.75	Mouse plasma proteases	ELISA	Mouse plasma	in vitro	None	None	IC50=90nM
1768	16892368	2006	WDREINNYTSLIH	C46	13	Glycosylation	Amidation	Linear	L	None	Derived from T20	HIV-1 fusion inhibitory peptide	Not reported	41 ng peptide/200 mL plasma	2	Rat plasma proteases	ELISA	Rat plasma	in vitro	None	None	IC50=90nM
1769	16892368	2006	WDREINNYTSLIH	C46	13	Glycosylation	Amidation	Linear	L	None	Derived from T20	HIV-1 fusion inhibitory peptide	Not reported	40 ng peptide/200 mL buffer	0.75	Not mentioned	ELISA	PBS/1% BSA	in vitro	None	None	IC50=90nM
1974	19223422	2009	SPRGDLAVLGHKY	HBP-1	13	Free	Free	Linear	L	None	Synthetic peptide	Not mentioned	Not reported	Not mentioned	55	Not mentioned	HPLC	Human serum	in vitro	None	None	IC50=38.9nM
1977	19413309	2009	IRRADRAAVPGGGGRGD	HM3	17	Free	Free	Linear	L	None	RGD- modified endostatin derived peptide	Antitumor	Not reported	1mg/ml	27.66 ± 7.37	Rat blood proteases	RP-HPLC	Rat blood serum (Intravenous injection)	in vivo	None	None	Less active in the inhibition of angiogenesis in the chorioallantoic membrane of chick embryos
1978	19413309	2009	IRRADRAAVPGGGGRGD	PEG10k-HM-3	17	Methoxypoly(ethylene glycol)-aldehyde (mPEG-ALD)	Free	Linear	L	None	RGD- modified endostatin derived peptide	Antitumor	Not reported	1mg/ml	162.08 ± 36.57	Rat blood proteases	RP-HPLC	Rat blood serum (Intravenous injection)	in vivo	None	None	More active in the inhibition of angiogenesis in the chorioallantoic membrane of chick embryos
1984	19572636	2009	NISHTKEKKKGKAKKKRLTK	N-WASP181-200	20	Free	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	1 mg/mL	6.7	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=0.041 mM with gentamicin
1985	19572636	2009	NISHTKEKKKGKAKKKRLTK	PEG1k-N-W	20	Pegylation	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100 µg/mL	12.9	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=0.128 mM with gentamicin
1986	19572636	2009	NISHTKEKKKGKAKKKRLTK	N-WASP181-200	20	Free	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100 µg/mL	6.7	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=46.1 mg/kg with Arbekacin
1987	19572636	2009	NISHTKEKKKGKAKKKRLTK	N-WASP181-200	20	Free	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100mg/kg	2.7	Not mentioned	HPLC	Rat blood plasma (Intravenous)	in vivo	None	None	IC50=46.1 mg/kg with Arbekacin
1988	19572636	2009	NISHTKEKKKGKAKKKRLTK	PEG1k-N-W	20	Pegylation	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100mg/kg	4.6	Not mentioned	HPLC	Rat blood plasma (Intravenous)	in vivo	None	None	IC50=17.8 mg/kg with Arbekacin
1989	19572636	2009	NISHTKEKKKGKAKKKRLTK	PEG1k-N-W	20	Pegylation	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100 µg/mL	12.9	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=17.8 mg/kg with Arbekacin
1990	19601640	2009	YGRKKRRQRRR	TATp	11	Free	Free	Linear	L	None	Synthetic peptide	Cell penetrating peptide	Not reported	10 µL	>400	Not mentioned	HPLC	Human plasma	in vitro	None	None	Not available
1994	19715558	2009	LEQYANQLADQIIKEATE	RIAD	18	Free	Free	Linear	L	None	Synthetic peptide	Displaces PKA (protein kinase A) type I from the AKAP (A-kinase-anchoring protein) ezrin	Not reported	Not mentioned	1.5	Human serum proteases	HPLC	Human serum	in vitro	None	None	Not available
2037	19041716	2009	AGCKNFFWKTFTSC	SST (Somatostatin)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin	Neurotransmitter	Not reported	1.8 mg/ml	7.6	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2038	19041716	2009	AGCKNFFWKTFTSC	LCNP/SST (Somatostatin adsorbed on Liquid crystalline nanoparticles for 10 min)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin adsorbed on Liquid crystalline nanoparticles	Neurotransmitter	Not reported	1.8 mg/ml	0.73 ±0.03	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2039	19041716	2009	AGCKNFFWKTFTSC	LCNP/SST (Somatostatin adsorbed on Liquid crystalline nanoparticles for 18 hours)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin adsorbed on Liquid crystalline nanoparticles	Neurotransmitter	Not reported	1.8 mg/ml	0.79 ±0.17	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2040	19041716	2009	AGCKNFFWKTFTSC	LCNP/SST (encapsulated within Liquid crystalline nanoparticles)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin encapsulated within Liquid crystalline nanoparticles	Neurotransmitter	Not reported	1.8 mg/ml	1.23 ±0.16	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2051	19533722	2009	NPVENMMDRDSQ	C6	12	Free	Free	Linear	L	None	Synthetic peptide	Mimic putative inhibitor epitopes (mimotopes),	Not reported	150 µM	~12	Human plasma proteases	ELISA	Human plasma	in vitro	None	None	IC50 =30 €“50 µM
2071	3348603	1987	N-MeVal-EtPro-N-MeThr-Leu-MePro-AMHA-Pro-N-MeLeu- Gly	DihydromycoplanecinA (DHMP A)	10	alpha-hydroxybutyric acid	Free	Cyclic	L	N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine	Active metabolite in urine of mice and dogs	Antibiotic	Not reported	10 mg/kg	0.5	Mouse blood proteases	Not mentioned	Mice serum (Intravenous)	in vivo	None	None	LD50>6000mg/kg administered orally to mice
2072	3348603	1987	N-MeVal-EtPro-N-MeThr-Leu-MePro-AMHA-Pro-N-MeLeu- Gly	DihydromycoplanecinA (DHMP A)	10	alpha-hydroxybutyric acid	Free	Cyclic	L	N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine	Active metabolite in urine of mice and dogs	Antibiotic	Not reported	10 mg/kg	19.3	Mouse blood proteases	Not mentioned	Mice serum (Intravenous)	in vivo	None	None	LD50>6000mg/kg administered orally to mice
2073	3348603	1987	N-MeVal-EtPro-N-MeThr-Leu-MePro-AMHA-Pro-N-MeLeu- Gly	DihydromycoplanecinA (DHMP A)	10	Free	Free	Cyclic	L	N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine	Active metabolite in urine of mice and dogs	Antibiotic	Not reported	10 mg/kg	5.5	Dog blood proteases	Not mentioned	Dog serum (Intravenous)	in vivo	None	None	LD50>6000mg/kg administered orally to mice
2077	8910426	1996	KPTFRRLKWK	LL:36 €“45	10	Free	Free	Linear	L	None	Analogue of Limulus anti-lipopolysaccharide factor	Antibacterial	Not reported	2.5 µg/ml	17	Proteases present in fetal calf serum	RP-HPLC	Fetal calf serum	in vitro	None	None	No cell lysis done by this peptide
2078	8910426	1996	GCTFRRLKWKCG	LALF-10 (38 €“45)	12	Free	Free	Cyclic (C2-C11)	L	None	Analogue of Limulus anti-lipopolysaccharide factor	Antibacterial	Not reported	2.5 µg/ml	77	Proteases present in fetal calf serum	RP-HPLC	Fetal calf serum	in vitro	None	None	LD50=2.58 mg/ml
2079	8910426	1996	GCKPTFRRLKWKYKCG	LALF-14 (36 €“47)	16	Free	Free	Cyclic (C2-C15)	L	None	Analogue of Limulus anti-lipopolysaccharide factor	Antibacterial	Not reported	2.5 µg/ml	84	Proteases present in fetal calf serum	RP-HPLC	Fetal calf serum	in vitro	None	None	LD50=2.33 mg/ml
2084	N.A.	2004	EAAGIGILTV	Melan-A26-35	10	Free	Free	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	45	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.25 nM
2085	N.A.	2004	ELAGIGILTV	Melan-A26-35 A27L	10	Free	Free	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	40	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.01 nM
2086	N.A.	2004	ELAGIGILTV	[NMeEI, Î±MeL8]-Melan-A	10	Free	Free	Linear	L	Methylation of nitrogen of amide bond b/w Glu1 and Leu2 (NMe); Methylation of carboxyl of Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(0.5 nM); isomer2(20 nM)
2087	N.A.	2004	ELAGIGILTV	[NMeEI, amide]-Melan-A	10	Free	Amidation	Linear	L	Methylation of nitrogen of amide bond b/w Glu1 and Leu2 (NMe)	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	12	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 1 nM
2088	N.A.	2004	pGlu-LAGIGILTV	[pEI, amide]-Melan-A	10	PyroGlutamic acid at 1st position	Amidation	Linear	L	Pyroglutamic acid	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	11	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.3 nM
2089	N.A.	2004	PyroGlu-LAGIGILTV	[pEI, Î±MeL8]-Melan-A	10	PyroGlutamic acid at 1st position	Free	Linear	L	Methylation of carboxyl of Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(0.02 nM); isomer2(3 nM)
2090	N.A.	2004	ALAGIGILTV	[Î²Al, amide] -Melan-A	10	Beta-Alanine1	Amidation	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	11	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.03 nM
2091	N.A.	2004	ALAGIGILTV	[Î²Al, Î±MeL8]-Melan-A	10	Beta-Alanine1	Free	Linear	L	Methylation of carboxyl of Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(0.02 nM); isomer2(0.06 nM)
2092	N.A.	2004	ELAGIGILTV	[Î²El, amide]-Melan-A	10	Beta-Glu1	Amidation	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	20	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.3 nM
2093	N.A.	2004	ELAGIGILTV	[Î²El, Î±MeL8]-Melan-A	10	Beta-Glu1	Free	Linear	L	Methylation of carboxyl of Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(0.3 nM); isomer2(0.015 nM)
2094	N.A.	2004	DLAGIGILTV	[Î²Dl, amide] -Melan-A	10	Beta-Asp1	Amidation	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	12	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 10 nM
2095	N.A.	2004	DLAGIGILTV	[Î²Dl, Î±MeL8]-Melan-A	10	Beta-Asp1	Free	Linear	L	Methylation of carboxyl of Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(0.2 nM); isomer2(0.02 nM)
2096	N.A.	2004	GLAGIGILTV	[NOHG1, amide]-Melan-A	10	Hydroxylation of N-terminal of Glycine	Amidation	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	13	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.04 nM
2097	N.A.	2004	GLAGIGILTV	[NOHG1, Î±MeL8]-Melan-A	10	Hydroxylation of N-terminal of Glycine	Free	Linear	L	Methylation of carboxyl of Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(0.15 nM); isomer2(30 nM)
2098	N.A.	2004	ELAGIGILTV	[Î±MeL2, Î±MeL8]-Melan-A	10	Free	Free	Linear	L	Methylation of carboxyl of Leu2 and Leu8	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= Not mentioned
2099	N.A.	2004	ELAGIGILTV	[Î±MeL2, V10-amide]-Melan-A	10	Free	Amidation	Linear	L	Methylation of carboxyl of Leu2	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	12	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= isomer1(2.5 nM); isomer2(0.1 nM)
2100	N.A.	2004	ELAGIGILTV	[Î±MeL2, NMeT9] -Melan-A	10	Free	Free	Linear	L	Methylation of carboxyl of Leu2 and amino-group of Thr9 used in peptide bond	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.5 nM
2101	N.A.	2004	ELAGIGILtV	[Î±MeL2, dT9]-Melan-A	10	Free	Free	Linear	Mix	Methylation of carboxyl of Leu2	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 10.5 nM
2102	N.A.	2004	Î²ALAGIGILTV	[Î²Al, Ïˆ8-9(CH2-NH)]-Melan-A	10	Beta-Alanine	Free	Linear	L	Reduced bond between Leu8 and Thr9	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	24	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.35 nM
2120	N.A.	2011	FVPIFTYGELQRQRVQQRK	Chimeric Motilin M	19	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	2.39	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2180	N.A.	2009	YGGFLRRIRPK	Modified Dynorphin (1-13)	13	Free	Addition of hydroxyl group	Linear	L	None	Dynorphin peptide	Endogenous opioid found in CNS	N.A.	4 mg/ ml	10	Not mentioned	LC/MS	plasma	in vitro	None	US 20090175821Al	Not mentioned
2181	N.A.	2009	YGGFLRRIRPK	Modified Dynorphin(1-13)	13	Free	Amidation	Linear	L	None	Dynorphin peptide	Endogenous opioid found in CNS	N.A.	4 mg/ ml	30	Not mentioned	LC/MS	plasma	in vitro	None	US 20090175821Al	Not mentioned
2182	N.A.	2013	VKFNKPFVFLMIEQNTK	SP16	13	Free	Free	Linear	L	None	Human alpha-1-antitrypsin	Anti-inflammatory and immune modulator peptide	N.A.	5 mg/ Kg	1.9	Rat blood proteases	LC-MS/MS	Rat plasma (Intravenous)	in vivo	None	WO2013106273A2	Not mentioned
2219	12954066	2003	ELYENKPRRPYIL	Neurotensin	13	Free	Free	Linear	L	None	Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	5.9 ±0.2	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2220	12954066	2003	ELYENKP-N3-Hlys-RPYIL	KK1	13	Free	Free	Linear	L	N₃-L-Hlys at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	153 ±4	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2221	12954066	2003	ELYENKP-N3-1d-RPYIL	KK2	13	Free	Free	Linear	L	N₃-1^d= COOH-CH(NH2)CH2-(CH2)3-CH2-NHMe at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	211 ±6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2222	12954066	2003	ELYENKP-N3-2-RPYIL	KK3	13	Free	Free	Linear	L	N₃-2= COOH-CH(NH2)CH2-(CH2)3-CH2-NMe₂at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	126 ±18	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2223	12954066	2003	ELYENKP-N3-3-RPYIL	KK4	13	Free	Free	Linear	L	N₃-3= COOH-CH(NH2)CH2-(CH2)3-CH2-NMe₂at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	103 ±10	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2224	12954066	2003	ELYENKP-N3-Lys-RPYIL	KK5	13	Free	Free	Linear	L	N₃-L-lys at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	136 ±6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2225	12954066	2003	ELYENKP-N3-4-RPYIL	KK6	13	Free	Free	Linear	L	N₃-4^d= COOH-CH(NH2)CH2-(CH2)3-CH2-NHMe at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	128 ±6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2226	12954066	2003	ELYENKP-N3-5-RPYIL	KK7	13	Free	Free	Linear	L	N₃-5^d= COOH-CH(NH2)CH2-(CH2)3-CH2-NMe₂ at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	127 ±2	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2227	12954066	2003	ELYENKP-N3-6-RPYIL	KK8	13	Free	Free	Linear	L	N₃-6^d= COOH-CH(NH2)CH2-(CH2)3-CH2-⁺NMe₃ at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	128 ±30	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2228	12954066	2003	ELYENKP-N3-Orn-RPYIL	KK9	13	Free	Free	Linear	L	N₃-L-Orn at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	134 ±27	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2229	12954066	2003	ELYENKP-N3-7-RPYIL	KK10	13	Free	Free	Linear	L	N₃-7^d= COOH-CH(NH2)CH2-(CH2)3-CH2-⁺NHMe at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	131 ±27	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2230	12954066	2003	ELYENKP-N3-8-RPYIL	KK11	13	Free	Free	Linear	L	N₃-8^d= COOH-CH(NH2)CH2-(CH2)3-CH2-Nme₂ at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	126 ±9	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2231	12954066	2003	ELYENKP-N3-9-RPYIL	KK12	13	Free	Free	Linear	L	N₃-9^d= COOH-CH(NH2)CH2-(CH2)3-CH2-⁺Nme₃ at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	216 ±33	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2232	12954066	2003	ELYENKP-N3-Hlys-RPY-tert-Leu-L	KK13	13	Free	Free	Linear	L	N₃-L-Hlys at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	>24	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2233	12954066	2003	ELYENKP-N3-Hlys-RPY-tert-Leu-L	KK14	13	Free	Free	Linear	L	N₃-L-Hlys at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	>24	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2234	12954066	2003	ELYENKP-N3-Arg-RPYIL	KK15	13	Free	Free	Linear	L	N₃-L-Arg at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	174 ±7	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2235	12954066	2003	ELYENKP-10-RPYIL	KK16	13	Free	Free	Linear	L	COOH-CH(NH2)-CH-CH-CH(NH)-C=NR(H2N) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	14.2 ±0.3	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2236	12954066	2003	ELYENKP-11-RPYIL	KK17	13	Free	Free	Linear	L	COOH-CH(H2N)CH-CH-CH(HN)-CH(imidazole) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	31.5 ±0.6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2237	12954066	2003	ELYENKP-12-RPYIL	KK18	13	Free	Free	Linear	L	COOH-CH(NH2)CH-CH-CH(N-CH-CH-NH-C=NH-CH) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	15.9 ±1.6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2238	12954066	2003	ELYENKP-13-RPYIL	KK19	13	Free	Free	Linear	L	COOH-CH(NH2)CH-CH-CH(N-CH-CH-NH-C=NH-CH) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	16.5 ±0.6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2239	14640680	2003	ICLKKWPWWPWRRCK	cycloCP-11	15	Free	Amidation	Cyclic (C2-C14)	L	None	Analogue of indolicidin	Antibacterial	0,5,10,20,40,60 minutes	50 µg/mL peptide and 0.2 µg/mL trypsin in 100 mM Tris buffer	18	Trypsin	HPLC and MALDI-TOF	cycloCP-11 in presence of trypsin	in vitro	None	None	MIC for E.coli=16 µg/ml
2240	14640680	2003	ILKKWPWWPWRRK	CP11	13	Free	Amidation	Linear	L	None	Indolicidin analogue	Antibacterial	0,5,10,20,40,60 minutes	50 µg/mL peptide and 0.2 µg/mL trypsin in 100 mM Tris buffer	4	Trypsin	HPLC and MALDI-TOF	CP-11 in presence of trypsin	in vitro	None	None	MIC for E.coli=8 µg/ml
2241	12220890	2002	CKAFSNSYPYDVPDYASL	Influenza hemagglutinin [(HA) 91 €“108] derivative	18	Acetylation	Amidation	Linear	L	None	Derivative of B-cell epitope hemagglutinin (HA) 91 €“108 from influenza	Modulate immune response	Not mentioned	1 mg/ml	2	Mice lung homogenate proteases	RP-HPLC	BALB/c mice lung homogenate	in vitro	None	None	IFN-y production in presence of peptide was measured. Splenocyte was collected after 12 days of immunization, cultured in presence / absence of Inactivated virus(500 HAU/well). Level of IFN-y in presence of virus is ~2500 pg/ml as measured by ELISA.
2242	12220890	2002	lsaydpvdypysnsfakc	Retro-inverso hemagglutinin [(HA) 91 €“108] derivative	18	Acetylation	Amidation	Linear	D	None	Derivative of B-cell epitope hemagglutinin (HA) 91 €“108 from influenza	Modulate immune response	Not mentioned	1 mg/ml	>24	Mice lung homogenate proteases	RP-HPLC	BALB/c mice lung homogenate	in vitro	None	None	IFN-y production in presence of peptide was measured. Splenocyte was collected after 12 days of immunization, cultured in presence / absence of Inactivated virus(500 HAU/well). Level of IFN-y in presence of virus is ~2500 pg/ml as measured by ELISA.
2274	4070016	1985	GGFMTSEKSQTPLVTL	DTÎ³E( Des-Tyr1-Î³-Endorphin) (Î²-endorphin-(2-17))	16	Free	Free	Linear	L	None	CNS and piyuitary gland of Humans	Neuropeptide, non-opioid y-type endorphins	Not given	3.1-7.1 µg	0.7 (distribution phase)	Rat blood proteases	RP-HPLC	Male wistar Rats (intravenously)	in vivo	None	None	Not reported
2275	4070016	1985	GGFMTSEKSQTPLVTL	DTÎ³E( Des-Tyr1-Î³-Endorphin) (Î²-endorphin-(2-17))	16	Free	Free	Linear	L	None	CNS and piyuitary gland of Humans	Neuropeptide, non-opioid y-type endorphins	Not given	3.1-7.1 µg	5.5 (elimination phase)	Rat blood proteases	RP-HPLC	Male wistar Rats (intravenously)	in vivo	None	None	Not reported
2276	4070016	1985	TSEKSQTPLVTL	DEÎ³E (Des-Enkephalin-Î³-Endorphin) (Î²-endorphin-(6--17))	12	Free	Free	Linear	L	None	CNS and piyuitary gland of Humans	Neuropeptide, non-opioid y-type endorphins	Not given	1.0-1.15 µg	0.6 (distribution phase)	Rat blood proteases	RP-HPLC	Male wistar Rats (intravenously)	in vivo	None	None	Not reported
2278	6127205	1982	AGCKNFFWKTFTSC	Somatostatin 14	14	Free	Free	Cyclic (C3-C14)	L	None	Ovine hypothalamus	Regulates the endocrine system and affects neurotransmission and cell proliferation	30-45 minute	10 µg	1.7 ±0.2	Dog blood proteases	SS Radioimmunoassay assay	Intravenous infusion in Dog plasma	in vivo	http://www.anaspec.com/products/product.asp?id=574	None	Radiolabelled peptide was administered in rats and blood plasma was taken and analysed by HPLC. Brain level of radioactivity increased with time.
2280	6128770	1982	AGCKNFFWKTFTSC	Somatostatin 14	14	Free	Free	Cyclic (C3-C14)	L	None	Ovine hypothalamus	Regulates the endocrine system and affects neurotransmission and cell proliferation	1 hour	1.7nmol	2.4	cat blood protease	Not mentioned	Intravenous infusion to cat plasma	in vivo	http://www.anaspec.com/products/product.asp?id=574	None	When 100ng of SS28 is injected there is 73% decreased portal venous blood flow as compared to basal blood flow.
2292	6291099	1982	DRDYMGWMDF	CCK10 (Cholecystokinin-10)	10	Free	Amidation	Linear	L	Sulphation of tyrosine residue at position 4	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	30	Human blood proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2293	6291099	1982	DRDYMGWMDF	CCK10 (Cholecystokinin-10)	10	Free	Amidation	Linear	L	Sulphation of tyrosine residue at position 4	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	45	Rat plasma protease	HPLC	Rat Plasma	in vitro	None	None	Not reported
2294	6344071	1983	MKAIFVLKGWWRTS	E.Coli leader peptide of tryptophan operon	14	Free	Free	Linear	L	None	E.coli trp operon	Regulatory peptide	Not given	Not mentioned	03-Apr	Cell-free (S-30) extracts prepared from E. coli strain W3110 trpR tnaA2 AtrpEA2 rna	Radioactivity decay assay (3H) .Leader peptide is radiolabelled and then decay in radioactivity is measured.	Not reported	in vitro	None	None	Not reported
2310	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	5 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	30 (radioactivity)	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2311	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	6 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	7 (radioactivity)	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2312	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	7 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	30 (radioactivity)	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2313	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	8 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	180 (radioactivity)	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2314	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	9 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	30	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	None	None	Not reported
2315	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	10 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	3.5	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	None	None	Not reported
2316	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	11 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	15	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	None	None	Not reported
2317	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	12 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	90	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	None	None	Not reported
2318	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	2 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	30 (radioactivity)	Nephrectomized rabbits blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of nephrectomized rabbits	in vivo	None	None	Not reported
2319	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	3 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	7 (radioactivity)	Nephrectomized rabbits blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of nephrectomized rabbits	in vivo	None	None	Not reported
2320	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	4 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	30	Nephrectomized rabbits blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of nephrectomized rabbits	in vivo	None	None	Not reported
2321	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	5 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	4	Nephrectomized rabbits blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of nephrectomized rabbits	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2363	9357069	1997	rPKPfQwFwLL	[D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P	11	Free	Amidation	Linear	Mix	None	Substance P	Neuropeptide growth factor antagonist	upto 360 minutes	12 µg/g body weight of mice	45.9 (terminal t1/2)	Mice blood proteases	RP-HPLC	Intraperitonial injection to Nu/Nu mice	in vivo	http://www.abcam.com/d-arg1d-phe5d-trp79leu11-subs	None	Not reported
2391	10973845	2000	NQEQVSPLTLLK	Alpha 2-antiplasmin peptide (Î±2AP13-24 )	12	Free	Free	Linear	L	Biotinylation at lysine residue(position 24)	Human SERPINF2 gene	Clotting factor	2 hours	0.5mMol/L	21	Mouse blood proteases	Not mentioned	Mouse blood fibrin clots	in vitro	None	None	Immunoblotting assay was done by taking 50 µL of fibrin clots with 2mg/ml of alpha2 AP and alpha2 AP peptide and cross linking was determined by electroblotting to PVDF membrane and detected by streptavidin-peroxidase.
2402	2147684	1990	AQDFVQWLMNT	Glucagon(19-29)	11	Free	Free	Linear	L	None	Glucagon derivative	Growth Hormone	Not mentioned	200pmol/2.5ml	<10	Hepatic plasma membrane proteases	Radioimmunoassay and HPLC	Hepatic plasma membrane	in vitro	None	None	Inhibit calcium pump at 20% concentration
2404	4572061	1972	pGlu-HWSTGLRPG	Luteinizing Hormone Releasing Hormone(LHRH)	10	Free	Amidation	Linear	L	pGlu=pyroglutamic acid, Tritium labeling	Gonadotropic cells in the anterior pituitary gland	Behavior influencing hormones	2 minutes	1 .0 Î¼Ci	6.97 ±0.4	Female Sprague Dawley rats blood protease	Radioimmunoassay	Intarvenous administration to Female Sprague Dawley rats	in vivo	None	None	LH-RH acts on the anterior pituitary to evoke the release of LH
2423	11778971	2001	AGCKNFFWKTFTSC	Glycosylated sms-14	14	Dextran 70kDa conjugation	Free	Cyclic (C3-C14)	L	Glycosylation	Somatostatin derivative	Growth Hormone	24 hours	100 Î¼l	27	Mice blood protease	HPLC	Subcutaneously injected in mice	in vivo	None	None	It inhibits tumor growth at IC50 ~2.5 nM
2444	7522585	1994	RwFWLMRPKPQQFFGLM	Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11)	17	Free	Free	Linear	Mix	Methylation of phenylalanine at 3rd position	Substance P (SP) analogue	Anticancer drugs	1, 2, 5 and 24 hours	0.1 Î¼g/ml	20.9	None	RP-HPLC and Electrochemical Detection	Water	in vitro	None	None	Act as growth factors
2445	7522585	1994	RwFWLMRPKPQQFFGLM	Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11)	17	Free	Free	Linear	Mix	Methylation of phenylalanine at 3rd position	Substance P (SP) analogue	Anticancer drugs	1, 2, 5 and 24 hours	0.1 Î¼g/ml	>24	None	RP-HPLC and Electrochemical Detection	Acetic acid	in vitro	None	None	Act as growth factors
2446	7522585	1994	RwFWLMRPKPQQFFGLM	Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11)	17	Free	Free	Linear	Mix	Methylation of phenylalanine at 3rd position	Substance P (SP) analogue	Anticancer drugs	1, 2, 5 and 24 hours	0.1 Î¼g/ml	4.4	Human plasma proteases	RP-HPLC and Electrochemical Detection	Human plasma	in vitro	None	None	Act as growth factors
2447	7522585	1994	RwFWLMRPKPQQFFGLM	Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11)	17	Free	Free	Linear	Mix	Methylation of phenylalanine at 3rd position	Substance P (SP) analogue	Anticancer drugs	1, 2, 5 and 24 hours	0.1 Î¼g/ml	14.6	Mouse liver proteases	RP-HPLC and Electrochemical Detection	Mouse liver homogenate	in vitro	None	None	Act as growth factors
2448	7522585	1994	RwFWLMRPKPQQFFGLM	Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11)	17	Free	Free	Linear	Mix	Methylation of phenylalanine at 3rd position	Substance P (SP) analogue	Anticancer drugs	1, 2, 5 and 24 hours	0.1 Î¼g/ml	22.8	SCLC proteases	RP-HPLC and Electrochemical Detection	Small cell lung cancer (SCLC)	in vitro	None	None	Act as growth factors
2449	7522585	1994	RwFWLMRPKPQQFFGLM	Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11)	17	Free	Free	Linear	Mix	Methylation of phenylalanine at 3rd position	Substance P (SP) analogue	Anticancer drugs	1, 2, 5 and 24 hours	10 Î¼g/ml	>24	SCLC proteases	RP-HPLC and Electrochemical Detection	Small cell lung cancer (SCLC)	in vitro	None	None	Act as growth factors
2452	7529108	1994	VNTPEHVVPYGLGSPRS	C-terminal fragment of Human Endothelin-1 (CTF)	17	Free	Free	Linear	L	None	Human Endothelin-1	Vasoconstricting peptide	180 minute	3 nmol of peptide with 200 ng of enzyme	57 (t1/2 of hydrolysis)	Endopeptidase-24.11(E-24.11)	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2455	7529108	1994	VNTPERVVPYGLGSPSRS	C-terminal fragment of Porcine Endothelin-1 (Porcine CTF)	18	Free	Free	Linear	L	None	Porcine Endothelin-1	Vasoconstricting peptide	80 minute	3 nmol of peptide with 50 ng of enzyme	47 (t1/2 of hydrolysis)	Thermolysin	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2456	7529108	1994	RPKPQQFFGLM	Substance P	11	Free	Free	Linear	L	None	Spinal cord	Vasoconstricting peptide	180 minute	3 nmol of peptide with 200 ng of enzyme	2.1 (t1/2 of hydrolysis)	Endopeptidase-24.11(E-24.11)	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	None	None	Not reported
2464	7991443	1994	YEPGKSSILQHERPVTKPQA	C-20 Sorbin	20	Free	Amidation	Linear	L	None	Derived from Sorbin	Electrolyte absorbing peptide	1, 2, 4, 8, 16, and 32 min	200 Î¼g/kg/h	9.5 ±1.8	Rat blood proteases	Radioimmunoassay	Male Sprague-Dawley rats blood	in vivo	None	None	Increases absorption of water and ions
2476	8353526	1993	YDPAPPPPPP	Trypsin modulating oostatic factor (TMOF)	10	Acetylation	Free	Linear	L	None	A. aegypti ovary	Growth regulatory peptide	Not mentioned	Not mentioned	1.6	Mosquito ovary endopeptidases	Radioimmunoassay	Ovaries of A. aegypti, Culex quinquefasciatus and Anopheles quadrimaculatus	in vivo	None	None	At concentrations of 3 x 10-9 M and 6.8 x 10-6 M, TMOF inhibited 50 and 90% of trypsin-like enzyme biosynthesis, respectively.
2481	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-1	17	Free	Free	Linear	L	None	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	42	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2482	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-2	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 1-2	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	67	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2483	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-3	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 3-4	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	43	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2484	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-4	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 4-5	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	100	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2485	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-5	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 5-6	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	>500	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2486	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-6	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 6-7	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	80	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2487	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-7	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 7-8	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	192	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2488	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-8	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 8-9	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	191	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2489	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-9	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 9-10	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	93	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2507	12852770	2003	pGlu-LYENKPRRPYIL	Neurotensin	13	Free	Free	Linear	L	Post translationaly modified Glu residue at first position	Bovine hypothalamus	Neuromodulator peptide	24 hour	50 Î¼g/well	1.5	Mice blood proteases	HPLC	NTR-positive HT29 tumor- bearing SCID mice	in vivo	None	None	IC50 value reported was 0.2 nM
2508	19767127	2011	VGDGGLFEKKL	Peptide 6	11	Acetylation	Amidation	Linear	L	None	Ciliary neurotrophic factor (CNTF)	Neurotrophic peptide	0, 15, 30, 60 and 120 min	5 Î¼g	>6	Rat blood proteases	LC/MS/MS	Sprague-Dawley Rat plasma	in vivo	None	None	Peptide 6 effectively inhibited the LIF-mediated signaling and ˆ¼50% inhibition of 10 pM LIF was achieved with 100 pM Peptide 6.
2521	17682073	2007	NQEEVSPYTLLKG	NC100668	13	Acetylation	Tc chelator (NC100194)	Linear	L	Tyr residue at 8 position is Iodionated	Cell penetrating peptides-Phosphorodiamidate morpholino oligomers	Tracer tested for nuclear medical imaging	1, 1.5, 3, 6, 12, and 24 hours	20, 100, 500, 1000, and 2000 Î¼g	1.2	Human plasma proteases	LC-MS	Injected in human plasma	in vivo	None	None	Not reported
2522	17682073	2007	NQEEVSPYTLLKG	NC100668	13	Acetylation	Tc chelator (NC100194)	Linear	L	Tyr residue at 8 position is Iodionated	Cell penetrating peptides-Phosphorodiamidate morpholino oligomers	Tracer tested for nuclear medical imaging	1, 1.5, 3, 6, 12, and 24 hours	20, 100, 500, 1000, and 2000 Î¼g	10.5 (terminal elimination)	Human plasma proteases	LC-MS	Injected in human plasma	in vivo	None	None	Not reported
2523	17704241	2007	EDYELMDLLAYLK	FROPDOTA	13	Free	lys coupled to the chelator DOTA (DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)	Linear	L	111In radiolabeling	Somatostatin receptor-binding octreotide	Tumor-Targeting Peptide	1, 2, 5, 15, 30, 60, and 120 min	200 Î¼l	71	Human serum proteases	Radioimmunoassay and RP-HPLC	Human serum	in vitro	None	None	The inhibition constant was 494 nM.
2527	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	10Î¼g/100g body wt	32 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Subcutaneous administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2528	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	1Î¼g/100g body wt	90.6 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Vaginal administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2529	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	10Î¼g/100g body wt	109.8 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Vaginal administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2530	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	100Î¼g/100g body wt	55.5 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Rectal administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2531	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	100Î¼g/100g body wt	43.7 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Nasal administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2542	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	5 Î¼g	2.6 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	No odification in the activity of ACTH analog-2 peptide
2543	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	7.32 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Showed higher potencies than Native ACTH in all the method tested
2544	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	9.6 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	The intravenous and intramuscular potencies of peptide V, Ibu1 ACTH (1-18) amide were 480-757U/mg, 4-5 times higher than the values for native hormone but subcutaneous potency was rather low (264U/mg) and in vitro potency was much lower (83U/mg) than the intravenous and intramuscular potencies.
2545	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 6	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	10.06 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Showed an activity about 2/3 of that of the original Lys15 peptides IV
2547	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	1.95 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2548	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	3.08 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2549	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	3.32 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2550	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 6	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	4.53 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2551	4327730	1971	Ibu-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 7	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	6 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity more than ACTH
2553	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	30 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 610-6mg/50mg tissue and rabbit = 0.410-6mg/50mg tissue)
2554	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	20 Î¼g	35.4 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 0.610-6mg/50mg tissue and rabbit = 0.0710-6mg/50mg tissue)
2555	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	20 Î¼g	32.43 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 0.210-6mg/50mg tissue and rabbit = 0.00210-6mg/50mg tissue)
2556	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 6	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	76.2 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Similar or higher activity in rat than in rabbit (rat = 0.410-6mg/50mg tissue and rabbit = 0.110-6mg/50mg tissue
2557	4327730	1971	Ibu-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 7	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	80.63 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Similar or higher activity in rat than in rabbit (rat = 0.0610-6mg/50mg tissue and rabbit = 0.510-6mg/50mg tissue
2558	4327730	1971	Î²Ala-YSMEHfRYGKPVGKKR-Orn	ACTH analogue- 8	18	Free	Amidation	Linear	Mix	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	88.12 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Similar or higher activity in rat than in rabbit (rat = 0.0710-6mg/50mg tissue and rabbit = 0.210-6mg/50mg tissue
2560	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	42.6 (lipolytic activity t1/2)	Rat muscle proteases	Not mentioned	Rat muscle slices	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 610-6mg/50mg tissue and rabbit = 0.410-6mg/50mg tissue)
2561	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	20 Î¼g	88.2 (lipolytic activity t1/2)	Rat muscle proteases	Not mentioned	Rat muscle slices	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 0.610-6mg/50mg tissue and rabbit = 0.0710-6mg/50mg tissue)
2562	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	20 Î¼g	122.88 (lipolytic activity t1/2)	Rat muscle proteases	Not mentioned	Rat muscle slices	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 0.210-6mg/50mg tissue and rabbit = 0.00210-6mg/50mg tissue)
2563	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 6	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	102.62 (lipolytic activity t1/2)	Rat muscle proteases	Not mentioned	Rat muscle slices	in vitro	4286483	None	Similar or higher activity in rat than in rabbit (rat = 0.410-6mg/50mg tissue and rabbit = 0.110-6mg/50mg tissue
2564	4327730	1971	Ibu-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 7	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	261.78 (lipolytic activity t1/2)	Rat muscle proteases	Not mentioned	Rat muscle slices	in vitro	4286483	None	Similar or higher activity in rat than in rabbit (rat = 0.0610-6mg/50mg tissue and rabbit = 0.510-6mg/50mg tissue
2595	16287259	2005	HHLGGAKQAGDV	H12 (Fibrinogen Î³ chain dodecapeptide)	12	Free	Free	Linear	L	conjugated with PEG	Derived from Fibrinogen gamma chain	Induce Thrombosis	Not mentioned	40mg/kg peptide infused	200 ±23	Proteases from (thrombocytopenic rats)plasma	Spectrofluorometer	Rat(thrombocytopenic)plasma	in vivo	None	None	10 mg/kg slightly reduced the Bleeding time to 573 ± 127 seconds in comparison control group 618 ± 51 seconds
2608	17408666	2007	PPPPPARPYSFGL	Cydiastatin 4-alpha	13	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	71	M. sexta larval midgut tissue extract proteases	RP-HPLC	Midgut tissues of M. sexta	in vitro	None	None	Not reported
2609	17408666	2007	PPPPPARPYSFGL	Cydiastatin 4-alpha	13	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	4.5	M. sexta larval midgut lumen proteases	RP-HPLC	Midgut lumen of M. sexta	in vitro	None	None	Not reported
2610	17408666	2007	PPPPPARPYSFGL	Cydiastatin 4-alpha	13	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	31 °C for 20 minutes	1nmol	52	M. sexta haemolymph proteases	RP-HPLC	Haemolymph of M. sexta	in vitro	None	None	Not reported
2611	17408666	2007	PPPPPARPYSF-(Acpc)	Cydiastatin 4-alpha	12	Free	Amidation	Linear	L	Acpc=cyclopropylalanine	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	116	M. sexta larval midgut tissue proteases	RP-HPLC	Midgut tissue	in vitro	None	None	Not reported
2612	17408666	2007	PPPPPARPYSF-(Acpc)	Cydiastatin 4-alpha	12	Free	Amidation	Linear	L	Acpc=cyclopropylalanine	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	7.5	M. sexta larval midgut lumen proteases	RP-HPLC	Midgut lumen	in vitro	None	None	Not reported
2625	17532097	2007	FGGFTGARKSARKLANQ	N/OFQ (Nociceptin/Orphanin FQ peptide receptor)	17	Free	Free	Linear	L	None	Derived from the prepronociceptin protein	NOP-Receptor ligands	37 °C for 240 min	6 Î¼g/Î¼l	64 ±1	Mouse plasma proteases	RP-HPLC	Mouse Plasma	in vitro	None	None	Hypotensive and bradycardic effects evoked by N/OFQ after i.v. administration in rats, was lasting (about 10 min)
2626	17532097	2007	FGGFTGARKSARKLANQ	N/OFQ (Nociceptin/Orphanin FQ peptide receptor)	17	Free	Free	Linear	L	None	Derived from the prepronociceptin protein	NOP-Receptor ligands	37 °C for 240 min	6 Î¼g/Î¼l	3.2 ±1.8	Mouse brain homogenate proteases	RP-HPLC	Mouse brain homogenate	in vitro	None	None	Hypotensive and bradycardic effects evoked by N/OFQ after i.v. administration in rats, was lasting (about 10 min)
2627	17532097	2007	FGG-(pF)F-TG-Aib-RKSARKRKNQ	UFP-112 (Nociceptin/Orphanin FQ receptor antagonist)	17	Free	Amidation	Linear	L	(pF)F = p-flouro Phenylalanine; Aib= 2-Aminoisobutyric acid	Synthetic	NOP-Receptor ligands	37 °C for 240 min	6 Î¼g/Î¼l	11.3 ±1.4	Mouse brain homogenate proteases	RP-HPLC	Mouse brain homogenate	in vitro	20497197	None	Hypotensive and bradycardic effects evoked by UFP-112 after i.v. administration in rats wast lasting for (i.e. 80 min
2628	17532097	2007	FGG-(pF)F-TG-Aib-RKSARKRKNQ	UFP-112 (Nociceptin/Orphanin FQ receptor antagonist)	17	Free	Amidation	Linear	L	(pF)F = p-flouro Phenylalanine; Aib= 2-Aminoisobutyric acid	Synthetic	NOP-Receptor ligands	37 °C for 240 min	6 Î¼g/Î¼l	167 ±9	Mouse plasma proteases	RP-HPLC	Mouse Plasma	in vitro	20497197	None	Hypotensive and bradycardic effects evoked by UFP-112 after i.v. administration in rats wast lasting for (i.e. 80 min
2629	17766836	2003	Pyr-Glu-LYENKPRRPYIL	Neurotensin (NT)	13	Free	Free	Linear	L	Pyr-Glu= pyro-glutamate	Neurotransmitter-like hypothalamic peptide	Regulates luteinizing hormone and prolactinrelease	37 °C for 2-24 hours	Not mentioned	<2	Human plasma proteases	HPLC-MS	Human plasma	in vivo	None	None	Tetra-branched NT(8-13)-methotrexate cause 60% reduction in tumor growth was observed with respect to mice treated with free drug
2637	19770015	2009	AEIYNKDGNKLDLYG	VrAPI (Aspartic protease inhibitor in seeds of V. radiata)	15	Free	Free	Linear	L	None	From plant Vigna radiata	Protease inhibitor	pH 2-10, Temp 20-100 °C	2mg -5mg at pH 3 and temperature 100	~30	None	Bradford assay	Buffer	in vitro	None	None	Total (aspartic protease) activity 2516 U
2638	21185160	2011	VDKPPYLPRPRPPRRIYNR	O-1(Oncocin)	19	Free	Amidation	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	68 ±15	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 8 Î¼g/mL M.luteus
2639	21185160	2011	VDKPPYLPRPRPPRRIYNR	O-1(Oncocin)	19	Free	Amidation	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	25 ±4	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 8 Î¼g/mL M.luteus
2640	21185160	2011	VDKPPYLPRPRPPRRIYN	O-2 (Oncocin)	18	Free	Free	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	120	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 64 Î¼g/mL in E.coli BL21A1 and 128 Î¼g/mL M.luteus
2641	21185160	2011	VDKPPYLPRPRPPRRIYNN	O-4 (Oncocin)	19	Free	Amidation	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	120	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC =16Î¼g/mL in E.coli BL21A1 and 64 Î¼g/mL M.luteus
2642	21185160	2011	VDKPPYLPRPRPPRRIYNH	O-5 (Oncocin)	19	Free	Amidation	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	90 ±1	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 16 Î¼g/mL in E.coli BL21A1 and 16 Î¼g/mL M.luteus
2643	21185160	2011	VDKPPYLPRPRPPRRIYN-Orn	O-6 (Oncocin)	19	Free	Amidation	Linear	L	Orn=Ornithine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	210 ±60	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and 16 Î¼g/mL M.luteus
2644	21185160	2011	VDKPPYLPRPRPPRRIYN-Agp	O-7 (Oncocin)	19	Free	Amidation	Linear	L	Agp = Î±-amino-3-guanidinopropionic acid	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	98 ±6	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and 8Î¼g/mL M.luteus
2645	21185160	2011	VDKPPYLPRPRPPRRIYN-Nir	O-8 (Oncocin)	19	Free	Amidation	Linear	L	Nir=Nitro-arginine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	78 ±2	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and 16 Î¼g/mL M.luteus
2646	21185160	2011	VDKPPYLPRPRPPRRIYN-Nmr	O-9 (Oncocin)	19	Free	Amidation	Linear	L	Nmr =N-methylarginine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	79 ±3	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2647	21185160	2011	VDKPPYLPRPRPPRRIYN-Har	O-10 (Oncocin)	19	Free	Amidation	Linear	L	Har=Homoarginine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	94 ±1	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and8 Î¼g/mL M.luteus
2648	21185160	2011	VDKPPYLPRPRPPRRIYNr	O-11 (Oncocin)	19	Free	Amidation	Linear	Mix	D-Arg at 19th position	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	160 ±5	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 4Î¼g/mL in E.coli BL21A1
2649	21185160	2011	VDKPPYLPRPRPPRRIYNR-NHpr	O-12 (Oncocin)	19	Free	Propylamidation	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	>120	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 8 Î¼g/mL M.luteus
2650	21185160	2011	VDKPPYLPRPRPPR-Orn-IYNR	O-14 (Oncocin)	19	Free	Amidation	Linear	L	orn =Ornithine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	90	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and 16 Î¼g/mL M.luteus
2651	21185160	2011	VDKPPYLPRPRPPR-beta-Hr-IYNR	O-15 (Oncocin)	19	Free	Amidation	Linear	L	Beta-Hr =Î²-homoarginine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	150	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 4Î¼g/mL in E.coli BL21A1 and 16 Î¼g/mL M.luteus
2652	21185160	2011	VDKPPYLPRPRPPRrIYNR	O-16 (Oncocin)	19	Free	Amidation	Linear	Mix	D-Arg at 15th position	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	58 ±2	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2653	21185160	2011	VDKPPYLPRPRPPR-Har-IYN-Har	O-17 (Oncocin)	19	Free	Amidation	Linear	L	Har=Homoarginine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	55	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2654	21185160	2011	VDKPPYLPRPRPPR-Har-IYN-Agp	O-18 (Oncocin)	19	Free	Amidation	Linear	L	Har=Homoarginine, Agp = Î±-amino-3-guanidinopropionic acid	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	62 ±4	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2655	21185160	2011	VDKPPYLPRPRPPR-Agp-IYN-Har	O-19 (Oncocin)	19	Free	Amidation	Linear	L	Har=Homoarginine, Agp = Î±-amino-3-guanidinopropionic acid	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	111 ±6	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 2 Î¼g/mL M.luteus
2656	21185160	2011	VDKPPYLPRPRPPR-Agp-IYN-Agp	O-20 (Oncocin)	19	Free	Amidation	Linear	L	Agp = Î±-amino-3-guanidinopropionic acid	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	171 ±20	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC =8 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2657	21185160	2011	VDKPPYLPRPRPPR-Orn-IYN-Har	O-21 (Oncocin)	19	Free	Amidation	Linear	L	Har=homoarginine, Orn=Ornithine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	75 ±1	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2658	21185160	2011	VDKPPYLPRPRPPR-Orn-IYN-Agp	O-22 (Oncocin)	19	Free	Amidation	Linear	L	Agp = Î±-amino-3-guanidinopropionic acid, Orn=Ornithine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	103 ±5	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2659	21185160	2011	VDKPPYLPRPRPPR-Orn-IYN-Orn	O-23(Oncocin)	19	Free	Amidation	Linear	L	Orn=Ornithine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	176 ±8	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 8 Î¼g/mL in E.coli BL21A1 and 8 Î¼g/mL M.luteus
2660	21185160	2011	VDKPPYLPRPRPPRrIYNr	O-24 (Oncocin)	19	Free	Amidation	Linear	Mix	D-Arg at 19th position	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	>480(79.6 ±0.2%)	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1
2661	21185160	2011	VDKPPYLPRPRPPR-Orn-IYNR	O-25 (Oncocin)	19	Free	Propylamidation	Linear	L	Orn=Ornithine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	102 ±2	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 8 Î¼g/mL M.luteus
2662	22186872	2011	DRVYIHPFHL	Angiotensin I	10	Free	Free	Linear	L	None	Derived from angiotensinogen	Precursor of angiotensin-II	Room Temperature	1mg/mL	1	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2666	22186872	2011	RPKPQQFFGLM	Substance P	11	Free	Amidation	Linear	L	None	Member of the tachykinin neuropeptide family.	Neurotransmitter	Room Temperature	1mg/mL	10	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2668	22186872	2011	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Neuropeptide secreted by Hypothalamus	Inhibits insulin and glucagon secretion.	Room Temperature	1mg/mL	10	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2709	25324697	2014	MIFVKTLTGKTIL	SHSMP(Sadat-Habdan Mesenchymal stimulating Peptide)	13	Free	Free	Linear	L	None	SHSMP(Sadat-Habdan Mesenchymal stimulating Peptide)	Angiogenesis Factor	Blood sample collected after 30-480 minutes after the infusion of peptide	5mg/kg	90	Rat plasma proteases	HPLC	Sprague Dawley rats (Dose i/m injected)	in vivo	Patent US7399826 B1	None	Not reported
2710	25894376	2015	PlLQAtLGGGS	P32 (Fibroblast growth factor 2- binding peptide derivative)	11	Free	Amidation	Linear	Mix	None	Fibroblast growth factor 2- binding peptide derivative	Anti-proliferative	37 °C for 1-48hours	0.3478Î¼M	12	Human plasma proteases	HPLC	Human plasma	in vitro	None	None	P32 significantly inhibited the proliferation of SGC-7901, MGC-803, and KATOIII cells induced with 20ng/ml of FGF2, and the IC50 values of P32 were 0.77, 1.69, and 1.09 Î¼mol/L, respectively
2768	26325323	2015	pGlu-HWSYGLRPG	Endogenous LHRH	10	Free	Amidation	Linear	L	Pyro-Glutamate at 1st position	Hypothalamus	Stimulates pitutiary gland to secretes to release gonadotropins(LH, FSH)	Blood sample collected after0.5-24 hours after the injection of peptide	2.5mg/Kg	4-8min	Human plasma proteases	LC/MS	Human plasma (Dose s/c injected)	in vivo	None	None	Not reported
2769	26325323	2015	p-Gln-HWSYwLRPG	Compound 1(lactose [Q1][w6]LHRH )	10	Lactose	Amidation	Linear	L	Lactose at N-ter, pyro-Glutamine at n-ter, D-Trp at 6 pos	Hypothalamus	Stimulates pitutiary gland to secretes to release gonadotropins(LH, FSH)	Blood sample collected after0.5-24 hours after the injection of peptide	2.5mg/Kg	2.9 ±0.63	Rat plasma proteases	LC/MS	Rat Plasma (Dose i/v injected)	in vivo	None	None	Increase in the level of LH was observed i.e. nAUC = 11.33 ± 1.65 ng/24 hafter oral administration of 20 mg/kg of compound 1 compared to the control nAUC = 4.45 ± 1.028 ng/24 h
2770	26325323	2015	p-Gln-HWSYwLRPG	Compound 1(lactose [Q1][w6]LHRH )	10	Lactose	Amidation	Linear	L	Lactose at N-ter, pyro-Glutamine at n-ter, D-Trp at 6 pos	Hypothalamus	Stimulates pitutiary gland to secretes to release gonadotropins(LH, FSH)	Blood sample collected after0.5-24 hours after the injection of peptide	10mg/Kg	2.6 ±0.84	Rat plasma proteases	LC/MS	Rat Plasma (Dose i/p injected)	in vivo	None	None	Increase in the level of LH was observed i.e. nAUC = 11.33 ± 1.65 ng/24 hafter oral administration of 20 mg/kg of compound 1 compared to the control nAUC = 4.45 ± 1.028 ng/24 h
2771	26337231	2015	LLTHTISRIAVSYQTKVNLL	P16 [TNF Î± (75 €“94)]	20	Free	Free	Linear	L	None	Tumor necrosis factor-derived (TNF)	Tumor growth inhibitor and anti-angiogenic	Blood sample collected after0.5-24 hours after the injection of peptide	5mg/kg	0.096 ±0.008	BALB/c mice plasma proteases	LC/MS	BALB/c mice plasma (Dose i/v injected)	in vivo	None	None	Growth inhibition effect of RMP16 was observed in DU145 cells (IC50 = 17.20 ± 1.95 nM, Tumor inhibition rates of P16-treated mice was 21.81%
2773	26400022	2015	fPRPGGGGQGDFEEIPEEYL	Hirulog-1	20	Free	Free	Linear	Mix	None	Hirudin derived	Anti-coagulant	Not mentioned	1.0Î¼M/Kg	20-25	Human plasma proteases	HPLC, MS-MS	Human plasma (Dose i/v injected)	in vivo	None	None	Inhibition constant for peptides (Ki, nM) in rat thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 20.50 ± 0.62nM; Inhibition constant for peptides (Ki, nM) in human thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 11.77 ± 0.09nM
2774	26400022	2015	fPRPGGGGQGDFEEIPEEYL	Hirulog-1	20	Free	Free	Linear	Mix	None	Hirudin derived	Anti-coagulant	Not mentioned	1.0Î¼M/Kg	15 ±1.3	Rat plasma proteases	HPLC, MS-MS	Sprague-Dawley (SD) rats plasma (Dose i/v injected)	in vivo	None	None	Inhibition constant for peptides (Ki, nM) in rat thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 20.50 ± 0.62nM; Inhibition constant for peptides (Ki, nM) in human thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 11.77 ± 0.09nM
2777	18632826	2008	CKQSCSFGPFTFVCDGNTK	99m Tc-Duramycin	19	Free	Free	Linear	L	Succinimidyl 6-hydrazinonicotinate acetone hydrazone (HYNIC) derivatized, HYNIC conjugated at either at Cys -1 or Amine group Of Lys-2	Phosphatidylethanolamine binding probe and employed in In Vivo Imaging of Acute Cardiac Cell Death	Molecular probe for imaging PtdE	Blood sample collected at 1-60 minutes	2.3nmol	<4	Rat blood proteases	HPLC radiodetection (radio-HPLC)	Healthy Sprague €“Dawley rats blood	in vivo	None	None	Binding of 99mTc-duramycin to apoptotic cells was elevated by a factor of 32 ± 6
2815	16266798	2005	k(Nic)-P-Pal-Pf(Cl2)-NwFwL-Nle	Spantide II (Neurokinin-1 receptor (NK-1R) antagonist)	11	Nicotinoylation	Amidation	Linear	Mix	Pal=3-(2-Pyridyl)-L-alanine , k(Nic)=Nicotinoyl)Lys , Nle=NorLeucine, Dichloro at 5th Phenyl	Neurokinin-1 receptor (NK-1R) antagonist	Anti-inflammatory	Not mentioned	5mg/ml	95 days at pH 3 at 60 C	None	HPLC, LC-MS	Ethanol -water mixture	in vitro	None	None	Not reported
2820	1329046	1992	Pyr-QRLGNQWAVGHLM	Bombesin	14	Free	Amidation	Linear	L	Pyr=Pyro-glutamine	Autocrine peptide of SCLC cell line	Growth stimulator	0-1080 minutes	50Î¼M	417	Degradative enzymes or SCLC cell line proteases	RP-HPLC	SCLC cell line NCI-H345	in vitro	None	None	IC50= 1nM, Peptide were added at a 1 Î¼M dose to inhibit growth of SCLC cell line
2821	1329046	1992	Pyr-QRLGNQWAVGHLL	[Psi13,14]BN [Bombesin antagonist]	14	Free	Amidation	Linear	L	Pyr=Pyro-glutamine	Bombesin analogue	Growth inhibitors	0-1080 minutes	50Î¼M	646	Degradative enzymes or SCLC cell line proteases	RP-HPLC	SCLC cell line NCI-H345	in vitro	None	None	IC50= 30nM, Peptide were added at a 1 Î¼M dose to inhibit growth of SCLC cell line
2832	1346149	1992	AGCKNFFWKTFTSC	SS-14 (Somatostatin-14)	14	Free	Free	Cyclic (C3-C14)	L	None	Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus.	Inhibitor of growth hormone release	37 °C for 30-180 minutes	50Î¼M	140.1 ±36.5 (Metabolic half life)	Brodmann Area tissues proteases	Radioimmunoassay	Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	in vitro	None	None	Not reported
2833	1346149	1992	AGCKNFFWKTFTSC	SS-14 (Somatostatin-14)	14	Free	Free	Cyclic (C3-C14)	L	None	Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus.	Inhibitor of growth hormone release	37 °C for 30-180 minutes	50Î¼M	129.8 ±53.2(Metabolic half life)	Hippucampul tissues proteases	Radioimmunoassay	Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	in vitro	None	None	Not reported
2834	1346149	1992	AGCKNFFWKTFTSC	SS-14 (Somatostatin-14)	14	Free	Free	Cyclic (C3-C14)	L	None	Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus.	Inhibitor of growth hormone release	37 °C for 30-180 minutes	50Î¼M	79.8 ±11.1(Metabolic half life)	Hippucampul tissues proteases	Radioimmunoassay	Posterior Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	in vitro	None	None	Not reported
2843	1723638	1991	GWTLNSAGYLLGPHAI	Galanin(1-16)	16	Free	Free	Linear	L	None	High affinity synthetic agonist	Neuroendocrine activities, stimulates growth hormone secretion	37 °C	2 Î¼M	28	Hypothalamic membrane protaeses	HPLC	Hypothalamic membranes of Male Sprague-Dawley rats	in vitro	None	None	Not reported
2872	2940625	1986	pyr-EHWSYwLRPG	[D-Trp6]-LHRH (Luteinizing hormone-releasing hormone)	10	Free	Amidation	Linear	Mix	Pyr=Pyro-glutamic acid	LHRH (Luteinizing hormone-releasing hormone) derivative	Release Luteinizing hormone	Blood collected 1-240 minutes after peptide infused	100 µg/ml	>10 (alpha t1/2)	Dog plasma proteases	HPLC	Two male Beagle dogs plasma (Dose s/c injected)	in vivo	None	None	Not reported
2873	2940625	1986	pyr-EHWSYwLRPG	[D-Trp6]-LHRH (Luteinizing hormone-releasing hormone)	10	Free	Amidation	Linear	Mix	Pyr=Pyro-glutamic acid	LHRH (Luteinizing hormone-releasing hormone) derivative	Release Luteinizing hormone	Blood collected 1-240 minutes after peptide infused	100 µg/ml	>84 (beta t1/2)	Dog plasma proteases	HPLC	Two male Beagle dogs plasma (Dose s/c injected)	in vivo	None	None	Not reported
2889	2970910	1988	pEHWSY{nnr:Nal}{d}LRPG{ct:Amid}	Naferlin	10	Free	Amidation	Linear	L	pE=Pyro-glutamate, D-alanin= 3-(2Naphthyl)-D-alanine	GnRH (Gonadotropin releasing hormone) agonist	It decreases pituitary secretion of the gonadotropins	Not mentioned	400 µg	2.3 ±0.2	Human serum proteases	Radioimmunoassay	Subcutaneous route of injection in human serum	in vivo	None	None	Not reported
2890	2970910	1988	pEHWSY-(D-Nal(2))LRPG	Naferlin	10	Free	Amidation	Linear	L	pE=Pyro-glutamate, D-alanin= 3-(2Naphthyl)-D-alanine	GnRH (Gonadotropin releasing hormone) agonist	It decreases pituitary secretion of the gonadotropins	Not mentioned	304 ± 2.2 µg	2.7 ±0.2	Human serum proteases	Radioimmunoassay	Nasal route of injection in human serum	in vivo	None	None	Not reported
2919	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	37 °C	40mg/ml	10.5	Proteases from Rat ovary tissues	Radioimmunoassay	Rat ovary tissues	in vitro	1631133	None	Not reported
2920	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	37 °C	40mg/ml	45	Proteases from Rat Lung tissues	Radioimmunoassay	Rat lung tissues	in vitro	1631133	None	Not reported
2921	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	2.66 (t1/2 alpha)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2922	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	12.16 (t1/2 beta)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2923	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	0.69 (t1/2 alpha)	Rat plasma proteases	Radioimmunoassay	(Dose i/m injected)Rat plasma	in vivo	1631133	None	Not reported
2924	1882091	1991	PGlu-HWSYfLRPG	D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	14.53	Rat plasma proteases	Radioimmunoassay	(Dose i/m injected)Rat plasma	in vivo	1631133	None	Not reported
2925	1882091	1991	PGlu-HWSYfLRPG	D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	0.83	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2926	1882091	1991	PGlu-HwSYfLRPG	D-Trp3-D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	25.8 (t1/2 beta)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2927	1882091	1991	PGlu-HwSYfLRPG	D-Trp3-D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	36.4	Rat plasma proteases	Radioimmunoassay	(Dose i/m injected)Rat plasma	in vivo	1631133	None	Not reported
2937	2298867	1990	D-Nal-FASKkLKPA	Antide(Nal-Lys)	10	Acetylation	Amidation	Linear	Mix	None	Nal-Lys GnRH antagonist	Regulates or inhibits LH release or gonadotropins	Blood collected upto 30 days after peptide injection	3.5mg/kg injected i/v	6.5	Proteases from OVX monkey serum	Radioactive assay	(Dose i/v injected)OVX monkey Serum	in vivo	None	None	Gonadotropin inhibition;Following sc or iv Antide injection, peripheral Luteinizing hormone (LH) levels declined from 281 + 19 ng/ml to 29 + 3 ng/ml within one day
2953	2868381	1986	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Growth hormone €“inhibiting hormone (GHIH)	Inhibitor of Growth hormone secretion	Blood sample collected after 10 minutes in 5 minutes interval, followed by 30 minutes thricely at 1	250 µg peptide infused	1.2-3.6	Proteases from plasma of healthy Human	Radioimmunoassay	Human plasma	in vivo	None	None	Not reported
2954	2868381	1986	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Growth hormone €“inhibiting hormone (GHIH)	Inhibitor of Growth hormone secretion	Blood sample collected after 10 minutes in 5 minutes interval, followed by 30 minutes thricely at 1	250 µg peptide infused	1.4-4.1	Proteases from plasma of Human patient (cirrhotic subjects)	Radioimmunoassay	Plasma of Human patient (cirrhotic subjects)	in vivo	None	None	Not reported
2960	2524034	1989	GGFMTSEKSQTPLVTL	[Leu5]Enkephalin	18	Free	Free	Linear	L	None	Somatostatin	Inhibitor of Growth hormone secretion	Not mentioned	Peptide 0.04 w/v in 154mM KCl	33 ±7	Proteases from rat rectal proteases	HPLC	Rat rectal lumen	in vitro	None	None	Not mentioned
2961	2524034	1989	GGFMTSEKSQTPLVTL	DE-gamma-E (Des-enkephalin-gamma-endorphin)	18	Free	Free	Linear	L	None	Neuroleptic peptide	Neuroregulator	Not mentioned	Peptide 0.04 w/v in 154mM KCl + 0.25% w/v Na2EDTA co-administeration	93 ±45	Proteases from rat rectal proteases	HPLC	Rat rectal lumen	in vitro	None	None	Not mentioned
2962	2524034	1989	GGFMTSEKSQTPLVTL	[3H-Lys9]DE-gamma-E	18	Free	Free	Linear	L	None	Neuroleptic peptide	Neuroregulator	Not mentioned	6 µg or 200uCi	1.2 ±0.6	Proteases from rat blood	HPLC	Rat blood	in vivo	None	None	Not mentioned
2963	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	9.2	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (2.5%)	in vitro	None	None	Not mentioned
2964	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	4	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (5%)	in vitro	None	None	Not mentioned
2965	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	1.9	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (10%)	in vitro	None	None	Not mentioned
2966	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	0.6	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (20%)	in vitro	None	None	Not mentioned
2967	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	44.6	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (2.5%) + converting enzyme inhibitor (MK422) with conc 10-6 M	in vitro	None	None	Not mentioned
2968	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	8.3	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (5%) + converting enzyme inhibitor (MK422) with conc 10-6 M	in vitro	None	None	Not mentioned
2969	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	4	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10-6 M	in vitro	None	None	Not mentioned
2970	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	1.2	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (20%) + converting enzyme inhibitor (MK422) with conc 10-6 M	in vitro	None	None	Not mentioned
2971	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	12.6	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (5%) + heat inactvation	in vitro	None	None	Not mentioned
2972	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	8.7	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (10%) + Heat inactivation	in vitro	None	None	Not mentioned
2973	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	9.9	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10-6 M + heat inactivation	in vitro	None	None	Not mentioned
2997	8353526	1993	YDPAPPPPPP	TMOF (Trypsin modulatinf oostatic factor)	10	Free	Free	Linear	L	None	Hormone is secreted from the ovary of Mosquitoes	Inhibitor of trypsin and chymotrypsin biosynthesis	Not mentioned	30ng/group	1.6	Proteases from A. aegypti blood	RP-HPLC	A. aegypti blood	in vivo	None	None	Not reported
3000	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 1 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	42	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3001	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 2 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	67	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3002	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 3 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	43	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3003	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 4 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	100	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3004	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 5 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	>500	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3005	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 6 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	80	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3006	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 7 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	192	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3007	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 8 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	191	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3008	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 9 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	93	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3032	16197609	2005	PGDSTRKCMDLKGNK	PCK3145 (Prostate secretory protein 94 derived peptide)	15	Free	Free	Linear	L	None	Prostate secretory protein 94 (PSP94) derivative	Anti cancer	Not mentioned	5-80mg/m2	Mean Elimination half life: 0.35-1.45 (Mean Elimination half life)	Proteases from Human plasma	Not mentioned	Human plamsa	in vivo	http://www.drugbank.ca/drugs/DB04985	None	Not reported
3033	20158487	2010	DRDYMGWMDF	PEG10kDa-[(123)I]-CCK-10	10	Free	Amidation	Linear	L	SO3H Group at Tyr-4, Coupled to PEG(10KDa), PEG=Polyethylene glycol, CCK-10=Cholecystokinin	Peptide Hormone produced by small intestine	Stimulates the digestion of fat and protein	Not mentioned	Not available	8 (Elimination half life t1/2 alpha)	Rat blood proteases	HPLC	Rat blood	in vivo	None	None	Not reported
3034	20158487	2010	DRDYMGWMDF	PEG10kDa-[(123)I]-CCK-10	10	Free	Amidation	Linear	L	SO3H Group at Tyr-4, Coupled to PEG(10KDa), PEG=Polyethylene glycol, CCK-10=Cholecystokinin	Peptide Hormone produced by small intestine	Stimulates the digestion of fat and protein	Not mentioned	Not available	15	Rat blood proteases	HPLC	Rat blood	in vivo	None	None	Not reported
3037	20221650	2010	NHHGRRRRRRRRRRR	R1(NH2GR11) (An arginine-rich cell permeable peptide)	15	Cu-DOTA (DOTA=1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid)	Free	Linear	L	Cu-labelled	Derived from prostate cancer cell lines, an arginine-rich cell permeable peptide	Cell permeable peptide	Not mentioned	Not available	10.7	Proteases from mouse blood	Fluorescence Imaging	Mouse blood	in vivo	None	None	In PC3, LNCaP, PZ-HPV-7, DU145 and DU145, FITC-NHGR11 displayed much higher uptake efficiency
3038	20221650	2010	NHHGRRRRRRRRRRR	R1(NH2GR11) (An arginine-rich cell permeable peptide)	15	Cu-DOTA (DOTA=1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid)	Free	Linear	L	Cu-labelled	Derived from prostate cancer cell lines, an arginine-rich cell permeable peptide	Cell permeable peptide	Not mentioned	Not available	17.2 (Elimination half life)	Proteases from mouse blood	Fluorescence Imaging	Mouse blood	in vivo	None	None	In PC3, LNCaP, PZ-HPV-7, DU145 and DU145, FITC-NHGR11 displayed much higher uptake efficiency
3044	6361234	1983	Pyr-QRLGNQWAVGHLM	Amphibian bombesin	14	Free	Amidation	Linear	L	Pyr=Pyro-glutamine	Skin of the frog Bombina bombina	Insulinotropic agent	Not reported	5 pmol/kg . min for 30 min and a volume of 1 ml/min.	3	Calf blood proteases	Radioimmunoassay	Arterial blood sample of pedigree jersey calves	in vivo	18185064	None	Not mentioned
3080	12083977	2002	pGlu-HWSYGLRPG	GnRH (Gonadotropin-releasing hormone)	10	PyroGlu=Pyroglutamic acid	Free	Linear	L	pGlu=pyroglutamic acid	Hypothalamic neurons	Regulating the synthesis and secretion of the gonadotropins luteinising hormone (LH) and follicle-stimulating hormone (FSH).	Not mentioned	Not mentioned	less than 15	Human plasma proteases	Radioimmunoassay	Human blood	in vivo	None	None	Not mentioned
3158	23099431	2012	HwAWfK	GHRP-6 (Growth Hormone-Releasing Peptide-6)	10	Free	Amidation	Linear	Mix	None	Synthetic molecule structurally related to Met-enkephalin	Cytoprotective,antioxidant in nature	Not mentioned	400 Î¼g/kg of the body weight	0.09 ±0.01(t1/2Î±)	human plasma proteases	LC-MS	Intravenous bolus administartion in 9 healthy male subjects	in vivo	http://www.drugbank.ca/drugs/DB00177	None	Not mentioned
3159	23099431	2012	HwAWfK	GHRP-6 (Growth Hormone-Releasing Peptide-6)	11	Free	Amidation	Linear	Mix	None	Synthetic molecule structurally related to Met-enkephalin	Cytoprotective,antioxidant in nature	Not mentioned	400 Î¼g/kg of the body weight	1.15 ±0.17(t1/2Î²)	human plasma proteases	LC-MS	Intravenous bolus administartion in 9 healthy male subjects	in vivo	http://www.drugbank.ca/drugs/DB00178	None	Not mentioned
3160	23196806	2012	YGRKKRRQRRR	TAMRA-TAT [5-(and-6)-carboxytetramethylrhodamine labeled HIV transactivator protein TAT]	11	5-(and-6)-carboxytetramethylrhodamine(TAMRA)	Free	Linear	L	None	HIV	Cell penetrating peptide	Not mentioned	60 Î¼g/g	6.7	Modified simulated intestinal fluid with pancreatic enzymes	HPLC with fluorescence detection	Modified simulated intestinal fluid	in vitro	http://www.drugbank.ca/drugs/DB00179	None	Fluorescence intensity (intestinal delivery)=4.0Ã—105 in Duodenum, 6.0Ã—105 in Jejunum, 4.0Ã—105 in Ileum, 1Ã—105 in Colon
3161	23196806	2012	YGRKKRRQRRR	TAMRA-TAT microemulsion	11	5-(and-6)-carboxytetramethylrhodamine(TAMRA)	Free	Linear	L	None	HIV	Cell penetrating peptide	Not mentioned	Microemulsion composition: Miglyol 812/Capmul MCM/Tween 80/TAMRA-TAT solution at the weight ratio of	19.4	Modified simulated intestinal fluid with pancreatic enzymes	HPLC with fluorescence detection	Modified simulated intestinal fluid	in vitro	http://www.drugbank.ca/drugs/DB00180	None	Fluorescence I ntensity (intestinal delivery)< 1.0Ã—105 in Duodenum, Jejunum, Ileum, Colon
3162	23696181	2013	VDCFLSRPTEKT	Cx43MP (Connexin43 mimetic peptides)	12	Free	Free	Linear	L	None	Synthetic, matching amino acids 199-210 on the extracellular loop 2 of Cx43	Blocking Cx43 hemichannel mediated vascular leakage in case of retinal ischemia	Aliquots were collected at 0, 5, 30, 60, 120, and 240 min	500Î¼M	145.57 ±14.57	Bovine vitreous proteases	RP-HPLC	500 Î¼L of freshly collected bovine vitreous	in vitro	http://www.drugbank.ca/drugs/DB00181	None	Cell viability of NT2/ D1 cells at 100Î¼M of peptide= 90% approx. after 48 hours
3163	23696181	2013	VDCFLSRPTEKT	C12-Cx43 MP (Connexin43 mimetic peptide derivative)	12	C12-Laa	Free	Linear	L	None	Synthetic, matching amino acids 199-210 on the extracellular loop 2 of Cx43	Blocking Cx43 hemichannel mediated vascular leakage in case of retinal ischemia	Aliquots were collected at 0, 5, 30, 60, 120, and 240 min	500Î¼M	301.34 ±18.93	Bovine vitreous proteases	RP-HPLC	500 Î¼L of freshly collected bovine vitreous	in vitro	http://www.drugbank.ca/drugs/DB00182	None	Cell viability of NT2/ D1 cells at 100Î¼M of peptide= 85% approx. after 48 hours
3164	23696181	2013	VDCFLSRPTEKT	C12-C12-Cx43 MP (Connexin43 mimetic peptide derivative)	12	Two C12-Laa	Free	Linear	L	None	Synthetic, matching amino acids 199-210 on the extracellular loop 2 of Cx43	Blocking Cx43 hemichannel mediated vascular leakage in case of retinal ischemia	Aliquots were collected at 0, 5, 30, 60, 120, and 240 min	500Î¼M	353.39 ±13.63	Bovine vitreous proteases	RP-HPLC	500 Î¼L of freshly collected bovine vitreous	in vitro	http://www.drugbank.ca/drugs/DB00183	None	Cell viability of NT2/ D1 cells at 100Î¼M of peptide= 80% approx. after 48 hours
3165	23696181	2013	VDCFLSRPTEKT	GlcNS-Cx43 MP (Connexin43 mimetic peptide derivative)	12	N-Î²-D-glucosamine succinamic acid(GlcNS)	Free	Linear	L	None	Synthetic, matching amino acids 199-210 on the extracellular loop 2 of Cx43	Blocking Cx43 hemichannel mediated vascular leakage in case of retinal ischemia	Aliquots were collected at 0, 5, 30, 60, 120, and 240 min	500Î¼M	318.04 ±75.13	Bovine vitreous proteases	RP-HPLC	500 Î¼L of freshly collected bovine vitreous	in vitro	http://www.drugbank.ca/drugs/DB00184	None	Cell viability of NT2/ D1 cells at 100Î¼M of peptide= 85% approx. after 48 hours
3175	8100840	1993	AGCKNFFWKTFTSC	Somatostatin (SOM)	14	Free	Free	Cyclic (C3-C14)	L	None	Synthetic	Growth hormone inhibiting hormone (GHIH)	Not reported	Not reported	<5	Rats blood proteases	Not mentioned	Rats plasma	in vivo	http://www.drugbank.ca/drugs/DB00194	None	Not reported
4011	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides therapy for PV and Hemochromatosis	N.A.	1 mg	17.9 ± 2.1	Human plasma protease	HPLC-MS	Human plasma	In Vivo	None	None	N.A.
4012	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides therapy for PV and Hemochromatosis	N.A.	3 mg	21.3 ± 6.2	Human plasma protease	HPLC-MS	Human plasma	In Vivo	None	None	N.A.
4013	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides therapy for PV and Hemochromatosis	N.A.	10 mg	26.1 ± 7.0	Human plasma protease	HPLC-MS	Human plasma	In Vivo	None	None	N.A.
4014	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides therapy for PV and Hemochromatosis	N.A.	20 mg	35.4 ± 9.6	Human plasma protease	HPLC-MS	Human plasma	In Vivo	None	None	N.A.
4015	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides therapy for PV and Hemochromatosis	N.A.	40 mg	45.0 ± 13	Human plasma protease	HPLC-MS	Human plasma	In Vivo	None	None	N.A.
4016	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides therapy for PV and Hemochromatosis	N.A.	80 mg	52.5 ± 17	Human plasma protease	HPLC-MS	Human plasma	In Vivo	None	None	N.A.
4017	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides Therapy For Pv And Hemochromatosis	N.A.	40 mg	49.6 ± 18	Human Plasma Protease	high-performance liquidchromatography–tandem mass spectrometry method	Human plasma after 2 once weekly repeated dose	In Vivo	None	None	N.A.
4018	38785334	2024	IsoV-DTHFPCIKFEPRSKGCK	Rusfertide (PTG-300)	18	IsoV = Isovaeryl at position 1	Amidation	Cyclic(C7-C17 Disulfide Linkage)	L	Lys8 conjugation with palmitoyl-Glu(2)-OH	Synthetic	Provides Therapy For Pv And Hemochromatosis	N.A.	40 mg	36.1 ± 21	Human Plasma Protease	high-performance liquidchromatography–tandem mass spectrometry method	Human plasma after 2 once weekly repeated dose	In Vivo	None	None	N.A.
4032	38613996	2024	WRRRYRRWRRRRRWRRRPRR	vCPP2319	20	Free	Amidation	Linear	L	None	Synthetic	Anticancer	At different time points (0, 1, 5, 10, 30, 60, 120, and 360 min), 120 µL aliquots were collected and incubated with equal volume of 96% ethanol for 30 min at 4⁰C	1 mM	280.40 ± 59.20	Human serum protease	RP-HPLC	Human serum	In Vitro	None	None	IC50 = 4.00±1.03 for TNBC MDA-MB-231 Monolayer
4037	38555444	2024	CGSNKGAIIGLM	Aβ11/T80@CSs-TGC	12	Free	Linked with Chol using PEG2k linker	Linear	L	None	Synthetic	Treating intracranial infections caused by multidrug resistant Acinetobacter Baumannii	Blood samples were collected at predetermined time points (0.25, 0.5, 1, 2, 4, 6, and 8 h),	12.5 mg/kg	1.26 ± 0.21	SD rats plasma protease	HPLC	SD rats plasma	In Vivo	None	None	Both free TGC and Aβ11/T80@CSs-TGC displayed potent antimicrobial activity with a minimum inhibitory concentration of 2 μg/mL
4041	38493673	2024	ALWPPNLHAWVP	Peptide ALW	12	Free	Free	Linear	L	None	Synthetic	Alleviating Lupus Nephritis	N.A.	12.5 mg/kg	0.315 (Elimination Half Life)	Cd1 mice plasma protease	N.A.	CD1 mice plasma	In Vivo	None	None	KD(M) = 1.99*10-4 (Binding affinity of peptides to anti-dsDNA IgG3)
4174	37880318	2023	VAIALKAAHYHTHKE	L1	15	Acetylation	Free	Linear	L	None	Derived from calcitermin	Antimicrobial	37 °C	0.0001 M	>2	Human plasma protease	HPLC	Human plasma with 1 ml of ammonium acetate buffer (pH 7.4)	In Vitro	None	None	CFU = 40 ± 10 for 0.032 mg/mL peptide concentration (0.1 mL of microbial suspension after 24 hours of incubation at 37°C) (Effect of peptide derivatives on Candida albicans (ATCC 10231) proliferation)
4175	37880318	2023	VAIALKAAHYHTHKE	L2	15	Acetylation	Amidation	Linear	L	None	Derived from calcitermin	Antimicrobial	37 °C	0.0001 M	68	Human plasma protease	HPLC	Human plasma with 1 ml of ammonium acetate buffer (pH 7.4)	In Vitro	None	None	CFU = 211 ± 25 for 0.032 mg/mL peptide concentration (0.1 mL of microbial suspension after 24 hours of incubation at 37°C) (Effect of peptide derivatives on Candida albicans (ATCC 10231) proliferation)
4176	37880318	2023	VAIALKAAHYHTHKE	L3	15	Free	Amidation	Linear	L	None	Derived from calcitermin	Antimicrobial	37 °C	0.0001 M	20	Human plasma protease	HPLC	Human plasma with 1 ml of ammonium acetate buffer (pH 7.4)	In Vitro	None	None	CFU = 189 ± 23 for 0.032 mg/mL peptide concentration (0.1 mL of microbial suspension after 24 hours of incubation at 37°C) (Effect of peptide derivatives on Candida albicans (ATCC 10231) proliferation)
4177	37880318	2023	VAIALKAAHYHTHKE	Wild-type Calcitermin (WT)	15	Free	Free	Linear	L	None	C-terminal cleavage fragment of calgranulin C	Antimicrobial	37 °C	0.0001 M	18 ± 3	Human plasma protease	HPLC	Human plasma with 1 ml of ammonium acetate buffer (pH 7.4)	In Vitro	None	None	CFU = 28 ± 15 for 0.032 mg/mL peptide concentration (0.1 mL of microbial suspension after 24 hours of incubation at 37°C) (Effect of peptide derivatives on Candida albicans (ATCC 10231) proliferation)
4183	37835489	2023	QQTNWSLGGGSC	QQT*-IRDye800	12	QQT* conjugated with IRDye800 at C terminus using linker	Free	Linear	L	None	Synthetic	Used for in vivo imaging to identify premalignant Colorectal Lesions	RP-HPLC was performed at 0, 0.5, 1, 2, 4, 8, and 24 h	30 μM	3.6	APC mice serum protease	RP-HPLC	APC mice serum	In Vivo	None	None	Not mentioned
4192	37384895	2023	HRHTKQRHTALH	CLA-coated PTX-SPIONs@HRH	12	Free	Free	Linear	L	None	Synthetic	Antiangiogenic (used for targeted delivery of Paclitaxel in non-small cell lung carcinoma)	Mice were euthanized over 24 h at t = 0.5, 1, 4, 8, and 24 h	15.6 μg/mL	17.1	Mice Plasma Protease	HPLC	Mice plasma	In Vivo	None	None	The activity value for CLA-coated PTX-SPIONs@HRH at the maximal therapeutic concentration (100 μg/mL) resulted in 12.8% cell viability on A549 lung adenocarcinoma cells
4193	37384895	2023	HRHTKQRHTALH	CLA-coated PTX-SPIONs@HRH	12	Free	Free	Linear	L	None	Synthetic	Antiangiogenic (used for targeted delivery of Paclitaxel in non-small cell lung carcinoma)	Mice were euthanized over 24 h at t = 0.5, 1, 4, 8, and 24 h	15.6 μg/mL	17.1	Mice Plasma Protease	HPLC	Mice plasma	In Vivo	None	None	The activity value for CLA-coated PTX-SPIONs@HRH at the maximal therapeutic concentration (100 μg/mL) resulted in 12.8% cell viability on A549 lung adenocarcinoma cells
4194	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	164	Human plasma protease	Triple Quadrupole Mass spectrometry	Human plasma	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4195	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	82.5	SD rats plasma protease	Triple Quadrupole Mass spectrometry	SD rats plasma	In Vitro	None	None	Not mentioned
4196	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	54.6	Beagle dogs plasma protease	Triple Quadrupole Mass spectrometry	Beagle dogs plasma	In Vitro	None	None	Not mentioned
4197	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	52.7	Cynomolgus monkeys plasma protease	Triple Quadrupole Mass spectrometry	Cynomolgus monkeys plasma	In Vitro	None	None	Not mentioned
4198	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	5.68	CD-1 mouse plasma protease	Triple Quadrupole Mass spectrometry	CD-1 mouse plasma	In Vitro	None	None	Not mentioned
4199	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	120 minutes	2 μM	372	Gastric fluid protease	Triple Quadrupole Mass spectrometry	Simulated Gastric Fluid (SGF) at pH = 1.3	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4200	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	120 minutes	2 μM	2.72	Intestinal fluid protease	Triple Quadrupole Mass spectrometry	Simulated Intestinal Fluid (SIF) at pH = 5.5	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4201	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	120 minutes	2 μM	>120	N.A.	Triple Quadrupole Mass spectrometry	potassium phosphate buffers of pH 1.3 (acidic)	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4202	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	120 minutes	2 μM	>120	N.A.	Triple Quadrupole Mass spectrometry	potassium phosphate buffers of pH 5.5 (slightly acidic)	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4203	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	120 minutes	2 μM	433	N.A.	Triple Quadrupole Mass spectrometry	potassium phosphate buffers of pH 7.4 (basic)	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4204	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	32.5	CD-1 mouse Liver Microsomes protease	LC-MS/MS	CD-1 mouse Liver Microsomes	In Vitro	None	None	N.A.
4205	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	27.7	SD rats Liver Microsome Protease	LC-MS/MS	SD rats Liver Microsome	In Vitro	None	None	N.A.
4206	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	33	Beagle dogs Liver Microsome Protease	LC-MS/MS	Beagle dogs Liver Microsome	In Vitro	None	None	N.A.
4207	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	21.8	Cynomolgus monkeys Liver Microsome Protease	LC-MS/MS	Cynomolgus monkeys Liver microsome	In Vitro	None	None	N.A.
4208	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	20.3	Human Liver Microsome protease	LC-MS/MS	Human Liver Microsome	In Vitro	None	None	N.A.
4209	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	<15	CD-1 mouse Hepatocytes Lysate Protease	LC-MS/MS	CD-1 mouse Hepatocytes Lysate	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4210	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.81	SD rats Hepatocytes Lysates protease	LC-MS/MS	SD rats hepatocytes Lysates	In Vitro	None	None	N.A.
4211	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	10.7	Beagle dogs Hepatocytes Lysates protease	LC-MS/MS	Beagle dogs Hepatocytes Lysates	In Vitro	None	None	N.A.
4212	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	12.1	Cynomolgus monkeys Hepatocytes Lysates protease	LC-MS/MS	Cynomolgus monkeys Hepatocytes Lysates	In Vitro	None	None	N.A.
4213	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.28	Human Hepatocytes Lysates protease	LC-MS/MS	Human Hepatocytes	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4214	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.28	Human Hepatocytes Lysates protease	LC-MS/MS	Human Hepatocytes Lysates	In Vitro	None	None	Enzyme Activity = 3.18 at 2 microMolar of HM1010 (Cytochrome P450 (CYP2B6) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4215	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.28	Human Hepatocytes Lysates protease	LC-MS/MS	Human Hepatocytes Lysates	In Vitro	None	None	Enzyme Activity = 2.06 at 2 microMolar of HM1010 (Cytochrome P450 (CYP3A4) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4216	37094132	2023	GQWHCTTSFPHHYCLY-Bip	SNIO–CBP	16	Single nanometer iron oxide and PEG conjugation at N terminal	Amidation	Cyclic (C5-C14 Disulfide Bond)	L	None	SINO-CBP product	Used in detection of Liver Fibrosis	N.A.	2 nmol/g animal	5.7 ± 1.9 (Elimination Half Life)	Mice blood protease	Dynamic T1-weighted MRI	Mice blood	In Vivo	None	None	Kd = 18.4 µM (Binding affinity of SNIO–CBP toward human type I collagen)
4217	37073494	2023	pGlu-LTPTPNW(Man)GT	Carmo‐HrTH‐I	10	pGlu = Pyroglutamate	Amidation	Linear	L	C‐mannosylated tryptophan residue at position 8	Derived from the corpora cardiaca (CC) of the Indian stick insect Carausius morosus	Hypertrehalosemia In Ligated Stick Insects	0, 2‐, 5‐, 10‐and 30 min at Room temp	100 pmol	5	C.Morosus hemolymph protease	HPLC	C.Morosus hemolymph	In Vitro	None	None	[Lipid]T0 min(µg/µL) = 9.32 ± 1.59 for Natural Carmo‐HrTH‐I (10 pmol) (Biological activity of a crude methanolic extract of corpora cardiaca (CC) from the natural hypertrehalosemic hormones (HrTHs) extracted from the CC of the Indian stick insect(Carausius morosus) in an in vivo bioassay withL. migratoria)
4241	36902021	2023	RNWELRLK-(PEG)4-RNWELRLK-(PEG)4	PDC	16	Free	PEG4 spacer was designed and subsequently reacted with a cysteine at the carboxyl terminus then, the elongated thiol-modified homodimer peptide was conjugated with DOX	Linear	L	None	HER2-targeting peptide–DOX conjugate	Antitumor	The PDC was incubated with human plasma (final peptide concentration of 50 μM) for 0, 2, 4, 8, 12, 24, and 48 h	50 μM	24	Human plasma protease	HPLC	Human plasma	In Vitro	None	None	The IC50 value for the PDC (Peptide-Drug Conjugate) is 140 nM. This value indicates that the PDC is more potent in killing HER2-positive SKBR-3 cells compared to free DOX, which has an IC50 of 410 nM
4250	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	(Onc72 in 19% MHB2 medium) MIC = 12.5 μmol L−1 (29 mg L−1) on E.coli BW25113
4251	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	(Onc72 in 25% mouse serum ) MIC = 25 μmol L−1 (58 mg L−1) on E.coli BW25113
4252	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	Onc72 Showed negligible hemolytic activity (below 0.2%) up to the highest tested concentration (50 μmol L−1), similar to the negative control (PBS)
4253	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	Onc72: Non-toxic to human HepG2 and HEK293 cell lines at 50 μmol L−1
4260	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Synthetic	Antimicrobial	Aliquots weretaken in triplicates after 0, 1, 2, 4, and 8 h for Onc72 and 0, 4, 8, and 24 hfor both prodrugs	31.5 μmol/L	≈80	Cell lysate protease (Obtained From An E. Coli Bw25113 Culture)	RP-HPLC	E. coli BW25113 cell lysate	In Vitro	None	None	(Onc72 in 19% MHB2 medium) MIC = 12.5 μmol L−1 (29 mg L−1) on E.coli BW25113
4272	36509220	2023	KLLKINLKALAALAKKIL	KM8	18	Free	Amidation	Linear	L	None	Analogue of Mastoparan	Antitumor	N.A.	N.A.	30	Mouse plasma protease	Plasma stability assay	Mouse plasma	In Vivo	None	None	N.A.
4304	N.A.	2023	GFCRCLCRRGVCRCIC	RTD-1	16	Free	Free	Linear	L	None	Theta Defensin	Antimicrobial	Blood samples were collected at 0.25, 1, 2, 4, 8, and 24 H post-dose via terminal cardiac puncture	5 mg/kg	6.05 (Elimination Half Life)	Mouse plasma protease	LC-MS with reverse phase liquid chromatography	Mouse plasma	In Vivo	None	US 2022/0048569 W	Administering an effective amount of the effective 9-defensin or the effective 0-dcfcnsin analog to the individual in need of treatment, wherein the effective amount provides antimicrobial activity directed to the microbe
4395	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration	20 μg/kg	15.2	SD rats plasma protease	LC-MS/MS	SD rats plasma	In Vivo	None	None	N.A.
4396	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	18.5	SD rats plasma protease	LC-MS/MS	SD rats plasma dosed with BPC once a day for seven consecutive days	In Vivo	None	None	N.A.
4397	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration	20 μg/kg	7.87	SD rats plasma protease	LC-MS/MS	SD rats plasma	In Vivo	None	None	N.A.
4398	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	17.1	SD rats plasma protease	LC-MS/MS	SD rats plasma dosed with BPC once a day for seven consecutive days	In Vivo	None	None	N.A.
4399	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration	500 μg/kg	29.7	SD rats plasma protease	LC-MS/MS	SD rats plasma	In Vivo	None	None	N.A.
4400	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	6 μg/kg	5.27 ± 2.25	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4401	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	30 μg/kg	19.6 ± 3.72	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma with repeated dose of 30 μg/kg for seven consecutive days	In Vivo	None	None	N.A.
4402	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	6 μg/kg	20.0 ± 5.53	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4403	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	30 μg/kg	25.5 ± 7.08	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4404	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	150 μg/kg	29.3 ± 5.06	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4405	36588717	2022	GEPPPPGKPADDAGLV	[3H]BPC157	15	Free	Free	Linear	L	all Proline radiolabelled with [3H]	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Whole blood and plasma samples of six JVC rats were collected at 0.05, 0.167, 0.5, 1, 2, 4, 8, 24, 48, and 72 h after administration (three males and three females at each time point) for the examination of radio pharmacokinetics of total plasma	100 µg/300 μCi/kg	102 ± 32	JVC rats plasma protease	Liquid scintillation counter	JVC Rats plasma	In Vivo	None	None	N.A.
4406	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	https://pmc.ncbi.nlm.nih.gov/articles/PMC7994712/	None	IC50(nM) = 1.7 (relative affinities of CST for the different Somatostatin receptor SSTR1)
4407	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.09 (relative affinities of CST for the different Somatostatin receptor SSTR2)
4408	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.3 (relative affinities of CST for the different Somatostatin receptor SSTR3)
4409	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.2 (relative affinities of CST for the different Somatostatin receptor SSTR4)
4410	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.3 (relative affinities of CST for the different Somatostatin receptor SSTR1)
4411	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 47.3 (relative affinities of A5 for the different Somatostatin receptor SSTR1)
4412	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 35 (relative affinities of A5 for the different Somatostatin receptor SSTR2)
4413	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 5.1 (relative affinities of A5 for the different Somatostatin receptor SSTR3)
4414	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 4.1 (relative affinities of A5 for the different Somatostatin receptor SSTR4)
4415	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 1.12 (relative affinities of A5 for the different Somatostatin receptor SSTR1)
4419	36499357	2022	ILRWSRKLPCVS	JM#21	12	Free	Free	Linear	L	Cysteine was introduced at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	1.7	Human plasma protease	Flow cytometry-based functional assay and mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4420	36499357	2022	IVRWSKKVPCVS	WSC02	12	Free	Free	Linear	L	Cysteine was introduced in the sequence of both peptides at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	0.7	Human plasma protease	Flow cytometry-based functional assay and mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4421	36499357	2022	ILRWSRKLPCVS	JM#21	12	Free	Free	Linear	L	Cysteine was introduced at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	7	Human plasma protease	Antibody-competition assay	Human plasma	In Vitro	None	None	N.A.
4422	36499357	2022	IVRWSKKVPCVS	WSC02	12	Free	Free	Linear	L	Cysteine was introduced in the sequence of both peptides at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	9	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4423	36499357	2022	IVRWSKKVPCVS	WSC02	12	Free	Free	Linear	L	Cysteine was introduced in the sequence of both peptides at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	6	Human plasma protease	Functional stability assay	Human plasma after GuHCl + DTT treatment	In Vitro	None	None	N.A.
4424	36499357	2022	ILRWSRKLPCVS	JM#21	12	Free	Free	Linear	L	Cysteine was introduced at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	5	Human plasma protease	Mass spectrometry	Human plasma after GuHCl + DTT treatment	In Vitro	None	None	N.A.
4425	36499357	2022	IVRWSKKVPSVS	WSC02 (C10S)	12	Free	Free	Linear	L	Cys10 replaced by Ser10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	4	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4426	36499357	2022	IVRWSKKVPCVS	WSC02 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys10 residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	5	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4427	36499357	2022	ILRWSRKLPSVS	JM#21 (C10S)	12	Free	Free	Linear	L	Cys replaced by Ser	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	4	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4428	36499357	2022	ILRWSRKLPCVS	JM#21 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	3	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4429	36499357	2022	IVRWSKKVPCVS	WSC02 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	6	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4430	36499357	2022	IVRWSKKVPSVS	WSC02 (C10S)	12	Free	Free	Linear	L	Cys replaced by Ser	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	7	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4431	36499357	2022	ILRWSRKLPCVS	JM#21 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	3	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4432	36499357	2022	ILRWSRKLPSVS	JM#21 (C10S)	12	Free	Free	Linear	L	Cys replaced by Ser	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	4	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4493	36142749	2022	Dmt-kFFKKPFTL	PK20	10	Replacing tyrosine (Tyr) with 2,6-dimethyltyrosine (Dmt) at position 1	Free	Linear	Mix	D-amino acid residue (D-Lys) inserted at position 2	opioid–neurotensin hybrid peptide	Analgesic	37°C for 24 h	50 μg/mL	204.4	N.A.	LC-MS	1M HCl	In Vitro	None	None	Emax = 149.17% ± 2.9 for PK20 (intrinsic activity of the receptor)
4494	36142749	2022	Dmt-kFFKKPFTL	PK20	10	Replacing tyrosine (Tyr) with 2,6-dimethyltyrosine (Dmt) at position 1	Free	Linear	Mix	D-amino acid residue (D-Lys) inserted at position 2	opioid–neurotensin hybrid peptide	Analgesic	37°C for 24 h	50 μg/mL	11.36	N.A.	LC-MS	1M NaOH	In Vitro	None	None	EC50 = 79 nM (potency at mu opioid receptor)
4495	36142749	2022	Dmt-kFFKKPFIL	[Ile9]PK20	10	Replacing tyrosine (Tyr) with 2,6-dimethyltyrosine (Dmt) at position 1	Free	Linear	Mix	D-amino acid residue (D-Lys) inserted at position 2	PK20 derivative	Analgesic	37°C for 24 h	50 μg/mL	117.7	N.A.	LC-MS	1M HCl	In Vitro	None	None	Emax = 151.2% ± 74.5 for [Ile9]PK20 (intrinsic activity of the receptor)
4496	36142749	2022	Dmt-kFFKKPFIL	[Ile9]PK20	10	Replacing tyrosine (Tyr) with 2,6-dimethyltyrosine (Dmt) at position 1	Free	Linear	Mix	D-amino acid residue (D-Lys) inserted at position 2	PK20 derivative	Analgesic	37°C for 24 h	50 μg/mL	4.69	N.A.	LC-MS	1M NaOH	In Vitro	None	None	EC50 = 1244 nM (potency at mu opioid receptor)
4503	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	N.A.	1 mg/kg	1	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	KD(nM) = 2.9±1.1 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Mouse)
4504	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	N.A.	1 mg/kg	0.9	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	KD(nM) = 6.0±1.2 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Rat)
4505	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	N.A.	1.25 mg/kg	1.7	NHP plasma protease	LC-MS/MS	NHP plasma	In Vivo	None	None	KD(nM) = 6.3±1.3 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in NHP)
4506	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	>57.8	Human plasma protease	LC-MS/MS	Human plasma	In Vitro	None	None	KD(nM) = 2.5±1.3 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in human)
4507	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	>57.8	NHP plasma protease	LC-MS/MS	NHP plasma	In Vitro	None	None	KD(nM) = 6.3±1.3 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in NHP)
4508	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	60.7	Rats plasma protease	LC-MS/MS	Rats plasma	In Vitro	None	None	KD(nM) = 6.0±1.2 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Rat)
4509	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	2.3 - 4.4	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vitro	None	None	KD(nM) = 2.9±1.1 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Mouse)
4510	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	26.1	Human blood Protease	LC-MS/MS	Human blood sample	In Vitro	None	None	KD(nM) = 2.5±1.3 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in human)
4511	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	28.3	NHP blood protease	LC-MS/MS	NHP blood sample	In Vitro	None	None	KD(nM) = 6.3±1.3 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in NHP)
4512	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	8.5	Rats blood protease	LC-MS/MS	Rats blood sample	In Vitro	None	None	KD(nM) = 6.0±1.2 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Rat)
4513	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	24 hours	2 µM	5	Mouse blood protease	LC-MS/MS	Mouse blood sample	In Vitro	None	None	KD(nM) = 2.9±1.1 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Mouse)
4569	35779189	2022	WSGWSSCSRSCG	NX210	12	Free	Free	Linear	L	None	Derived from the subcommissural organ (SCO)-spondin	Treatment of Neurodegenerative Diseases	Blood PK samples (4 mL) for the analysis of NX210 via its metabolite NX210c were collected prior to dosing, immediately after bolus injection or termination of the infusion and at 5, 10, 15, 20, 25, 30, 70, 120, and 180 min after bolus injection or termination of infusion	2.5 mg/kg	13.3	Human plasma protease	HPLC–MS/MS	Human plasma	In Vivo	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965545/	None	N.A.
4570	35779189	2022	WSGWSSCSRSCG	NX210	12	Free	Free	Linear	L	None	Derived from the subcommissural organ (SCO)-spondin	Treatment of Neurodegenerative Diseases	Blood PK samples (4 mL) for the analysis of NX210 via its metabolite NX210c were collected prior to dosing, immediately after bolus injection or termination of the infusion and at 5, 10, 15, 20, 25, 30, 70, 120, and 180 min after bolus injection or termination of infusion	5 mg/kg	6.19	Human plasma protease	HPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4571	35779189	2022	WSGWSSCSRSCG	NX210	12	Free	Free	Linear	L	None	Derived from the subcommissural organ (SCO)-spondin	Treatment of Neurodegenerative Diseases	Blood PK samples (4 mL) for the analysis of NX210 via its metabolite NX210c were collected prior to dosing, immediately after bolus injection or termination of the infusion and at 5, 10, 15, 20, 25, 30, 70, 120, and 180 min after bolus injection or termination of infusion	10 mg/kg	20	Human plasma protease	HPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4604	35653695	2022	GCTRQYPCGKG	KLK5 inhibitor	11	Free	A short linker GKG was attached at C terminal and then ALbumin tag was linked with Lys via PEG2	Cyclic (C2-C8 Disulfide Bond)	L	None	Synthetic	Treatment for Netherton syndrome	N.A.	6.2 mg/kg	4.4 ± 0.3 (Terminal Half Life)	Mice plasma protease	HPLC analysis with fluorescence detection	Mice plasma	In Vivo	None	None	Ki(KLK5)(nM) = 1.2, Kd(albumin)(nM) = 119 (for KLK5(1)-tag)
4605	35653695	2022	PCLYLARCSGKG	KLK7 inhibitor	11	Free	A short linker GKG was attached at C terminal and then ALbumin tag was linked with Lys via PEG2	Cyclic (C2-C8 Disulfide Bond)	L	None	Synthetic	Treatment for Netherton syndrome	N.A.	6.2 mg/kg	6.2 ± 0.9 (Terminal Half Life)	Mice plasma protease	HPLC analysis with fluorescence detection	Mice plasma	In Vivo	None	None	Ki(KLK7)(nM) = 32, Kd(albumin)(nM) = 164 (for KLK7(1)-tag)
4606	35653695	2022	GCTRQYPCGKG	KLK5 inhibitor	11	Free	A short linker GKG was attached at C terminal and then ALbumin tag was linked with Lys via PEG2	Cyclic (C2-C8 Disulfide Bond)	L	None	Synthetic	Treatment for Netherton syndrome	N.A.	6.2 mg/kg	5.1 ± 0.7 (Terminal Half Life)	Mice plasma protease	HPLC analysis with fluorescence detection	Mice plasma	In Vivo	None	None	Ki(KLK5)(nM) = 1.2, Kd(albumin)(nM) = 119 (for KLK5(1)-tag)
4607	35653695	2022	GCTRQYPCGKG	KLK5 inhibitor	11	free	A short linker GKG was attached at C terminal and then ALbumin tag was linked with Lys via PEG2	Cyclic (C2-C8 Disulfide Bond)	L	None	Synthetic	Treatment for Netherton syndrome	N.A.	6.2 mg/kg	5.8 ± 0.4 (Terminal Half Life)	Mice plasma protease	HPLC analysis with fluorescence detection	Mice plasma	In Vivo	None	None	Ki(KLK5)(nM) = 1.2, Kd(albumin)(nM) = 119 (for KLK5(1)-tag)
4627	35414877	2022	MCFTHFHMLWPFC	B_1275.3	14	C18 diacid-gGlu-2xOEG	Amidation, FLAG tag	Cyclic	L	None	Synthetic	Targets GIP receptor	At selected time points samples were taken: 5, 15, 30, 60, 120, 210, 300 mins	1 μM	Stable	Human plasma protease	LC-MS	80% pooled human Li-heparin plasma	In Vitro	None	None	IC50(nM) = 159
4629	35414877	2022	ACFTHFDLLWPFC	B_1275.5	14	Acetylation	Free	Cyclic	L	None	Synthetic	Targets GIP receptor	At selected time points samples were taken: 5, 15, 30, 60, 120, 210, 300 mins	1 μM	Stable	Human plasma protease	LC-MS	80% pooled human Li-heparin plasma	In Vitro	None	None	IC50(nM) = 2300
4630	35414877	2022	ACFTHFDLLWPFC	B_1275.6	14	C18 diacid-gGlu-2xOEG	Free	Cyclic	L	None	Synthetic	Targets GIP receptor	At selected time points samples were taken: 5, 15, 30, 60, 120, 210, 300 mins	1 μM	Stable	Human plasma protease	LC-MS	80% pooled human Li-heparin plasma	In Vitro	None	None	IC50(nM) = 860
4636	35414877	2022	ACFTHFDLLWPFC	B_1275.5	14	Acetylation	Free	Cyclic	L	None	Synthetic	Targets GIP receptor	N.A.	2 μM	2.367 (Elimination half life)	Rats plasma protease	LC-MS	Rats plasma	In Vivo	None	None	IC50(nM) = 2300
4637	35414877	2022	ACFTHFDLLWPFC	B_1275.6	14	C18 diacid-gGlu-2xOEG	Free	Cyclic	L	None	Synthetic	Targets GIP receptor	N.A.	2 μM	250 (Elimination Half Life)	Rats plasma protease	LC-MS	Rats plasma	In Vivo	None	None	IC50(nM) = 860
4638	35359494	2022	EMRLSKFFRDFILQRKK	CSP1	17	Free	Free	Linear	L	None	Competence stimulating peptide	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	30	Trypsin	RP-HPLC	PBS solution	In Vitro	None	None	EC50(nM) = 10 for CSP1 against ComD1 receptor, EC50(nM) = 530 for CSP1 against ComD2 receptor
4639	35359494	2022	EMRLSKFFRDFILQRKK	CSP1	17	Free	Free	Linear	L	None	Competence stimulating peptide	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	1	Chymotrypsin	RP-HPLC	PBS solution	In Vitro	None	None	EC50(nM) = 10 for CSP1 against ComD1 receptor, EC50(nM) = 530 for CSP1 against ComD2 receptor
4640	35359494	2022	AMRLSK-Cha-FRDFILQRKK	CSP1-E1A/F7Cha	17	Free	Free	Linear	L	introduction of Cha = cyclohexylalanine residues at position 7,E1A substituitions	CSP1 analog	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	4	Trypsin	RP-HPLC	PBS solution	In Vitro	None	None	IC50(nM) = 36 for CSP1-E1A/F7Cha against ComD1 receptor
4641	35359494	2022	AMRLSK-Cha-FRDFILQRKK	CSP1-E1A/F7Cha	17	Free	Free	Linear	L	introduction of Cha = cyclohexylalanine residues at position 7	CSP1 analog	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	4	Chymotrypsin	RP-HPLC	PBS solution	In Vitro	None	None	IC50(nM) = 36 for CSP1-E1A/F7Cha against ComD1 receptor
4642	35359494	2022	EMRLSK-Cha-FRDF-Cha-LQRKK	CSP1-F7Cha/I12Cha	17	Free	Free	Linear	L	introduction of Cha residues at positions 7 and 12	CSP1 analog	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	3	Trypsin	RP-HPLC	PBS solution	In Vitro	None	None	EC50(nM) = 0.97 for CSP1-F7Cha/I12Cha against ComD1 receptor, EC50(nM) = 70 for CSP1-F7Cha/I12Cha against ComD2 receptor
4643	35359494	2022	EMRLSK-Cha-FRDF-Cha-LQRKK	CSP1-F7Cha/I12Cha	17	Free	Free	Linear	L	introduction of Cha residues at positions 7 and 12	CSP1 analog	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	6	Chymotrypsin	RP-HPLC	PBS solution	In Vitro	None	None	EC50(nM) = 0.97 for CSP1-F7Cha/I12Cha against ComD1 receptor, EC50(nM) = 70 for CSP1-F7Cha/I12Cha against ComD2 receptor
4663	35053417	2022	WRWRWRWRWRWRWRWRWK-βA	(WR)8WK(Glutaryl-Dox)βA]	19	Free	βAlanine at C terminal conjugation	Cyclic	L	An ester bond is utilized to attach Dox with a glutaryl linker	Synthetic	Treat Breast, Leukemia, and Lymphoma Malignancies	4 h at 37 °C	5 µM	∼6	Human Serum Protease	HPLC	25% Human serum	In Vitro	None	None	At 10 μM: 65% reduction in cell viability after 72 hours for SK-OV-3 Cells (antiproliferative activity values for the [(WR)8WKβA]-Dox conjugate ), At 10 μM: 19% cell viability after 72 hours for MDA-MB-231 Cells (antiproliferative activity values for the [(WR)8WKβA]-Dox conjugate ), At 10 μM: 77% reduction in cell viability after 72 hours for MCF-7 Cells (antiproliferative activity values for the [(WR)8WKβA]-Dox conjugate ), At 10 μM: 64% reduction in cell viability after 24 hours for MES-SA/MX2 Cells (DOX-resistant) Cells (antiproliferative activity values for the [(WR)8WKβA]-Dox conjugate )
4695	34217775	2022	vYC-Agp-DVGPFC-3Pal	FE 992325	10	D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Agp	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 30, 45, 60, 90, 120 min	0.3 mg/kg	21 ± 2	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 50 ± 5, Human(%Plasma Protein Binding) = 46 ± 4 for FE 992325
4696	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 40, 60, 90, 135, 180 min	0.2 mg/kg	25 ± 8	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4698	34217775	2022	vYC-Agp-DVGPFC-3Pal	FE 992325	10	D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Agp	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300 min	1 mg/kg	48 ± 11	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 50 ± 5, Human(%Plasma Protein Binding) = 46 ± 4 for FE 992325
4699	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 5, 10, 20, 40, 60, 90, 120, 180, 240, 300 min	0.6 mg/kg	23 ± 2	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4700	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 40, 60, 90, 135, 180 min	0.1 mg/kg	82 ± 9	Male göttingen minipigs plasma protease	LC-MS/MS	Male göttingen minipigs plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4701	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 5, 10, 20, 40, 60, 90, 120, 180, 240, 300 min	0.25 mg/kg	264 ± 80	Male göttingen minipigs plasma protease	LC-MS/MS	Male göttingen minipigs plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4702	34217775	2022	vYC-Agp-DVGPFC-3Pal	FE 992325	10	D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Agp	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 30, 45, 60, 90, 120 min	0.2 mg/kg	69 ± 7	Male cynomolgus monkeys plasma protease	LC-MS/MS	Male cynomolgus monkeys plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 50 ± 5, Human(%Plasma Protein Binding) = 46 ± 4 for FE 992325
4703	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 40, 60, 90, 135, 180 min	0.1 mg/kg	65 ± 5	Male cynomolgus monkeys plasma protease	LC-MS/MS	Male cynomolgus monkeys plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4704	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	18.5	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4705	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	20 μg/kg	7.87	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4706	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	17.1	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4707	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	500 μg/kg	29.7	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4708	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	6 μg/kg	5.27 ± 2.25	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4709	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	30 μg/kg	19.6 ± 3.72	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4710	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	6 μg/kg	20.0 ± 5.53	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4711	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	30 μg/kg	25.5 ± 7.08	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4712	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	150 μg/kg	29.3 ± 5.06	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4771	35177945	2022	RPRLSHKGPMPF	pE13F	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	7.2	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.56 ± 0.07
4772	35177945	2022	QRPRlS-Aib-Ka-P-Nle-P	P26	12	N-Acetylated Arg2	Free	Linear	Mix	D-Leu, D-ala = l and a, Proline side chain linked with (4Br-Phe) at C terminus	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	86	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 2.11 ± 0.40
4773	35177945	2022	KFRRQRPRLSHKGPMPF	K17F	17	Free	Free	Linear	L	None	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	4.6	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.06 ± 0.01
4774	35177945	2022	KFrRqRPRlS-Aib-kaP-Nle-P	P92	16	Lys1 acetylation	Free	Linear	Mix	D-Arg = r, D-Gln = q, D-Leu = l, D-ala = a, Proline side chain linked with (4Br-Phe) at C terminus	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	24	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.09 ± 0.02
4775	35177945	2022	KFRRQRPRLSHKGPMPF	LIT01-196	17	FC [CF3(CF2)7(CH2)2C(O)] conjugation at N terminal	Free	Linear	L	None	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	1440	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.08 ± 0.01
4776	35177945	2022	QRPRLSHKGPMPF	Apelin-13	13	Free	Free	Linear	L	None	Secreted by White Adipose Tissue (Wat) in both humans and animals	Antidiabetes, Anorexic Effects	N.A.	N.A.	2.1	Mouse plasma protease	RP-HPLC	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50 = 7.4 x 10⁻⁹ M
4777	35177945	2022	QRPRLSHKGPMPF	(Lys8GluPAL)apelin-13-amide	13	Free	Amidation	Linear	L	None	Apelin-13 Analogue	Antidiabetes, Anorexic Effects	N.A.	N.A.	>24	Mouse plasma protease	RP-HPLC	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50 = 1.2 x 10⁻¹⁰ M
4778	35177945	2022	QRPRLSHKGPMPY	Lys8GluPAL(Tyr13)apelin-13	13	Free	Tyr13 modifcation, carboxylation	Linear	L	None	Apelin-13 Analogue	Antidiabetes, Anorexic Effects	N.A.	N.A.	>24	Mouse plasma protease	RP-HPLC	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50 = 1.1 x 10⁻⁹ M
4779	35177945	2022	QRPRLSHKGPMPV	Lys8GluPAL(Val13)apelin-13	13	Free	Val13 modifcation, carboxylation	Linear	L	None	Apelin-13 Analogue	Antidiabetes, Anorexic Effects	N.A.	N.A.	>24	Mouse plasma protease	RP-HPLC	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50 = 2.2 x 10⁻¹⁰M
4780	35177945	2022	pGlu-RPRLSHKGPMPF	pGlu(Lys8GluPAL)apelin-13-amide	13	pGlu = Pyroglutamate	Amidation	Linear	L	None	Apelin-13 Analogue	Antidiabetes, Anorexic Effects	N.A.	N.A.	>24	Mouse plasma protease	RP-HPLC	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50 = 3.1 x 10⁻¹⁰M
4781	35177945	2022	QRPRLSHKGPMPY	Lys8GluPAL(Tyr13)apelin-13	13	Free	Tyr13 modifcation, carboxylation	Linear	L	I125 radioactive labeled	Apelin-13 Analogue	Antidiabetes, Anorexic Effects	Blood (20 microliter) collected at 0, 15, 30, 45, 60, 90, 120, 240, 480, 960 and 1440 min after injection	4.1 nmol/kg	2.5 - 3	NIH swiss mice plasma protease	RP-HPLC	NIH swiss mice plasma	In Vivo	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50 = 1.1 x 10⁻⁹ M
4782	35177945	2022	QRPRLSHKGPMPA	(Ala13)apelin-13	13	Free	Ala13 modifcation, carboxylation	Linear	L	None	Apelin-13 Analogue	Insulinotrophic activity	0, 2, 4, 8, 24 h	20 μg	10.3	Mouse plasma protease	RP-HPLC	Mouse plasma in the presence of 50 Mmol/L TEA-HCl Buffer	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50(M) = 1.74e-009 (In vitro insulin secretion)
4783	35177945	2022	pGlu-RPRLSHKGPMPF	(pGlu)apelin-13	13	pGlu = Pyroglutamate	Amidation	Linear	L	None	Apelin-13 Analogue	Insulinotrophic activity	0, 2, 4, 8, 24 h	20 μg	3.8	Mouse plasma protease	RP-HPLC	Mouse plasma in the presence of 50 Mmol/L TEA-HCl Buffer	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50(M) = 1.10e-008 (In vitro insulin secretion)
4784	35177945	2022	pGlu-RPRLSHKGPMPA	pGlu(Ala13)apelin-13	13	pGlu = Pyroglutamate	Ala13 modifcation, carboxylation	Linear	L	None	Apelin-13 Analogue	Insulinotrophic activity	0, 2, 4, 8, 24 h	20 μg	11.1	Mouse plasma protease	RP-HPLC	Mouse plasma in the presence of 50 Mmol/L TEA-HCl Buffer	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50(M) = 7.68e-009 (In vitro insulin secretion)
4785	35177945	2022	pGlu-RPRLSHKGPMPV	pGlu(Val13)apelin-13	13	pGlu = Pyroglutamate	Val13 modifcation, carboxylation	Linear	L	None	Apelin-13 Analogue	Insulinotrophic Activity	0, 2, 4, 8, 24 h	20 microgram	9.8	Mouse plasma protease	RP-HPLC	Mouse plasma in the presence of 50 Mmol/L TEA-HCl Buffer	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50(M) = 1.59e-008 (In vitro insulin secretion)
4786	35177945	2022	pGlu-RPRLSHKGPMPY	pGlu(Tyr13)apelin-13	13	pGlu = Pyroglutamate	Tyr13 modifcation, carboxylation	Linear	L	None	Apelin-13 Analogue	Insulinotrophic Activity	0, 2, 4, 8, 24 h	20 microgram	12.2	Mouse plasma protease	RP-HPLC	Mouse plasma in the presence of 50 Mmol/L TEA-HCl Buffer	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	EC50(M) = 1.48e-008 (In vitro insulin secretion)
4847	35036703	2021	CWRLRWHSPLKGM	[64Cu]CM-1	13	64Cu labeling	Free	Linear	L	None	Synthetic	PET Radiotracer For Cd133	1 hour	∼100 μCi	22.4 Of Intact [64Cu]Cm-1 Remained	Mouse serum protease	radio-HPLC	mouse serum	In Vitro	None	None	CM1 shows high binding affinity for CD133 (KD = 7.37 nM), 64Cu]CM-2 showed a binding affinity (IC50) of 44.95 nM, which is similar to that of [64Cu]CM-1 (IC50 = 52.55 nM)
4848	35036703	2021	CWRLRWHSPLKGM	[64Cu]CM-1	13	64Cu labeling	Free	Linear	L	None	Synthetic	PET Radiotracer For Cd133	2 hour	∼100 μCi	20.1% Of Intact [64Cu]Cm-1 Remained	Mouse serum protease	radio-HPLC	mouse serum	In Vitro	None	None	CM1 shows high binding affinity for CD133 (KD = 7.37 nM), 64Cu]CM-2 showed a binding affinity (IC50) of 44.95 nM, which is similar to that of [64Cu]CM-1 (IC50 = 52.55 nM)
4849	35036703	2021	CWRLRWHSPLKGM	[64Cu]CM-2	14	6-aminohexanoic acid (Ahx) linker is anchored between the N terminus of the peptide and the (DOTA) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid , 64Cu labeling	Free	Linear	L	None	Synthetic	PET Radiotracer For Cd133	1 hour	∼100 μCi	94.9 of intact tracers remained	Mouse serum protease	radio-HPLC	mouse serum	In Vitro	None	None	64Cu]CM-2 showed a binding affinity (IC50) of 44.95 nM, which is similar to that of [64Cu]CM-1 (IC50 = 52.55 nM)
4850	35036703	2021	CWRLRWHSPLKGM	[64Cu]CM-2	14	6-aminohexanoic acid (Ahx) linker is anchored between the N terminus of the peptide and the (DOTA) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid , 64Cu labeling	Free	Linear	L	None	Synthetic	PET Radiotracer For Cd133	2 hour	∼100 μCi	91.9% of intact tracers remained	Mouse serum protease	radio-HPLC	mouse serum	In Vitro	None	None	64Cu]CM-2 showed a binding affinity (IC50) of 44.95 nM, which is similar to that of [64Cu]CM-1 (IC50 = 52.55 nM)
4851	35011324	2021	SAVGRHGRRFGLRKHRKH	AWRK6	18	Free	Free	Linear	L	None	Based on the natural occurring peptide dybowskin-2CDYa	Antimicrobial	Blood samples were collected from orbital venous plexus at 0.083, 0.167, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 h	2.35 mg/kg	2.946 ± 2.048	SPF-grade male SD rats plasma protease	LC-MS/MS	SPF-grade male SD rats plasma	In Vivo	None	None	N.A.
4852	35011324	2021	SAVGRHGRRFGLRKHRKH	AWRK6	18	Free	Free	Linear	L	None	Based on the natural occurring peptide dybowskin-2CDYa	Antimicrobial	Blood samples were collected from orbital venous plexus at 0.083, 0.167, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 h	4.7 mg/kg	2.941 ± 1.399	SPF-grade male SD rats plasma protease	LC-MS/MS	SPF-grade male SD rats plasma	In Vivo	None	None	N.A.
4853	35011324	2021	SAVGRHGRRFGLRKHRKH	AWRK6	18	Free	Free	Linear	L	None	Based on the natural occurring peptide dybowskin-2CDYa	Antimicrobial	Blood samples were collected from orbital venous plexus at 0.083, 0.167, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 h	9.4 mg/kg	2.781 ± 1.021	SPF-grade male SD rats plasma protease	LC-MS/MS	SPF-grade male SD rats plasma	In Vivo	None	None	N.A.
4854	35011324	2021	SAVGRHGRRFGLRKHRKH	AWRK6	18	Free	Free	Linear	L	None	Based on the natural occurring peptide dybowskin-2CDYa	Antimicrobial	Blood samples were collected from orbital venous plexus at 0.083, 0.167, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 h	4.7 mg/kg	1.983 ± 0.583	SPF-grade male SD rats plasma protease	LC-MS/MS	SPF-grade male SD rats plasma	In Vivo	None	None	N.A.
4855	34859381	2021	pGlu-WNLNAAGYLLATHACG	M89b	17	pGlu = Pyroglutamate at position 1	Free	Linear	L	None	galanin analog	Interacts With Different G Protein-Coupled Receptors	>23 hours	10 µM	40% Of M89B Had Been Degraded	Rats serum protease	HPLC	Rats serum	In Vitro	None	None	EC50 ratios to Gal-(1-15)(n) = NA(3) (in GAL1R) (B-Arrestin), EC50 ratios to Gal-(1-15)(n) = NA(3) (in GAL1R) (Ca-efflux)
4856	34859381	2021	GWTLNSAGYLLGPHL	GAL-(1–15)	15	Free	Free	Linear	L	None	isolated from the porcine intestine	Interacts With Different G Protein-Coupled Receptors	>30 minutes	10 µM	80% Of Gal-(1–15) Was Degraded	Rats serum protease	HPLC	Rats serum	In Vitro	None	None	EC50 ratios to Gal-(1-15)(n) = 1.7(3) (in GAL2R) (B-Arrestin), EC50 ratios to Gal-(1-15)(n) = 1.4(3) (in GAL2R) (Ca-efflux)
4889	34661390	2021	VVGSPSAQDEASPLS	VVGS peptide	15	Free	Free	Linear	L	None	Synthetic	Targets tropoelastin	Aliquots (6 μL) taken after 0, 35, and 120 min	0.6 mM which is diluted in water at a final concentration of 0.06 mM when aliquoting	45	Pooled serum protease from human male AB plasma	RP-HPLC	50% pooled serum from human male AB plasma	In Vitro	None	None	KD (μM) = 41 ± 12 ( Interaction between Immobilized Human Recombinant Tropoelastin and Gd4TESMA)
4890	34661390	2021	KKK-Mal-CVVGSPSAQDEASPLS	Gd4-TESMA	19	Gd4	Free	Linear	L	Mal links KKK and other peptide	Synthetic	For imaging Atherosclerotic Plaque vulnerability	2 hours	0.6 mM which is diluted in water at a final concentration of 0.06 mM when aliquoting	No Degradation	Pooled serum protease from human male AB plasma	RP-HPLC	50% pooled serum from human male AB plasma	In Vitro	None	None	KD (μM) = 41 ± 12 ( Interaction between Immobilized Human Recombinant Tropoelastin and Gd4TESMA)
4907	34393794	2021	KFRRQRPRLSHLGPMPF	LIT01-196	17	Fluorocarbon chain (CF3(CF2)7(CH2)2C(O)) attached to the N-terminal part of K17F	Free	Linear	L	None	Apelin-17 Analog	Treatment of Hypertension	N.A.	15 nmol/kg	156	Rats plasma protease	RIA	Rats plasma	In Vivo	Pubchem CID Apelin: 56841713	None	IC50 = 0.56 ± 0.04 nmol/l for LIT01-196
4908	34393794	2021	KFRRQRPRLSHLGPMPF	K17F	17	Free	Free	Linear	L	None	Apelin-17 Analog	Treatment of Hypertension	N.A.	250 nmol/kg	50	Rats plasma protease	RIA	Rats plasma	In Vivo	Pubchem CID Apelin: 56841713	None	IC50: 0.11 ± 0.01 nmol/l for K17F
4909	34393794	2021	KFRRQRPRLSHLGPMPF	LIT01-196	17	Fluorocarbon chain (CF3(CF2)7(CH2)2C(O)) to the N-terminal part of K17F	Free	Linear	L	None	Apelin-17 Analog	Treatment of Hypertension	N.A.	900 nmol/kg	28	Rats plasma protease	RIA	Rats plasma	In Vivo	Pubchem CID Apelin: 56841713	None	IC50 = 0.56 ± 0.04 nmol/l for LIT01-196
4910	34358122	2021	GGGGDRVYIHPF	AT1-HSA-MRN-NPs	12	Free	HSA linked through PEG4	Linear	L	None	Synthetic	Treatment of Cardiovascular Disease	Blood was collected from the jugular vein at the following timepoints: 0, 5, 15, 30, 45, 60, 120, and 360 min	50 μg/kg	101.3	Rats plasma protease	HPLC	Rats plasma	In Vivo	None	None	N.A.
4917	34201398	2021	CAAKRRVRWIIWAAC	c-optP7	15	Free	Free	Cyclic(Cys1-Cys15)	L	All Alanine replaced by β-alanine	Synthetic	Antimicrobial	For 0, 0.5, 1, 3, 6, and 24 h at 37 °C	100 μM	9	Human serum protease	UPLC-MS	Human serum	In Vitro	None	None	MIC(µM) = 142 for Pseudomonas aeruginosa in growth media MH,MIC(µM) = 71 for E.coli in growth media MH,MIC(µM) > 142 for K. pneumoniae in growth media MH,MIC(µM) = ND for A. baumannii in growth media MH,MIC(µM) > 142 for VRE in growth media MH,MIC(µM) = 142 for MRSA in growth media MH
4919	34163352	2021	YHPYKEIEQLIELANYQVLS	OPT	20	Free	Free	Linear	L	None	Derived from the QKHPD-containing region of NCX1	Binds To Pser68-Plm	Aliquots of 50 μl were collected at different time points (0–48 h)	300 μM	0.86	Human serum protease	Mass spectrometry	Human serum	In Vitro	None	None	N.A.
4920	34163352	2021	NMP-YKEIEQLIELANYQV	NOPT	16	OPT substituted with an N-methyl proline at position 1	Free	Linear	L	None	Derived from OPT	Binds To Pser68-Plm	Aliquots of 50 μl were collected at different time points (0–48 h)	300 μM	14.9	Human serum protease	Mass spectrometry	Human serum	In Vitro	None	None	N.A.
4923	34122400	2021	RFGRFLRKIRRFRRKDVY	CbTP	18	Free	TP5 conjugation	Linear	L	None	A hybrid peptide combining TP5 and fragments of CATH2	Immunomodulatory	15 min at 37°C	10 µg/mL	353 ± 41.3	Human serum protease	HPLC	Human serum	In Vitro	None	None	CbTP induced cytotoxicity in a dose-dependent manner, while even a high dose (80 µg/mL) of CbTP was nontoxic to RAW264.7 cells
4932	33940058	2021	gqsehhmrvysf	OPBP-1	12	Free	Free	Linear	D	Substituition of A with Y at position 10	Derived from H12	Anticancer	Co-incubation of OPBP-1 with 10% human serum for 0 h, 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 32 h and 48 h.	8 mg/kg	0.33 ± 0.01	Male SD rats plasma protease	RP-HPLC	Male SD rats plasma	In Vivo	None	None	After 2 weeks of daily administration of 0.5 mg/kg OPBP-1, the tumor growth was significantly inhibited in CT26 and B16-OVA models.
4933	33940058	2021	gqsehhmrvysf	OPBP-1	12	Free	Free	Linear	D	Substituition of A with Y at position 10	Derived from H12	Anticancer	Co-incubation of OPBP-1 with 10% human serum for 0 h, 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 32 h and 48 h.	20 mg/kg	8.69 ± 1.19	Male SD rats plasma protease	RP-HPLC	Male SD rats plasma	In Vivo	None	None	After 2 weeks of daily administration of 0.5 mg/kg OPBP-1, the tumor growth was significantly inhibited in CT26 and B16-OVA models.
4934	33940058	2021	gqsehhmrvysf	OPBP-1@TMC	12	Free	Free	Linear	D	Substituition of A with Y at position 10	Derived from H12	Anticancer	Co-incubation of OPBP-1 with 10% human serum for 0 h, 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 32 h and 48 h.	20 mg/kg	14.55 ± 1.43	Male SD rats plasma protease	RP-HPLC	Male SD rats plasma	In Vivo	None	None	After 2 weeks of daily administration of 0.5 mg/kg OPBP-1, the tumor growth was significantly inhibited in CT26 and B16-OVA models.
5014	33129837	2021	VDKPPYLPRPRPIRrPGGr	OM19r-8	19	Free	Amidation	Linear	Mix	replacing L-Arg15,19 with D-Arg15,19	Derived from the antibacterial peptide OM19R	Antibacterial	Blood samples were collected in 1.5 mL capacity disposable tubes at 0.125, 0.25, 0.5, 0.75, 1, 5, 10, 15, 30, 45, 60 and 75min	1 mg/ml	1.632 ± 0.34 (Elimination Half Life)	Wistar rats blood protease	N.A.	Wistar rats blood sample	In Vivo	None	None	MIC(μM) = 1 for OM19r -8 in E. coli ATCC25922, OM19r-8 and 250 mPEG5-OM19r-8 showed no cytotoxicity at the concentration up to 32 µM, hemolytic activity of OM19r-8 and mPEG5-OM19r-8 was < 10% at the determined concentration (1-128 μM), which was obviously superior to the control peptide melittin
5015	33129837	2021	VDKPPYLPRPRPIRrPGGr	mPEG5- OM19r-8	19	mPEG5	Amidation	Linear	Mix	replacing L-Arg15,19 with D-Arg15,19	Derived from the antibacterial peptide OM19R	Antibacterial	Blood samples were collected in 1.5 mL capacity disposable tubes at 0.125, 0.25, 0.5, 0.75, 1, 5, 10, 15, 30, 45, 60 and 75min	1 mg/ml	28.09 ± 2.81 (Elimination Half Life)	Wistar rats blood protease	N.A.	Wistar rats blood sample	In Vivo	None	None	MIC(μM) = 1 for OM19r -8 in E. coli ATCC25922, OM19r-8 and 250 mPEG5-OM19r-8 showed no cytotoxicity at the concentration up to 32 µM, hemolytic activity of OM19r-8 and mPEG5-OM19r-8 was < 10% at the determined concentration (1-128 μM), which was obviously superior to the control peptide melittin
5016	33129837	2021	VDKPPYLPRPRPIRrPGGr	OM19r-8	19	Free	Amidation	Linear	Mix	replacing L-Arg15,19 with D-Arg15,19	Derived from the antibacterial peptide OM19R	Antibacterial	Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 175 and 270min	31.5 μmol/L	71.10 ± 3.43	Wistar rats blood plasma protease	HPLC	Wistar rats blood plasma	In Vitro	None	None	MIC(μM) = 1 for OM19r -8 in E. coli ATCC25922, OM19r-8 and 250 mPEG5-OM19r-8 showed no cytotoxicity at the concentration up to 32 µM, hemolytic activity of OM19r-8 and mPEG5-OM19r-8 was < 10% at the determined concentration (1-128 μM), which was obviously superior to the control peptide melittin
5017	33129837	2021	VDKPPYLPRPRPIRrPGGr	mPEG5- OM19r-8	19	mPEG5	Amidation	Linear	Mix	replacing L-Arg15,19 with D-Arg15,19	Derived from the antibacterial peptide OM19R	Antibacterial	Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 270, 300, 400, 600 and 1000min	31.5 μmol/L	242.44 ± 39.21	Wistar rats blood plasma protease	HPLC	Wistar rats blood plasma	In Vitro	None	None	MIC(μM) = 1 for OM19r -8 in E. coli ATCC25922, OM19r-8 and 250 mPEG5-OM19r-8 showed no cytotoxicity at the concentration up to 32 µM, hemolytic activity of OM19r-8 and mPEG5-OM19r-8 was < 10% at the determined concentration (1-128 μM), which was obviously superior to the control peptide melittin
5070	33008433	2020	HSQFIGYPITLFVEKER	Hypoxic-Ischemic Brain Damage Associated Peptide (HIBDAP)	17	Free	Free	Linear	L	None	derives from the 210st to 226st amino acids of HSP90AA1	Involved In The Nod-Like Receptor (Nlr) Signaling Pathway	N.A.	N.A.	3.5	Mammalian reticulocytes protease	N.A.	Mammalian reticulocytes with OGD ( oxygen and glucose deprivation (OGD))	In Vitro	None	None	N.A.
5087	32858124	2020	hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 3	16	Acetylation	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	0.362	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 1.95 ± 1.16
5088	32858124	2020	hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip{nt:C6-γGlu-OEG-OEG}	Cmpd# 6	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C6	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	2.31	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 2.31 ± 0.57
5089	32858124	2020	C13-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 10	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C13	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	3.4	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 6.22 ± 1.6
5090	32858124	2020	C15-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 12	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C15	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	1.84	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 4.39 ± 0.73
5091	32858124	2020	C17-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 14	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C17	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	2.18	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE =7.42 ± 0.9
5092	32858124	2020	(C6-diacid)-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 17	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C6 diacid	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	2.32	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 4.10 ± 0.62
5093	32858124	2020	(C18-diacid)-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 23	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C18-diacid	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	19.7	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 117 ± 23.3
5094	32858124	2020	C6-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 6	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C6	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.5 mg/kg	2.6	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 2.31 ± 0.57
5095	32858124	2020	C13-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 10	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C13	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.5 mg/kg	10.2	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 6.22 ± 1.6
5096	32858124	2020	C15-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 12	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C15	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.5 mg/kg	6.3	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 4.39 ± 0.73
5097	32858124	2020	C17-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 14	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C17	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.5 mg/kg	10.3	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE =7.42 ± 0.9
5098	32858124	2020	(C6-diacid)-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 17	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C6 diacid	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.5 mg/kg	4.1	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 4.10 ± 0.62
5099	32858124	2020	(C18-diacid)-γGlu-OEG-OEG-hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 23	16	Acetylation, N-terminus of apelin-13 linked via, liphophilic moiety pIPhe polypeptide spacer (-γGlu-OEG-OEG-) with C18-diacid	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.5 mg/kg	> 24	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 117 ± 23.3
5111	32812282	2020	SYSMEHFRWGKPVG	α-MSH	14	Free	Free	Linear	L	None	Deriving from the pro-opimelanocortin (POMC)	Stimulates The Production And Release Of Melanin By Melanocytes	4 ◦C for 15 min	40 μM	7.4	Human plasma protease	RP-HPLC	Human plasma	In Vitro	None	None	N.A.
5117	32781586	2020	AKRLKKLAKKIWKWK	TAMRA-HPA3NT3-A2	15	Free	Free	Linear	L	TAMRA labeled	HPA3NT3 analogue	Antimicrobial	Incubation times (0, 60, 120 min) at 37 °C	128, 64, 32, 16, 8, 4, 2, 1, and 0.5 µM	Degradation occured initially after 10 min	Human serum protease	HPLC	Human serum	In Vitro	None	None	Hemolysis % =0.3 for 250 micromolar (Toxicity of HPA3NT3 analogue peptide against RBCs)
5153	32506501	2020	SYSMEHFRWGKPVG	des-Ac-a-MSH	14	Free	Amidation	Linear	L	None	Derived from POMC	Antiinflammatory, Antipyretic	37 °C	2 µM	0.21	Human plasma protease	Glo-sensor transfected cell-based luminescence assay	Human plasma	In Vitro	None	None	EC50 (M) = 1.667E-09 for MC1R-des-Ac-a-MSH
5155	32506501	2020	YVMGHFRWDRFG	gamma2-MSH	12	Free	Amidation	Linear	L	None	Derived from POMC	Antiobesity	37 °C	2 µM	0.028	Human plasma protease	Glo-sensor transfected cell-based luminescence assay	Human plasma	In Vitro	None	None	EC50 (M) = 7.749E-10 for MC1R-g2-MSH
5157	32506501	2020	SYSMEHFRWGKPVG	des-Ac-a-MSH	14	Free	Amidation	Linear	L	None	Derived from POMC	Antiinflammatory, Antipyretic	37 °C	2 µM	32.06	Human plasma protease	Glo-sensor transfected cell-based luminescence assay	Human CSF	In Vitro	None	None	EC50 (M) = 1.667E-09 for MC1R-des-Ac-a-MSH
5159	32506501	2020	YVMGHFRWDRFG	gamma2-MSH	12	Free	Amidation	Linear	L	None	Derived from POMC	Antiobesity	37 °C	2 µM	1.44	Human CSF protease	Glo-sensor transfected cell-based luminescence assay	Human CSF	In Vitro	None	None	EC50 (M) = 7.749E-10 for MC1R-g2-MSH
5166	32380198	2020	RPRLSHKGPMPF	Apelin-12	12	Free	Free	Linear	L	None	Smallest fragment of a 77 amino acid prepropeptide	Cardioprotective Properties	N.A.	2-3 mg/ml	165 (Terminus Half Life)	Human blood plasma protease	1H-NMR	Human blood plasma	In Vitro	None	None	peptide M showed a significantly more pronounced effect in improving LV systolic function in Dox-induced cardiomyopathy compared to apelin-12 at a dose of 50 μg/kg
5179	32301996	2020	KLDLKLDLKLDLK	89Zr-NFP	13	mPEG2000, 89Zr labeling	Cy5.5 labelling	Linear	L	None	Synthetic	Diffuse intrinsic pontine glioma treatment	Mice were euthanized after 4 and 21 days for organ collection	20 μCi	60.3	Mice brain homogenize protease	Gamma counter	Mice brain homogenize	In Vivo	None	None	IC50 (nM) = 5.6 ± 0.4 for DM1 in SF8628
5184	32235388	2020	GCCSDPPCRNKHPDLC	TxIB	16	Free	Free	Linear	L	None	α-conotoxin derived from the venom of the cone snail species Conus textile	Blocks the Α6/Α3Β2Β3 Nicotinic Acetylcholine Receptors	Aliquots of each peptide were taken out at 0, 12, 24, 36, and 48 h.	100 μM	Stable	Male AB human serum protease	RP-UPLC	Male AB human serum	In Vitro	None	None	42% inhibition of α6β2* nAChRs by TxIB
5185	32235388	2020	GAAGGCCSDPPCRNKHPDLC	cTxIB-4	20	Linker	Free	Cyclic (C2-C8, C3-C16 Disulfide Bond And Linker-C16 Bond)	L	None	α-conotoxin TxIB analogue	Blocks the Α6/Α3Β2Β3 Nicotinic Acetylcholine Receptors	Aliquots of each peptide were taken out at 0, 12, 24, 36, and 48 h.	100 μM	Slightly lower stability than TXIB	Male AB human serum protease	RP-UPLC	Male AB human serum	In Vitro	None	None	Inhibition of cTxIB-4 is 35%
5234	31926774	2020	QHWSYLLRP	Leuprolide	10	Free	NHEt (Ethylamine)	Linear	L	None	Synthetic	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.43 ± 0.025	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The administration of same dose of PEGylated leuprolides also results in an initial testosterone surge. In addition, the extent of the testosterone surge is almost the same for all three peptides, either PEGylated or not
5235	31926774	2020	QHWSYLLRP	Leuprolide	10	Free	NHEt (Ethylamine)	Linear	L	None	(GnRH) agonist	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.43 ± 0.06	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The administration of same dose of PEGylated leuprolides also results in an initial testosterone surge. In addition, the extent of the testosterone surge is almost the same for all three peptides, either PEGylated or not
5236	31926774	2020	QHWSYLLRPX	PEG2K-LEU	10	Free	Free	Linear	L	PEGylation at His2	Derived from leuprolide	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.53 ± 0.032	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The weight of testis of the rats received unmodified leuprolide, PEG2K-LEU and PEG5K-LEU decreases to be ~57%, ~58%, and ~52% of the untreated group
5237	31926774	2020	QHWSYLLRPX	PEG2K-LEU	10	Free	Free	Linear	L	PEGylation at His2	Derived from leuprolide	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.59 ± 0.023	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The weight of testis of the rats received unmodified leuprolide, PEG2K-LEU and PEG5K-LEU decreases to be ~57%, ~58%, and ~52% of the untreated group
5238	31926774	2020	QHWSYLLRPX	PEG5K-LEU	10	Free	Free	Linear	L	PEGylation at His2	Derived from leuprolide	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	1.28 ± 0.64	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The weight of testis of the rats received unmodified leuprolide, PEG2K-LEU and PEG5K-LEU decreases to be ~57%, ~58%, and ~52% of the untreated group
5239	31926774	2020	QHWSYLLRPX	PEG5K-LEU	10	Free	Free	Linear	L	PEGylation at His2	Derived from leuprolide	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	1.51 ± 0.127	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The weight of testis of the rats received unmodified leuprolide, PEG2K-LEU and PEG5K-LEU decreases to be ~57%, ~58%, and ~52% of the untreated group
5242	31841696	2020	LSPPRYPGGGS	P9	11	Free	Amidation	Linear	L	None	Synthetic	Anticancer	37 °C for 5, 10, 20, 25, 30, 45 min	N.A.	19	Human plasma protease	HPLC	Human plasma	In Vitro	https://sci-hub.se/10.1007/s13277-015-3435-x	None	IC50 of P48 for Hela229 = 0.6 nM
5243	31841696	2020	SPPRYPGGGS	P48	10	Leucine reduction	Amidation	Linear	L	None	Generated with P9 degradation	Anticancer	1, 2, 3, 4, 5, 10, 12 h.	N.A.	4	Human plasma protease	HPLC	Human plasma	In Vitro	https://sci-hub.se/10.1007/s13277-015-3435-x	None	IC50 of P48 for Hela229 = 0.6 nM
5244	31809037	2020	LRKLRKRLLLRKLRKRLLC	ApoE-Ms-SF	19	Free	PEG-P(CL-DTC)	Linear	L	None	Synthetic	Targeted Delivery Of Sorafenib To Hepatocellular Carcinoma	At fixed time points, 75 μL of blood was taken from the ophthalmic vein into a heparinized tube	6 mg SF equiv/kg	6.8 (Elimination Half-Lives)	BALB/c mice plasma protease	HPLC	BALB/c mice plasma	In Vivo	None	None	IC50: 8.5 μg/mL for ApoE-MS-SF
5245	31786794	2020	GGGSGGGGSGGGGSA	DR10601	15	Free	IgG4 hinge-Fc fragment	Linear	L	None	Synthetic	Antiobesity, Antidiabetes	Blood samples were collected at 3, 8, 24, 36, 48, 72, 96, 120, 144 and 168 h after administration	16.3 nmol/kg	51.9 ± 12.2	SD rats serum protease	ELISA	SD rats serum	In Vivo	None	None	(EC50) value of DR10601 for GCGR was 37.39±3.95 nmol/L
5267	N.A.	2020	CSWPARCLHQDLC	Ac-(06-34-18) (wildtype)	12	Acetylation	Free	Linear	L	None	Synthetic	Targets plasma kallikrein	N.A.	5 uM	2.3	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 1.7
5268	N.A.	2020	CSWPA-hArg-CLHQDLC	Ac-(06-34-18) (HomoArg5)	12	Acetylation	Free	Linear	L	HomoArg6 replaces Arg (R)	Synthetic	Targets plasma kallikrein	N.A.	5 uM	10.7	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 64
5269	N.A.	2020	CSWPA-4GuanPhe-CLHQDLC	Ac-(06-34-18) ( 4GuanPhe5)	12	Acetylation	Free	Linear	L	4GuanPhe6 replaces Arg (R)	Synthetic	Targets plasma kallikrein	N.A.	5 uM	2.8	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 21
5270	N.A.	2020	CSWPA-NMeArg-CLHQDLC	Ac-(06-34-18) (NMeArg5)	12	Acetylation	Free	Linear	L	NMeArg6 replaces Arg (R)	Synthetic	Targets plasma kallikrein	N.A.	5 uM	>20	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 98
5271	N.A.	2020	CSW-Aze-A-hArg-CLHQDLC	Ac-(06-34-18) Aze3 (HomoArg5)	12	Acetylation	Free	Linear	L	Aze replaces Pro (P)at position 4 , HomoArg6 replaces Arg (R)	Synthetic	Targets plasma kallikrein	N.A.	5 uM	N.A.	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = NA
5272	N.A.	2020	CSW-Aze-A-4GuanPhe-CLHQDLC	Ac-(06-34-18) Aze3 (4GuanPhe5)	12	Acetylation	Free	Linear	L	Aze replaces Pro (P)at position 4 , 4GuanPhe6 replaces Arg (R)	Synthetic	Targets plasma kallikrein	N.A.	5 uM	N.A.	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = NA
5273	N.A.	2020	CSW-Aze-A-NMeArg-CLHQDLC	Ac-(06-34-18) Aze3 (NMeArg5)	12	Acetylation	Free	Linear	L	Aze replaces Pro (P)at position 4, NMeArg replaces Arg (R) at position 6	Synthetic	Targets plasma kallikrein	N.A.	5 uM	N.A.	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = NA
5274	N.A.	2020	CSFPYRCLHQDLC	Ac-(06-34-18) Phe2 Tyr4	12	Acetylation	Free	Linear	L	Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr	Synthetic	Targets plasma kallikrein	N.A.	5 uM	0.9	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 13.8
5275	N.A.	2020	CSFPY-hArg-CLHQDLC	Ac-(06-34-18) Phe2 Tyr4 HomoArg5	12	Acetylation	Free	Linear	L	HomoArg replaces Arg (R) at position 6,Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr	Synthetic	Targets plasma kallikrein	N.A.	5 uM	12.2	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 19.7
5276	N.A.	2020	CSFPY-4GuanPhe-CLHQDLC	Ac-(06-34-18) Phe2 Tyr4 4GuanPhe5	12	Acetylation	Free	Linear	L	4GuanPhe replaces Arg (R) at position 6,Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr	Synthetic	Targets plasma kallikrein	N.A.	5 uM	5	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 2.5
5277	N.A.	2020	CSFPY-NMeArg-CLHQDLC	Ac-(06-34-18) Phe2 Tyr4 NMeArg5	12	Acetylation	Free	Linear	L	NMeArg replaces Arg (R) at position 6,Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr	Synthetic	Targets plasma kallikrein	N.A.	5 uM	>20	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 60.2
5278	N.A.	2020	CSF-Aze-Y-hArg-CLHQDLC	Ac-(06-34-18) Phe2 Aze3 Tyr4 HomoArg5	12	Acetylation	Free	Linear	L	HomoArg replaces Arg (R) at position 6,Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr, Aze substituitons at position 4	Synthetic	Targets plasma kallikrein	N.A.	5 uM	N.A.	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = NA
5279	N.A.	2020	CSF-Aze-Y-4GuanPhe-CLHQDLC	Ac-(06-34-18) Phe2 Aze3Tyr4 4GuanPhe5	12	Acetylation	Free	Linear	L	4GuanPhe replaces Arg (R) at position 6,Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr, Aze substituitions at position 4	Synthetic	Targets plasma kallikrein	N.A.	5 uM	N.A.	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = NA
5280	N.A.	2020	CSF-Aze-Y-NMeArg-CLHQDLC	Ac-(06-34-18) Phe2 Aze3Tyr4 NMeArg5	12	Acetylation	Free	Linear	L	NMeArg replaces Arg (R) at position 6,Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr, Aze substituitions at position 4	Synthetic	Targets plasma kallikrein	N.A.	5 uM	N.A.	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = NA
5290	31840306	2020	RLYMRYYSPTTRRYG	conjugate 1 b	16	2A-Gossypol Conjugate Linked By Thiazolidine Imine Linkage	Free	Linear	L	None	Synthetic	Cancer‐cell‐specific drug delivery	After 10 hours	0.1 mg	52% Cleavage of the peptide	N.A.	HPLC	50 μL of 6M Gn·HCl, 200 mM phosphate buffer at pH 7	In Vitro	None	None	N.A.
5296	33270417	2020	IGLHDPSHGTLPNGS	INGAP-P	15	Free	Free	Linear	L	None	Synthetic	N.A.	N.A.	N.A.	55.9 (Deamidation Half Life)	N.A.	HPLC	N.A.	In Vitro	None	None	N.A.
5298	31843919	2019	VCKRWKKWKRKWKKWCV	ZY4	17	Free	Amidation	Cyclic (C2-C16 Disulfide Bond)	L	None	Cathelicidin-BF15 analogs	Antimicrobial	Blood samples were drawn retroorbitally under short-term anesthesia at different time points (1, 5, 10, 30, 60 min, and 2, 5, 10, 18, 24 h)	8 mg/kg	1.859	Mice plasma protease	LC-MS/MS	Mice plasma	In Vivo	None	None	MIC (µM) = 1.9 for ZY4 in P. aeruginosa CICC21625 , MIC (µM) = 2 for ZY4 in B. subtilis , MIC (µM) = 2 for ZY4 in S. aureus , MIC (µM) = 2 for ZY4 in C. albicans
5312	31632382	2019	Gu-ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O: L-ornithine at position 2	Apidaecin analog	Antimicrobial	N.A.	20 mg/kg	< 30	Mice plasma protease	RP-HPLC	Mice plasma	In Vivo	None	None	N.A.
5350	31277465	2019	CGFLG-C6-KTVRTSADE	Dox-peptide conjugate 13	14	DOX	Free	Cyclic (Lys6-Glu14 bond)	L	C6 fatty acid linked between	Synthetic	Anticancer	An aliquot (40 µL) was removed at different time intervals, such as 4, 24, and 84 h	0.25 mM	10	N.A.	RP-HPLC	PBS having pH values ranging from 6.5 to 7.4	In Vitro	None	None	Dox conjugate 13 was moderately toxic with a reduced cell proliferation to a range of 25–35% as compared to Dox which reduced cell proliferation in the range of 20–34% for all selected four cell lines
5351	31277465	2019	CGFLG-C6-KTVRTSADE	Dox-peptide conjugate 13	14	DOX	Free	Cyclic (Lys6-Glu14 bond)	L	C6 fatty acid linked between	Synthetic	Anticancer	Several aliquots (55 µL) were removed at 2, 5, 10, 15, 30, 60, 90, and 120 min	125 µM	11.8	Human serum protease	HPLC	25% human serum	In Vitro	None	None	Dox conjugate 13 was moderately toxic with a reduced cell proliferation to a range of 25–35% as compared to Dox which reduced cell proliferation in the range of 20–34% for all selected four cell lines
5352	31276085	2019	RWVRVpGOWIRQ	RWRWR peptide	12	Acetylation	Amidation	Linear	Mix	R amino acid substituition at 1,4, 11, FAM denotes 5,6-carboxyfluorescein conjugated with Orn,p=D-Proline6,O=Ornithine8	Synthetic	Cell penetrating peptide	37°C	2 mg/ml	420	HeLa lysates protease	RP-HPLC	HeLa lysates + Assay buffer(10 mM Tris-HCl, pH 7.6)	In Vitro	None	None	N.A.
5353	31276085	2019	RWVRWIOQVRpG	S-RWRWR peptide	12	Acetylation	Amidation	Linear	Mix	R amino acid substituition at 1,4, 11, FAM denotes 5,6-carboxyfluorescein conjugated with Orn,p=D-Proline11,O=Ornithine7	scrambled version of the RWRWR peptide	Cell penetrating peptide	37°C	2 mg/ml	30	HeLa lysates protease	RP-HPLC	HeLa lysates + Assay buffer(10 mM Tris-HCl, pH 7.6)	In Vitro	None	None	N.A.
5354	31276085	2019	GGAYAAPFKKKA	III-67B	12	FAM denotes 5,6-carboxyfluorescein	Amidation	Linear	L	None	Synthetic	Cell penetrating peptide	37°C	2 mg/ml	9.5	HeLa lysates protease	RP-HPLC	HeLa lysates + Assay buffer(10 mM Tris-HCl, pH 7.6)	In Vitro	None	None	N.A.
5366	31181805	2019	GCCSHPVCSAMSPIC	TxID	15	Free	Amidation	Cyclic (C2-C8, C3-C15 Disulfide Linkage)	L	None	Cloned from Hainan native Conus textile	Treatment of Neuropathic Pain, Addiction And Small Cell Lung Cancer	At 37 °C for 0, 1, 3, 6, 12, 24, and 48 h, respectively	0.25 mM	Less Stable	Human serum protease	RP-UPLC	Human serum	In Vitro	None	None	DSPE-PEG-TxID was still effective in inhibiting the α3β4 receptor, relative to TxID with slower reversible recovery.
5367	31181805	2019	GCCSHPVCSAMSPIC	DSPE-PEG-TxID	15	DSPE-PEG	Amidation	Cyclic (C2-C8, C3-C15 Disulfide Linkage)	L	None	Derived from TXID	Treatment of Neuropathic Pain, Addiction And Small Cell Lung Cancer	At 37 °C for 0, 1, 3, 6, 12, 24, and 48 h, respectively	0.25 mM	Stable	Human serum protease	RP-UPLC	Human serum	In Vitro	None	None	DSPE-PEG-TxID was still effective in inhibiting the α3β4 receptor, relative to TxID with slower reversible recovery.
5368	31181805	2019	GCCSHPVCSAMSPIC	DSPE-PEG-TxID	15	DSPE-PEG	Amidation	Cyclic (C2-C8, C3-C15 Disulfide Linkage)	L	None	Derived from TXID	Treatment of Neuropathic Pain, Addiction And Small Cell Lung Cancer	Investigations were made at 0, 30, 60, 90, 120, and 180 min (SIF) incubations	N.A.	Stable	Simulated intestinal fluid serum protease	N.A.	Simulated intestinal fluid serum	In Vitro	None	None	DSPE-PEG-TxID was still effective in inhibiting the α3β4 receptor, relative to TxID with slower reversible recovery.
5369	31181805	2019	GCCSHPVCSAMSPIC	TxID	15	Free	Amidation	Cyclic (C2-C8, C3-C15 Disulfide Linkage)	L	None	Cloned from Hainan native Conus textile	Treatment of Neuropathic Pain, Addiction And Small Cell Lung Cancer	Investigations were made at 0, 30, 60, 90, 120, and 180 min (SIF) incubations	N.A.	Less Stable	Simulated intestinal fluid serum protease	N.A.	Simulated intestinal fluid serum	In Vitro	None	None	DSPE-PEG-TxID was still effective in inhibiting the α3β4 receptor, relative to TxID with slower reversible recovery.
5397	31079216	2019	pGlu-LYENKPRRPYIL	NT	13	pGlu = Pyroglutamate	Free	Linear	L	None	Isolated from bovine hypothalamus	Dual function as a neurotransmitter/neuromodulator in the Central Nervous System (CNS) and as a hormone/cellular mediator in peripheral tissues, such as the gastrointestinal tract and adipose tissue	24 h incubation at 37 °C	160 μM	Lower Stability	Human plasma protease	UHPLC	Human plasma	In Vitro	PDB id: 2LNE	None	−LogIC50±SE = 9.54±0.42 in Neurotensin (1–13) for NTS1 receptor
5419	30986342	2019	KAANNLLMAAS	P-T4-Cy5.5	11	PEGylation	Conjugated with Cy5.5	Linear	L	Diethylaminopropyl isothiocyanate (DEAP) conjugation at Lys1 side chain	Synthetic	Antitumor	N.A.	N.A.	2	Mice plasma protease	Fluorescence assay	Mice plasma	In Vivo	None	None	Free T4 or P-T4 slowed tumor regrowth after chemotherapy, whereas the P-T4 treatment group exhibited a better suppressive effect
5420	30973007	2019	QNSPNIFGQWM	GBAP	11	Free	Free	Cyclic (Ser3-Met11 bond)	L	None	Produced by Enterococcus faecalis	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, and 24 hr	0.28 mM	4	N.A.	HPLC	pH 7.2 buffer	In Vitro	None	None	EC50 (nM) = 1.15 for GBAP
5421	30973007	2019	QNSPNIFGQWM	GBAP 12	11	Free	Free	Linear	L	None	GBAP analogs	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, and 24 hr	0.28 mM	>20	N.A.	HPLC	pH 7.2 buffer	In Vitro	None	None	EC50 (nM) = 1.15 for GBAP
5422	30973007	2019	QNSPNI-NMeF-GQWM	GBAP 11	14	Free	Free	Cyclic (Ser3-Met11 bond)	L	N-methylation at Phe7	GBAP analogs	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, and 24 hr	0.28 mM	Highly Stable	Chymotrypsin	HPLC	PBS buffer + chymotrypsin	In Vitro	None	None	EC50(nM) = 6.3 for GBAP-[N-MeF7]
5423	30973007	2019	QNSPNIFGQWM	GBAP	11	Free	Free	Cyclic (Ser3-Met11 bond)	L	None	Produced by Enterococcus faecalis	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8hr, and 24 hr	0.28 mM	<30	Human plasma protease	HPLC	Human plasma	In Vitro	None	None	EC50 (nM) = 1.15 for GBAP
5424	30973007	2019	QNSPNI-NMeF-GQWM	GBAP 11	14	Free	Free	Cyclic (Ser3-Met11 bond)	L	N-methylation at Phe7	GBAP analogs	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8hr, and 24 hr	0.28 mM	<30	Human plasma protease	HPLC	Human plasma	In Vitro	None	None	EC50(nM) = 6.3 for GBAP-[N-MeF7]
5442	30814652	2019	ASPAAPAPASPAAPAPSAPA	Adnectin C	20	Free	Free	Linear	L	None	Derived from the tenth domain of fibronectin type III (10thFn3)	Anticancer	Blood samples were taken after 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, and 96 h	5 mg/kg	49.41	Mice plasma protease	ELISA	Mice plasma	In Vivo	None	None	Kd(1/s) = 5.643E − 5
5443	30814652	2019	ASPAAPAPASPAAPAPSAPA	Adnectin C-PAS#1(200)	20	Free	PAS#1(200)	Linear	L	None	Adnectin C analogs	Anticancer	Blood samples were taken after 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, and 96 h	5 mg/kg	226.2	Mice plasma protease	ELISA	Mice plasma	In Vivo	None	None	Kd(1/s) =2.476E − 5
5459	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin1	17	Free	Free	Linear	L	None	Native apelin 17	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.4	RHNEP	LC-MS	Apelin1	In Vitro	None	None	EC50(nM) = 1.9 ± 1.0
5460	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin2	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=H	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1	RHNEP	LC-MS	Apelin2	In Vitro	None	None	EC50(nM) = 4.1 ± 1.0
5461	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin3	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=Me, Methylation at Glu8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	>30	RHNEP	LC-MS	Apelin3	In Vitro	None	None	EC50(nM) = 4.9 ± 1.0
5462	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin4	17	Free	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	N.A.	RHNEP	LC-MS	Apelin4	In Vitro	None	None	EC50(nM) = 568 ± 34
5463	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin5	17	Free	Free	Linear	L	R2=Me, Methylation at Gln5	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	N.A.	RHNEP	LC-MS	Apelin5	In Vitro	None	None	EC50(nM) = 176 ± 21
5464	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin6	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1.5	RHNEP	LC-MS	Apelin6	In Vitro	None	None	EC50(nM) = 2.6 ± 0.8
5465	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin7	20	R1 = PEG-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	>30	RHNEP	LC-MS	Apelin7	In Vitro	None	None	EC50(nM) = 6.3 ± 1.0
5466	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin8	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	R2= Me, Methylation at Gln8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	>30	RHNEP	LC-MS	Apelin8	In Vitro	None	None	EC50(nM) = 11.3 ± 2.1
5467	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin9	20	R1 = PEG-Lys-Phe-Arg	Free	Linear	L	R2= Me, Methylation at Gln8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	>30	RHNEP	LC-MS	Apelin9	In Vitro	None	None	EC50(nM) = 2.5 ± 1.5
5468	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin1	17	Free	Free	Linear	L	None	Native apelin 17	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.4	RhKLKB1	LC-MS	Apelin1	In Vitro	None	None	EC50(nM) = 1.9 ± 1.0
5469	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin2	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=H	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.7	RhKLKB1	LC-MS	Apelin2	In Vitro	None	None	EC50(nM) = 4.1 ± 1.0
5470	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin3	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=Me, Methylation at Glu8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.9	RhKLKB1	LC-MS	Apelin3	In Vitro	None	None	EC50(nM) = 4.9 ± 1.0
5471	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin4	17	Free	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	N.A.	RhKLKB1	LC-MS	Apelin4	In Vitro	None	None	EC50(nM) = 568 ± 34
5472	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin5	17	Free	Free	Linear	L	R2=Me, Methylation at Glu5	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	N.A.	RhKLKB1	LC-MS	Apelin5	In Vitro	None	None	EC50(nM) = 176 ± 21
5473	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin6	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1	RhKLKB1	LC-MS	Apelin6	In Vitro	None	None	EC50(nM) = 2.6 ± 0.8
5474	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin7	20	R1 = PEG-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1.4	RhKLKB1	LC-MS	Apelin7	In Vitro	None	None	EC50(nM) = 6.3 ± 1.0
5475	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin8	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	R2= Me, Methylation at Gln8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	2.1	RhKLKB1	LC-MS	Apelin8	In Vitro	None	None	EC50(nM) = 11.3 ± 2.1
5476	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin9	20	R1 = PEG-Lys-Phe-Arg	Free	Linear	L	R2= Me, Methylation at Gln8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	2.9	RhKLKB1	LC-MS	Apelin9	In Vitro	None	None	EC50(nM) = 2.5 ± 1.5
5477	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin1	17	Free	Free	Linear	L	None	Native apelin 17	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.02	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 1.9 ± 1.0
5478	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin2	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=H	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.3	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 4.1 ± 1.0
5479	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin3	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=Me, Methylation at Glu8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1.2	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 4.9 ± 1.0
5480	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin4	17	Free	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	N.A.	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 568 ± 34
5481	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin5	17	Free	Free	Linear	L	R2=Me, Methylation at Glu5	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	N.A.	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 176 ± 21
5482	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin6	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	4.5	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 2.6 ± 0.8
5483	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin7	20	R1 = PEG-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	18	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 6.3 ± 1.0
5484	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin8	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	R2= Me, Methylation at Gln8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	20.5	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 11.3 ± 2.1
5485	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin9	20	R1 = PEG-Lys-Phe-Arg	Free	Linear	L	R2= Me, Methylation at Gln8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	27	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 2.5 ± 1.5
5486	30658804	2019	IVRRADRAAVP	ES2	11	Free	FITC	Linear	L	None	derived from the C-terminus of endostatin	Antiangiogenic	Immediately, 0.5, 1, 2, 4, 6, 8, 12, 24, and 36 h after injection, blood was collected	20 mg/kg	18.04 ± 2.38	Mice plasma protease	Fluorescence assay	Mice plasma	In Vivo	None	None	Antitumor activity = 35.31%
5487	30658804	2019	IVRRADRAAVP	HTCOSC-ES2	11	Chitooligosaccharide chloride	FITC	Linear	L	None	derived from the C-terminus of endostatin	Antiangiogenic	Immediately, 0.5, 1, 2, 4, 6, 8, 12, 24, and 36 h after injection, blood was collected	80 mg/kg	29.17 ± 3.91	Mice plasma protease	Fluorescence assay	Mice plasma	In Vivo	None	None	Antitumor activity = 68.21%
5496	30624060	2019	yGlu-(OEG)2-K-OEG-Asp-phe(4sm)-Nle-GW-Nle-DMeAsp-MePhe	Compound 19	10	C18 fatty acid	Amidation	Linear	Mix	sTyr = Sulfated-Tyrosine, Nle = Nor-leucine, DMeAsp = N-methylated DAsp, MePhe = Methylated-phenylalanine	CCK-8 analogue	Role in the regulation of energy balance	The blood samples were collected at following time points relative to dosing: predose, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 120, 168, 192, 216, 240, 264, and 288 h	5 nmol/kg	36 (Terminal Half Life)	Female göttingen minipigs plasma protease	LC-MS	Female göttingen minipigs plasma	In Vivo	None	None	pEC50 = 9.67 (In Vitro CCK-1R Potency)
5504	30606721	2019	ACYNEFGCEDFYDIC	BCY-B5	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C8, C15)	L	None	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	11.5	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vitro	None	None	N.A.
5505	30606721	2019	ACYNEFGCEDFYDIC	BCY-B3	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C8, C15)	L	None	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Mouse plasma protease	Radio-HPLC	Mouse plasma	In Vitro	None	None	KD(nM) = 1.22 ± 0.40
5506	30606721	2019	ACaNE-1Nal-aCEDFYDC	BCY-C3	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C9, C15)	Mix	(1Nal),(D-Ala) at position 3,(tBuGly) at Asp14	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	N.A.
5507	30606721	2019	ACaNE-1Nal-aCEDFYDC	BCY-C2.	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C9, C15)	Mix	(1Nal),(D-Ala) at position 3,(tBuGly) at Asp14	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Mouse plasma protease	Radio-HPLC	Mouse plasma	In Vitro	None	None	KD(nM) = 0.5 ± 0.2
5508	30606721	2019	ACYNEFGCEDFYDIC	BCY-B5	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C8, C15)	L	None	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Human plasma protease	LC-MS/MS	Human plasma	In Vitro	None	None	N.A.
5509	30606721	2019	ACYNEFGCEDFYDIC	BCY-B3	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C8, C15)	L	None	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Human plasma protease	Radio-HPLC	Human plasma	In Vitro	None	None	KD(nM) = 1.22 ± 0.40
5510	30606721	2019	ACaNE-1Nal-aCEDFYDC	BCY-C3	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C9, C15)	Mix	(1Nal),(D-Ala) at position 3,(tBuGly) at Asp14	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Human plasma protease	LC-MS	Human plasma	In Vitro	None	None	N.A.
5511	30606721	2019	ACaNE-1Nal-aCEDFYDC	BCY-C2.	15	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C2, C9, C15)	Mix	(1Nal),(D-Ala) at position 3,(tBuGly) at Asp14	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	37C up to 24 hours	4 μmol/L	>48	Human plasma protease	Radio-HPLC	Human plasma	In Vitro	None	None	KD(nM) = 0.5 ± 0.2
5512	30606721	2019	CYNEFGCEDFYDIC	BCY-B2	14	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C1, C7, C14)	L	None	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	Blood samples were taken from two animals per time-point, at 0.08, 0.5, 1, 2, and 4 hours post injection (p.i.),	5.925 mg/kg	14 (Elimination Half Life)	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	KD(nM) = 25 ± 0.3
5513	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	50 mg/kg	13	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
5514	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	50 mg/kg	16	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
5515	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	50 mg/kg	11	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
5516	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	10 mg/kg	3.6	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
5517	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	10 mg/kg	11	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
5518	30600870	2019	VEPNCDIHVKWECFERLYal	cot-biPEPEDB-VEGF	20	Acetylation	Amidation	Cyclic (C5-C13 Disulfide Bond In pepVEGF)	Mix	Lys10 linked with (OEG-Cotinine-OEG-SSSPIQGSWTWENGKWTWKGIIRLEQ-NH2), D-alanine	Synthetic	Antitumor	N.A.	200nM	1.18 (Clearance Half Life)	Mice serum protease	ELISA	Mice serum	In Vivo	None	None	tumor growth inhibition was not significantly different between cot-biPEPEDB-VEGF and PBS control groups, despite a trend toward greater inhibition in the cot-biPEPEDB-VEGF group
5519	30600066	2019	IVRRADRAAVP	GSHP-ES2	11	FITC-GSHP	Free	Linear	L	None	Synthetic	Antitumour, Antiangiogenic	Blood samples were collected through the fundus venous plexus 0.5–72 h after administration	20 mg/kg	9.11	Mice plasma protease	fluorescence spectrometry	mice plasma	In Vivo	None	None	When the concentration was 5, 25, 50, 75, 100 and 125 μg/ml, the inhibitory rate of GSHP-ES2 was 6.47%, 16.47%, 24.57%, 31.36%, 44.45%, and 67.26%, respectively
5563	31536939	2019	ALLANHEELFQT-GGGSK	ALL*labeled nanocarriers	12	Free	D-Α-Tocopherol Succinate Linked Via Peg	Linear	L	Peptides are attached via a GGGSK linker to the nanocarrier surface via a thioether-mediated conjugation	Synthetic	Anticancer (therapy of hepatocellular carcinoma)	37 °C for 0, 1, 2, 6, 12, and 24 h	30 μM	22.7 ( Sorafenib Release Half Life)	Mouse serum protease	HPLC	Mouse serum	N.A.	None	None	IC50 = 3.6 μM show greater toxicity to Hep3B cells in vitro
5564	31536939	2019	QLELTFHANLEA-GGGSK	QLE* labeled nanocarriers	12	Free	D-Α-Tocopherol Succinate Linked Via Peg	Linear	L	Peptides are attached via a GGGSK linker to the nanocarrier surface via a thioether-mediated conjugation	Synthetic	Anticancer (therapy of hepatocellular carcinoma)	37 °C for 0, 1, 2, 6, 12, and 24 h	30 μM	19.5 (Sorafenib Release Half Life)	Mouse serum protease	HPLC	Mouse serum	N.A.	None	None	IC50 = 6.0 μM show lesser toxicity to Hep3B cells in vitro
5582	30684538	2019	GYNGLAEVGK	Tryptic peptide	10	Free	Free	Linear	L	N29G30	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	1100 ± 700(Deamidation Half Life)	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5583	30684538	2019	LYPFTWDAVRYNGK	Tryptic peptide	14	Free	Free	Linear	L	N111G112	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	18 ± 2 (Deamidation Half Life)	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5585	30684538	2019	GETAMTINGPWAWSNIDTSK	Tryptic peptide	20	Free	Free	Linear	L	N238G239	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	N.A.	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5586	30684538	2019	DVGVDNAGAK	Tryptic peptide	10	Free	Free	Linear	L	N196A197	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	120 ± 10 (Deamidation Half Life)	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5587	30684538	2019	TAVINAASGR	Tryptic peptide	10	Free	Free	Linear	L	N360A361	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	630 ± 30 ( Deamidation Half Life)	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5589	30684538	2019	GYNGLAEVGK	Peptic peptide	10	Free	Free	Linear	L	N29G30	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	500 ± 200 (Deamidation Half Life)	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5590	30684538	2019	LYPFTWDAVRYNGK	Peptic peptide	14	Free	Free	Linear	L	N111G112	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	12 ± 5 (Deamidation Half Life)	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5592	30684538	2019	GETAMTINGPWAWSNIDTSK	Peptic peptide	20	Free	Free	Linear	L	N238G239	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	N.A.	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5593	30684538	2019	DVGVDNAGAK	Peptic peptide	10	Free	Free	Linear	L	N196A197	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	50 ± 2 (Deamidation Half Life)	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5594	30684538	2019	TAVINAASGR	Peptic peptide	10	Free	Free	Linear	L	N360A361	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 µM	120 ± 4 (Deamidation Half Life)	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5605	30684538	2019	HMNADTDYSIAEAAFNK	Tryptic peptide	17	Free	Free	Linear	L	N216A217	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	N.A.	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5606	30684538	2019	PFVGVLSAGINAASPNK	Tryptic peptide	17	Free	Free	Linear	L	N278A279	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	N.A.	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5607	30684538	2019	IAATMENAQK	Tryptic peptide	10	Free	Free	Linear	L	N278A279	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	N.A.	Trypsin	LC-MS	WT - MBP	In Vitro	None	None	N.A.
5608	30684538	2019	HMNADTDYSIAEAAFNK	Peptic peptide	17	Free	Free	Linear	L	N216A217	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	N.A.	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5609	30684538	2019	PFVGVLSAGINAASPNK	Peptic peptide	17	Free	Free	Linear	L	N278A279	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	N.A.	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5610	30684538	2019	IAATMENAQK	Peptic peptide	10	Free	Free	Linear	L	N278A279	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	N.A.	Pepsin	LC-MS	Mutant MBP	In Vitro	None	None	N.A.
5611	30684538	2019	VIWINGDKGY	Tryptic peptide	10	Free	Free	Linear	L	N23G24	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	980 ± 60 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5612	30684538	2019	VIWINGDKGYNGL	Tryptic peptide	13	Free	Free	Linear	L	N29G30	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	1300 ± 100 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5615	30684538	2019	TINGPWAWSN	Tryptic peptide	10	Free	Free	Linear	L	N238G239	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	10,900 ± 400 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5616	30684538	2019	VGVDNAGAKAGLTF	Tryptic peptide	14	Free	Free	Linear	L	N196A197	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	<30 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5617	30684538	2019	YAVRTAVINAASGRQTVDE	Tryptic peptide	19	Free	Free	Linear	L	N360A361	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	<30 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5618	30684538	2019	VDLIKNKHMNADTDY	Tryptic peptide	15	Free	Free	Linear	L	N216A217	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	270 ± 30 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5619	30684538	2019	SAGINAASPNKEL	Tryptic peptide	13	Free	Free	Linear	L	N278A279	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	3800 ± 400 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5620	30684538	2019	AKDPRIAATMENAQKGEIM	Tryptic peptide	19	Free	Free	Linear	L	N278A279	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	35,000 ± 900 (Hx Half Life)	Trypsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	WT - MBP	In Vitro	None	None	N.A.
5621	30684538	2019	VIWINGDKGY	Peptic peptide	10	Free	Free	Linear	L	N23G24	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	700 ± 60 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5622	30684538	2019	VIWINGDKGYNGL	Peptic peptide	13	Free	Free	Linear	L	N29G30	MBP analog	Model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	600 ± 20 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5625	30684538	2019	TINGPWAWSN	Peptic peptide	10	Free	Free	Linear	L	N238G239	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	7800 ± 100 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5626	30684538	2019	VGVDNAGAKAGLTF	Peptic peptide	14	Free	Free	Linear	L	N196A197	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	<30 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5627	30684538	2019	YAVRTAVINAASGRQTVDE	Peptic peptide	19	Free	Free	Linear	L	N360A361	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	<30 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5628	30684538	2019	VDLIKNKHMNADTDY	Peptic peptide	15	Free	Free	Linear	L	N216A217	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	<30 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5629	30684538	2019	SAGINAASPNKEL	Peptic peptide	13	Free	Free	Linear	L	N278A279	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	2600 ± 100 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5630	30684538	2019	AKDPRIAATMENAQKGEIM	Peptic peptide	19	Free	Free	Linear	L	N278A279	MBP analog	model protein	Wild-type and mutant MBP samples were collected after 1, 3, 6, 9, and 12 and 1, 3, 5, 7, 9, and 12 calendar months,pH 7.0 at 23 ± 2C	20 μM	16,700 ± 20 (Hx Half Life)	Pepsin	Hydrogen Exchange Mass Spectrometry (HX-MS)	Mutant MBP	In Vitro	None	None	N.A.
5635	30555549	2018	TAWYANFEALLRC	AuNp-DPA	13	Free	Au	Linear	L	None	Synthetic	Antitumor	N.A.	2 mg/kg	7.5 ± 0.8	Mice blood protease	HPLC	Mice blood sample	In Vivo	None	None	AuNP-DPA inhibited tumor growth by 88% on day 13 compared to the control, even better than DOX (inhibition ratio of 64.3% in comparison with the control)
5638	30411073	2018	MVRIKPGSANKPSDD	sPIF	15	Free	Free	Linear	L	None	Human embryo‐derived peptide analogs	Treatment of Autoimmune Hepatitis	Patients’ serum samples were collected and analyzed at five different time points: screening (day ‐28 to day 0), pre‐injection (day 0), and postinjection days 1, 2, and 8	0.1 mg/kg	N.A.	Human serum protease	LC-MS	Human serum	In Vivo	None	None	N.A.
5639	30411073	2018	MVRIKPGSANKPSDD	sPIF	15	Free	Free	Linear	L	None	Human embryo‐derived peptide analogs	Treatment Of Autoimmune Hepatitis	Patients’ serum samples were collected and analyzed at five different time points: screening (day ‐28 to day 0), pre‐injection (day 0), and postinjection days 1, 2, and 8	0.5 mg/kg	63	Human serum protease	LC-MS	Human serum	In Vivo	None	None	N.A.
5640	30411073	2018	MVRIKPGSANKPSDD	sPIF	15	Free	Free	Linear	L	None	Human embryo‐derived peptide analogs	Treatment Of Autoimmune Hepatitis	Patients’ serum samples were collected and analyzed at five different time points: screening (day ‐28 to day 0), pre‐injection (day 0), and postinjection days 1, 2, and 8	1 mg/kg	109	Human serum protease	LC-MS	Human serum	In Vivo	None	None	N.A.
5641	30407790	2018	EEGYHWYGYTPQNVI	GENP-Gem-Ola	12	C18-EEG	Amidation	Linear	L	None	Synthetic	Treat Pancreatic Cancer With Breast Cancer 2 (Brca2) Mutation	Blood samples were collected at 0.5, 1, 2, 3, 5, 8, 12, and 24 h postinjection	equivalent concentrations of Gem (5 mg/kg) and Ola (50 mg/kg)	4	Mice plasma protease	HPLC	Mice plasma	In Vivo	None	None	Tumors from the GENP-Gem-Ola group showed extensive apoptosis (51% c-caspase-3 positive)
5649	30226777	2018	WILEYLWKVPFDFWRGVI	E1	18	Free	Free	Linear	L	None	Derived from the E1 envelope protein of GBV-C	HIV-1 fusion inhibitor peptide	At different incubation times (30 min, 1, 2, 4, 8, and 24 h)	1 mg/mL	8	Human serum protease	HPLC	Human serum	In Vitro	None	None	N.A.
5650	30226777	2018	WILEYLWKVPFDFWRGVI	E1-NP	18	Free	Free	Linear	L	None	Derived from the E1 envelope protein of GBV-C	HIV-1 fusion inhibitor peptide	At different incubation times (30 min, 1, 2, 4, 8, and 24 h)	1 mg/mL	24	Human serum protease	HPLC	Human serum	In Vitro	None	None	N.A.
5651	30175919	2018	GRP-MeArg-AFTF-MeAla-CKKK	Myristoylated peptide	14	6FAM labelled	Additional C terminal cysteine linked to peptide using dislufide bond	Linear	L	MeAla, MeArg,Lys1 modified with Myr	Synthetic	Substrate reporter for PKB	RT	1 µM	12 ± 1	N.A.	N.A.	Axenic D. discoideum K-AX3 DB or SorCM after myristoylated peptide loading	In Vitro	None	None	N.A.
5693	30012756	2018	L-threonyl-L-tryptophanyl-L-isoleucyl-L-2,4-diaminobutyryl-L-ornithyl-D-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-tryptophanyl-L-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-alanyl-L-seryl,D-prolyl-L-prolyl	Murepavadin	14	Free	Free	Cyclic (N-C terminal end)	Mix	Acetate	Synthetic	Antimicrobial	Blood samples were taken predose and 1, 2, 3, 3.5, 4, 5, 6, 9, 15, and 27 h after the start of infusion. For subjects with renal impairment, additional samples were taken at 30, 36, and 48 h, and at 72 h for subjects with severe renal function impairment	2.2 mg/kg	14.1	Human plasma protease	LC-MS with electrospray ionization assay	Human plasma (Mild Renal impairment group)	In Vivo	https://sci-hub.st/10.1080/14787210.2018.1441024	None	MIC50 = 0.12 mg/L against P. aeruginosa
5694	30012756	2018	L-threonyl-L-tryptophanyl-L-isoleucyl-L-2,4-diaminobutyryl-L-ornithyl-D-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-tryptophanyl-L-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-alanyl-L-seryl,D-prolyl-L-prolyl	Murepavadin	14	Free	Free	Cyclic (N-C terminal end)	Mix	Acetate	Synthetic	Antimicrobial	Blood samples were taken predose and 1, 2, 3, 3.5, 4, 5, 6, 9, 15, and 27 h after the start of infusion. For subjects with renal impairment, additional samples were taken at 30, 36, and 48 h, and at 72 h for subjects with severe renal function impairment	2.2 mg/kg	15.9	Human plasma protease	LC-MS with electrospray ionization assay	Human plasma (Moderate Renal impairment group)	In Vivo	https://sci-hub.st/10.1080/14787210.2018.1441024	None	MIC50 = 0.12 mg/L against P. aeruginosa
5695	30012756	2018	L-threonyl-L-tryptophanyl-L-isoleucyl-L-2,4-diaminobutyryl-L-ornithyl-D-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-tryptophanyl-L-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-alanyl-L-seryl,D-prolyl-L-prolyl	Murepavadin	14	Free	Free	Cyclic (N-C terminal end)	Mix	Acetate	Synthetic	Antimicrobial	Blood samples were taken predose and 1, 2, 3, 3.5, 4, 5, 6, 9, 15, and 27 h after the start of infusion. For subjects with renal impairment, additional samples were taken at 30, 36, and 48 h, and at 72 h for subjects with severe renal function impairment	2.2 mg/kg	24.1	Human plasma protease	LC-MS with electrospray ionization assay	Human plasma (Severe Renal impairment group)	In Vivo	https://sci-hub.st/10.1080/14787210.2018.1441024	None	MIC50 = 0.12 mg/L against P. aeruginosa
5696	30012756	2018	L-threonyl-L-tryptophanyl-L-isoleucyl-L-2,4-diaminobutyryl-L-ornithyl-D-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-tryptophanyl-L-2,4-diaminobutyryl-L-2,4-diaminobutyryl-L-alanyl-L-seryl,D-prolyl-L-prolyl	Murepavadin	14	Free	Free	Cyclic (N-C terminal end)	Mix	Acetate	Synthetic	Antimicrobial	Blood samples were taken predose and 1, 2, 3, 3.5, 4, 5, 6, 9, 15, and 27 h after the start of infusion	2.2 mg/kg	7.7	Human plasma protease	LC-MS with electrospray ionization assay	Human plasma (Healthy Renal impairment group)	In Vivo	https://sci-hub.st/10.1080/14787210.2018.1441024	None	MIC50 = 0.12 mg/L against P. aeruginosa
5737	29738954	2018	FGrKKRrQrRr-βAla	γTatM4	12	Acetylation	Amidation	Linear	L	None	Tat peptide analogue	Antibacterial and Anti-Tb	N.A.	10 mM	16	Trypsin	RP-HPLC	Tris-EDTA buffer	In Vitro	None	None	MIC(micrmolar) = 1.12 ± 0.01 for E.coli
5738	29738954	2018	FGRKKRRQRRR	CtrlTat	11	Acetylation	Amidation	Linear	L	None	Derived from the human immunodeficiency virus 1 (HIV-1) tat protein	Antibacterial and Anti-Tb	N.A.	10 mM	4	Trypsin	RP-HPLC	Tris-EDTA buffer	In Vitro	None	None	MIC (micromolar) = 6.27 ± 0.05 for E.coli
5743	29721065	2018	WHSDMEWWYLLG	64Cu-DOTA-F56-CM	12	64Cu-DOTA	maleimidopropionic acid (MPA) at the C-terminal	Linear	L	None	Maleimidopropionic acid-conjugated peptide	Antiangiogenic	At 10, 30, 60, and 120 min	7.4 mBq	6.967	SD rats blood protease	Radioactivity assay	SD rats blood	In Vivo	None	None	F56 and F56-CM reduced the angiogenesis of zebrafish embryos in a dose-dependent way
5744	29721065	2018	WHSDMEWWYLLG	64Cu-DOTA-F56	12	64Cu-DOTA	Free	Linear	L	None	Synthetic	Antiangiogenic	At 10, 30, 60, and 120 min	7.4 mBq	0.4249	Mice plasma protease	Radioactivity assay	Mice plasma	In Vivo	None	None	F56 and F56-CM reduced the angiogenesis of zebrafish embryos in a dose-dependent way
5766	29656472	2018	KVTAMTCFLL	[K6T]P8 peptide	10	Free	Amidation	Linear	L	K6T modification	Synthetic	IL‐15 antagonist peptide	At t = 0, 5, 8, 10, 20,30, 45, 60, 90, and 120 minutes	100 μM.	5.88 ± 1.73	Human synovial fluids protease	RP-HPLC	Human synovial fluids	In Vitro	None	None	IC50 values of 27.7 μM
5785	29577579	2018	RPRLSHKGPMPF	Fc‐apelin‐13 fusion protein	12	Fc linked by (GGGS)3 linker at N terminus	Free	Linear	L	None	Fc‐apelin‐13 fusion protein	Antidiabetes and Anti‐Heart Failure Activities	About 10 μL of blood was collected at each time point of 0, 1, 2, 4, 8, 24, 32, 48, 56, and 72 hours after administration	5 mg/kg	~33	Mice Plasma Protease	Western blotting	Mice plasma	In Vivo	None	None	EC50 values of the Fc‐apelin‐13 fusion protein= 12.0 ± 1.1 nM for cAMP suppression
5802	29517911	2018	CNTWNPWCPWDAPLCA-(Sar)3-rr	1b	18	Replaced the Nterminal Ala with an acetyl group	Cterminal extension following the C-terminal alanine composed of 3 sarcosines and 2 D-arginine residues	Bicyclic (Cyclized On C1, C8, C15 By 1,3,5 Trismethylbenzene)	Mix	None	1a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	Serial blood samples were taken from each animal via temporary indwelling tail vein cannulae at 5, 10, 20, 30, 60, 120, 180, and 240 min postdose,	5 mg/kg	78	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	Ki Values (nM) = 3.4 ± 1.1 against PKal from Rats
5803	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	Serial blood samples were taken from each animal via temporary indwelling tail vein cannulae at 5, 10, 20, 30, 60, 120, 180, and 240 min postdose,	5 mg/kg	48	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	Ki Values (nM) = 30 ± 9 against PKal from Rats
5804	29517911	2018	CSWPARCLHQDLC	2b	13	Free	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	None	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	Serial blood samples were taken from each animal via temporary indwelling tail vein cannulae at 5, 10, 20, 30, 60, 120, 180, and 240 min postdose,	10 mg/kg	N.A.	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	Ki Values (nM) = 2.0 ± 0.9 against PKal from Rats
5805	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	The animals were sacrificed 15 min, 1 h, 4 h, 8 h, 24 h, 48, and 96 h after injection	2 mg/mL	39 ± 2	Rabbit eye plasma protease	HPLC	Rabbit eye plasma	In Vivo	None	None	Ki Values (nM) = 3,400 ± 200 against PKal from Rabbit
5806	29517911	2018	CSF-Aze-Y-hArg-CVYYPDICA-(Sar)3-rr	4b	17	Acetylation	Cterminal extension following the C-terminal alanine composed of 3 sarcosines and 2 D-arginine residues	Bicyclic (Cyclized On C1, C7, C14 By 1,3,5 Trismethylbenzene)	L	HArg, Aze substituitions	synthetic	Antidiabetes (Treatment of Diabetic Macular Edema)	The animals were sacrificed 15 min, 1 h, 4 h, 8 h, 24 h, 48, and 96 h after injection	2 mg/mL	~22	Rabbit eye plasma protease	HPLC	Rabbit eye plasma	In Vivo	None	None	Ki Values (nM) = ∼2,650 against PKal from Rabbit
5807	29517911	2018	CNTWNPWCPWDAPLCA-(Sar)3-rr	1b	18	Replaced the Nterminal Ala with an acetyl group	Cterminal extension following the C-terminal alanine composed of 3 sarcosines and 2 D-arginine residues	Bicyclic (Cyclized On C1, C8, C15 By 1,3,5 Trismethylbenzene)	Mix	None	1a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Human vitreous protease	LC-MS/MS	Human vitreous	In Vitro	None	None	Ki Values (nM) = 3.4 ± 1.1 against PKal from Rats
5808	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Human vitreous protease	LC-MS/MS	Human vitreous	In Vitro	None	None	Ki Values (nM) = 30 ± 9 against PKal from Rats
5809	29517911	2018	CSWPARCLHQDLC	2b	13	Free	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	None	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Human vitreous protease	LC-MS/MS	Human vitreous	In Vitro	None	None	Ki Values (nM) = 2.0 ± 0.9 against PKal from Rats
5810	29517911	2018	CNTWNPWCPWDAPLCA-(Sar)3-rr	1b	18	Replaced the Nterminal Ala with an acetyl group	Cterminal extension following the C-terminal alanine composed of 3 sarcosines and 2 D-arginine residues	Bicyclic (Cyclized On C1, C8, C15 By 1,3,5 Trismethylbenzene)	Mix	None	1a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vitro	None	None	Ki Values (nM) = 3.4 ± 1.1 against PKal from Rats
5811	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vitro	None	None	Ki Values (nM) = 30 ± 9 against PKal from Rats
5812	29517911	2018	CSWPARCLHQDLC	2b	13	Free	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	None	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	1.5	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vitro	None	None	Ki Values (nM) = 2.0 ± 0.9 against PKal from Rats
5813	29517911	2018	CNTWNPWCPWDAPLCA-(Sar)3-rr	1b	18	Replaced the Nterminal Ala with an acetyl group	Cterminal extension following the C-terminal alanine composed of 3 sarcosines and 2 D-arginine residues	Bicyclic (Cyclized On C1, C8, C15 By 1,3,5 Trismethylbenzene)	Mix	None	1a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Rats plasma protease	LC-MS/MS	Rats plasma	In Vitro	None	None	Ki Values (nM) = 3.4 ± 1.1 against PKal from Rats
5814	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	>24	Rats plasma protease	LC-MS/MS	Rats plasma	In Vitro	None	None	Ki Values (nM) = 30 ± 9 against PKal from Rats
5815	29517911	2018	CSWPARCLHQDLC	2b	13	Free	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	None	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	24 h at 37 °C	0.16 mM	2.8	Rats plasma protease	LC-MS/MS	Rats plasma	In Vitro	None	None	Ki Values (nM) = 2.0 ± 0.9 against PKal from Rats
5816	29517911	2018	CNTWNPWCPWDAPLCA-(Sar)3-rr	1b	18	Replaced the Nterminal Ala with an acetyl group	Cterminal extension following the C-terminal alanine composed of 3 sarcosines and 2 D-arginine residues	Bicyclic (Cyclized On C1, C8, C15 By 1,3,5 Trismethylbenzene)	Mix	None	1a analogue	Antidiabetes	24 h at 37 °C	0.16 mM	>24	Human plasma protease	LC-MS/MS	Human plasma	In Vitro	None	None	Ki Values (nM) = 3.4 ± 1.1 against PKal from Rats
5817	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes	24 h at 37 °C	0.16 mM	>24	Human plasma protease	LC-MS/MS	Human plasma	In Vitro	None	None	Ki Values (nM) = 30 ± 9 against PKal from Rats
5818	29517911	2018	CSWPARCLHQDLC	2b	13	Free	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	None	2a analogue	Antidiabetes	24 h at 37 °C	0.16 mM	7	Human plasma protease	LC-MS/MS	Human plasma	In Vitro	None	None	Ki Values (nM) = 2.0 ± 0.9 against PKal from Rats
5820	29464007	2018	QWECPYGLCWIQ	99mTc-F1A	18	99mTc-HHEDEG	Free	Cyclic (C-C Disulfide Bond In C Terminal)	L	Interconnected through a diethylene glycol (DEG) spacer	Fibrin-specific natural peptide analogue	99MTC-F4A is a high-avidity prototype probe for characterizing thrombus in Lvads	Serial blood samples were obtained at 0, 2, 5, 10, 15, 20, 30, 60, 120, and 180 min via an indwelling jugular catheter	N.A.	124.7 ± 41.3 (T1/2b Elimination Half Life)	Mice plasma protease	Radioactivity assay	Mice plasma	In Vivo	None	None	99mTc-F4A probe was not displaced by F1A
5821	29464007	2018	QWECPYGLCWIQ	99mTc-F1A	18	99mTc-HHEDEG	Free	Cyclic (C-C Disulfide Bond In C Terminal)	L	Interconnected through a diethylene glycol (DEG) spacer	Fibrin-specific natural peptide analogue	99MTC-F4A is a high-avidity prototype probe for characterizing thrombus in Lvads	Serial blood samples were obtained at 0, 2, 5, 10, 15, 20, 30, 60, 120, and 180 min via an indwelling jugular catheter	N.A.	174.2 ± 26.2 (T1/2b Elimination Half Life)	Mice plasma protease	Radioactivity assay	Mice plasma	In Vivo	None	None	Kd ~10.2 µM for 99mTc-F1A (bound to uniform fibrin clots in PBS)
5822	29461833	2018	X-RPR-X-SHKGP-Nle-PF	Pyr analogue 2	13	Free	Free	Cyclic (X1-X5 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	0.8 ± 0.2	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 5.7 ±3.5 for 2
5823	29461833	2018	Rx-PRL-X-HKGP-Nle-PF	Pyr analogue 3	13	pGlu = Pyroglutamate	Free	Cyclic (Rx2-X6 Bond)	L	X= allylglycine, Rx=Na-ally-arginine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	2.2 ± 0.3	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 4.5 ±1.4 for 3
5824	29461833	2018	X-PRL-X-HKGP-Nle-PF	Pyr analogue 4	13	pGlu = Pyroglutamate	Free	Cyclic (X1-X6 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	0.7 ± 0.1	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 523 ±165 for 4L
5825	29461833	2018	R-X-RLS-X-KGP-Nle-PF	Pyr analogue 5	13	pGlu = Pyroglutamate	Free	Cyclic (X3-X7 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	3.9 ± 0.6	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 3 ±0.1 for 5
5826	29461833	2018	RP-Rx-LSH-X-GP-Nle-PF	Pyr analogue 6	13	pGlu = Pyroglutamate	Free	Cyclic (Rx4-X8 Bond)	L	X= allylglycine, Rx=Na-ally-arginine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	7.7 ± 0.3	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 9.1 ±1.4 for 6
5827	29461833	2018	RP-X-LSH-X-GP-Nle-PF	Pyr analogue 7	13	pGlu = Pyroglutamate	Free	Cyclic (X4-X8 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	9.9 ± 1.2	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 489 ±186 for 7L
5828	29461833	2018	RPR-X-SHK-X-P-Nle-PF	Pyr analogue 8	13	pGlu = Pyroglutamate	Free	Cyclic (X5-X9 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	3.5 ± 0.8	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 3.9 ±1.4 for 8L
5829	29461833	2018	RPRL-Sx-HKG-X-Nle-PF	Pyr analogue 9	13	pGlu = Pyroglutamate	Free	Cyclic (Sx6-X10 Bond)	L	X= allylglycine, Sx=Na-allyl-serine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	>24	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 41 ±4 for 9L
5830	29461833	2018	RPRL-X-HKG-X-Nle-PF	Pyr analogue 10	13	pGlu = Pyroglutamate	Free	Cyclic (X6-X10 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	4.1 ±0.8	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 194 ±70 for 10L
5831	29461833	2018	RPRLS-X-KGP-X-PF	Pyr analogue 11	13	pGlu = Pyroglutamate	Free	Cyclic (X7-X11 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	6.6 ±0.4	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 1.4 ±0.4 for 11
5832	29461833	2018	RPRLSH-X-GP-Nle-X-F	Pyr analogue 12	13	pGlu = Pyroglutamate	Free	Cyclic (X8-X12 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	4.6 ±0.7	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 14 ±7 for 12
5833	29461833	2018	RPRLSHK-X-P-Nle-P-X	Pyr analogue 13	13	pGlu = Pyroglutamate	Free	Cyclic (X9-X13 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	8.6 ±0.6	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 1.1 ±0.1 for 13
5834	29461833	2018	RPRLSHKG-X-Nle-PF-X	Pyr analogue 14	13	pGlu = Pyroglutamate	Free	Cyclic (X10-X14 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	7.8 ±1.1	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 445 ±62 for 14L
5835	29461833	2018	RPRLSHK-X-P-Nle-P-X	Pyr analogue 15	13	pGlu = Pyroglutamate	Free	Cyclic (X9-X13 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	6.8 ±1.6	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 0.15 ±0.01 for 15
5855	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	Day 1 (cycle 1 - 28days)	6 mg/m2	2.3	Human plasma protease	ELISA	Human plasma	In Vivo	https://www.lens.org/lens/patent/124-764-042-412-641/fulltext?l=en	None	N.A.
5856	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 1 (cycle 1 - 28days)	12 mg/m2	2.1	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5857	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 1 (cycle 1 - 28days)	24 mg/m2	3.2	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5858	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 1 (cycle 1 - 28days)	48 mg/m2	4.9	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5859	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 1 (cycle 1 - 28days)	96 mg/m2	6	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5860	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 29 (Cycle 2 day1)	6 mg/m2	2.8	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5861	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 29 (Cycle 2 day1)	12 mg/m2	2	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5862	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 29 (Cycle 2 day1)	24 mg/m2	3.7	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5863	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 29 (Cycle 2 day1)	48 mg/m2	4.6	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5864	29423221	2018	wwtfflpstlwerk	dTCApFs	14	Free	Free	Linear	D	None	Synthetic	Anticancer	day 29 (Cycle 2 day1)	96 mg/m2	8.5	Human plasma protease	N.A.	Human plasma	In Vivo	None	None	N.A.
5866	29421564	2018	RPKPQQFFGLM	SP	11	Free	Free	Linear	L	None	Synthetic	Therapeutic Angiogenesis in Diabetic Hindlimb Ischemia	0 to 72 h at 37°C	5 nmol	2	Human serum protease	ELISA	Human serum	In Vitro	None	None	N.A.
5868	29421564	2018	RPKPQQFFGLM	SP	11	Free	Free	Linear	L	None	Synthetic	Therapeutic Regeneration By Facilitating Mobilization Of Endogenous Stem Cells From Bone Marrow To The Injured Sites	0 to 72 h at 37°C	5 nmol	1.7	Diabetic rats serum protease	ELISA	Diabetic rats serum	In Vitro	None	None	N.A.
5869	29421564	2018	RPKPQQFFGLM	SP	11	Free	Free	Linear	L	None	Synthetic	Therapeutic Regeneration By Facilitating Mobilization Of Endogenous Stem Cells From Bone Marrow To The Injured Sites	0 to 72 h at 37°C	5 nmol	0.8	Mice serum protease	ELISA	Mice serum	In Vivo	None	None	N.A.
5871	29421564	2018	RPKPQQFFGLM	SP	11	Free	Free	Linear	L	None	Synthetic	Therapeutic Regeneration By Facilitating Mobilization Of Endogenous Stem Cells From Bone Marrow To The Injured Sites	0 to 72 h at 37°C	5 nmol	5	Diabetic rats serum protease	ELISA	Diabetic rats serum	In Vitro	None	None	N.A.
5890	29122441	2018	YGGEAAREACARCEAARE	FAMP1	18	FAM	Amidation	Cyclic (C10-C13 Disulfide Bond)	L	None	Synthetic	N.A.	37 C	10 µM	7	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5891	29122441	2018	YGGEAAREACARCEAARE	FAMP1	18	FAM	Amidation	Cyclic (C10-C13 Disulfide Bond)	L	None	Synthetic	Increases Half Life	37 C	10 µM	21	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5892	29122441	2018	YGGEAAREACARECAARE	FAM-P2	18	FAM	Amidation	Cyclic (C10-C14 Disulfide Bond)	L	None	Synthetic	N.A.	37 C	10 µM	16	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5893	29122441	2018	YGGEAAREACARECAARE	FAM-P2.L5	18	FAM	Amidation	Cyclic (C10-C14 Disulfide Bond)	L	1,3-bis(bromomethyl)benzene linker (L5) for stapling i, i+4 spacing	Synthetic	Increases Half Life	37 C	10 µM	10	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5896	29051342	2018	TGRAKRRMQYNRR	68Ga-NOTA-UBI	13	68Ga-NOTA	Free	Linear	L	None	Synthetic	Nuclear Imaging of Infectious Diseases	Image acquisition started 30, 60 and 120 min after IV	N.A.	29	NHP blood protease	PET-CT imaging	NHP blood sample	In Vivo	None	None	N.A.
5897	28954201	2018	GFCRCLCRRGVCRCICTR	RTD-1	18	Free	Free	Cyclic	L	None	Derived from rhesus	Attenuates Endotoxin-Induced Acute Lung Injury	Received RTD-1 at 0, 0.2, 1,5, or 25 mg/kg 0.5 hour before LPS challenge	5 or 25 mg/kg	30 (Terminal Half Life)	Mice plasma protease	LC-MS	Mice plasma (LPS-challenged )	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC3024902/	None	IC50= 4.5 μg/ml
5926	29464007	2018	QWECPYGLCWIQ	99mTc-F1A	18	99MTC-HHEDEG-DEG	Free	Cyclic (C-C Disulfide Bond In C Terminal)	L	None	Fibrin-specific natural peptide analogue	99mTc-F4A is a high-avidity prototype probe for characterizing thrombus in LVADs	serial blood samples were obtained at 0, 2, 5, 10, 15, 20, 30, 60, 120, and 180 min via an indwelling jugular catheter	N.A.	8.6 ± 1.9(T1/2A Distribution Half Life)	Mice plasma protease	Radioactivity assay	Mice plasma	In Vivo	None	None	N.A.
5929	29176766	2017	TRPASFWETS	M10	10	Free	Free	Linear	L	None	Derived from the C-terminal part of the MET receptor tyrosine kinase	Antifibrotic	Plasma samples were collected by cardiac puncture in the presence of 0.01% of Na-Citrate at time intervals of 15 min, 30 min, 1h, 2h, 4h, 6h, 12 h, 24 h, and 48 h following injection	1 mg/kg	6.8 ± 0.7	Mouse plasma protease	ELISA	Mouse plasma	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC4789156/	None	N.A.
5976	28714475	2017	ACSRYEVDCRGRGSACG	UK18	17	Free	Free	Bicyclic(C2-C9,C9-C16 Disulfide Bond)	L	None	Synthetic	Inhibit urokinase	N.A.	0.3 mg/kg	0.30 ± 0.02 (T1/2b)	Rats plasma protease	RP-HPLC using a fluorescence detector	Rats plasma	In Vivo	None	None	Albumin binding (Kd) (nM) > 100,000 for rat albumin
6001	28575099	2017	ONNRPVYIPRPRPPHPOL	Api134	18	Gu: N,N,N′,N′-tetramethylguanidine, O denotes L-ornithine	Amidation	Linear	L	Orn=Ornithine	Apidaecin analog	Antibacterial	Aliquots (20 or 40 μL) taken after 0 and 60 min (0, 10 and 30 min for Api88)	31.5 μmol/L	Highly Stable	Mouse blood/plasma/serum protease	RP-HPLC	Mouse blood/plasma/serum	In Vitro	None	None	N.A.
6002	28575099	2017	ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N′,N′-tetramethylguanidine, O denotes L-ornithine	Free	Linear	L	Orn=Ornithine	Apidaecin analog	Antibacterial	Aliquots (20 or 40 μL) taken after 0 and 60 min (0, 10 and 30 min for Api88)	31.5 μmol/L	Highly Stable	Mouse blood/plasma/serum protease	RP-HPLC	Mouse blood/plasma/serum	In Vitro	None	None	N.A.
6003	28575099	2017	VDKPPYLPRPRPPRrIYNr	Onc112	19	Free	Amidation	Linear	Mix	D-amino acid substituitons	Analog of Oncopeltus	Antibacterial	Aliquots (20 or 40 μL) taken after 0 and 60 min (0, 10 and 30 min for Api88)	31.5 μmol/L	Highly Stable	Mouse blood/plasma/serum protease	RP-HPLC	Mouse blood/plasma/serum	In Vitro	None	None	N.A.
6004	28575099	2017	VDKPPYLPRPRPPRRIYNR	Onc18	19	Free	Amidation	Linear	L	None	Analog of Oncopeltus	Antibacterial	Aliquots (20 or 40 μL) taken after 0 and 60 min (0, 10 and 30 min for Api88)	31.5 μmol/L	Medium Stable	Mouse blood/plasma/serum protease	RP-HPLC	Mouse blood/plasma/serum	In Vitro	None	None	N.A.
6005	28575099	2017	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation	Linear	L	L-ornithine (Orn)	Analog of Oncopeltus	Antibacterial	Aliquots (20 or 40 μL) taken after 0 and 60 min (0, 10 and 30 min for Api88)	31.5 μmol/L	Medium Stable	Mouse blood/plasma/serum protease	RP-HPLC	Mouse blood/plasma/serum	In Vitro	None	None	N.A.
6006	28575099	2017	ONNRPVYIPRPRPPHPRL	Api88	18	Gu: N,N,N′,N′-tetramethylguanidine, O denotes L-ornithine	Amidation	Linear	L	Orn=Ornithine	Apidaecin analog	Antibacterial	Aliquots (20 or 40 μL) taken after 0 and 60 min (0, 10 and 30 min for Api88)	31.5 μmol/L	Low Stable	Mouse blood/plasma/serum protease	RP-HPLC	Mouse blood/plasma/serum	In Vitro	None	None	N.A.
6011	28494253	2017	NKVPNLRGDLQVLAQKVART	Peptide 22	20	111In-DTPA = diethylenetriaminepentaacetic acid	Free	Linear	L	X1=Asn at position 1, X2=Leu at position , X3=Lys,X4 = Thr, Biotinylated Lysine	A20FMDV2 analogue	Antitumor	After 24 hrs at 37 ◦C	7.5 MBq	77% Stable	Human blood plasma protease	Radio-HPLC	Human blood plasma	In Vitro	None	None	Affinity for peptide 22 = 1.01 ± 0.21
6013	28494253	2017	NKVPNLRGDLQVLAQKVART	Peptide 24	20	111In-DTPA = diethylenetriaminepentaacetic acid	Amidation	Linear	L	X1=Asn, X2=Leu, X3=Lys,X4 = Thr, Biotinylated Lysine	A20FMDV2 analogue	Antitumor	After 24 hrs at 37 ◦C	7.5 MBq	52% Stable	Human blood plasma protease	Radio-HPLC	Human blood plasma	In Vitro	None	None	Affinity for peptide 24 = 1.19 ± 0.30
6014	28494253	2017	nKVPNLRGDLQVLAQKVART	Peptide 25	20	111In-DTPA = diethylenetriaminepentaacetic acid	Free	Linear	Mix	X1=D-Asn, X2=Leu, X3=Lys,X4 = Thr, Biotinylated Lysine	A20FMDV2 analogue	Antitumor	After 24 hrs at 37 ◦C	7.5 MBq	80% Stable	Human blood plasma protease	Radio-HPLC	Human blood plasma	In Vitro	None	None	Affinity for peptide 25 = 1.36 ± 0.42
6015	28494253	2017	nKVPNLRGDLQVLAQKVARt	Peptide 26	20	111In-DTPA = diethylenetriaminepentaacetic acid	X4 = D-Thr at C terminal	Linear	Mix	X1=D-Asn, X2=Leu, X3=Lys, Biotinylated Lysine	A20FMDV2 analogue	Antitumor	After 24 hrs at 37 ◦C	7.5 MBq	77% Stable	Human blood plasma protease	Radio-HPLC	Human blood plasma	In Vitro	None	None	Affinity for peptide 26 = 1.19 ± 0.40
6016	28464043	2017	YNWNSFGLRF	KP-10	10	Free	Amidation	Linear	L	None	kisspeptin analogue	Treatment of Specific Human Reproductive Disorders	100 μl of blood was collected from the lateral tail vein from groups of mice (n = 4) for each time point (0, 1min, 2 min, 5 min, 10 min, 30 min, 60 min and 120 min)	1 nmol	4	Mouse plasma protease	RIA	Mouse plasma	In Vivo	https://www.jbc.org/article/S0021-9258(19)77047-1/fulltext	None	N.A.
6025	28373972	2017	ONNRPVYIPRPRPPHPRL	Api88	18	Gu: N,N,N',N' tetramethylguanidino	Amidation	Linear	L	O denotes L-ornithine	Apidaecin analog	Antibacterial	After 10, 20, 30, 60, or90 min animals (n = 7)	5 mg/kg	17.3	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	MIC = Api88 > Api137
6026	28373972	2017	ONNRPVYIPRPRPPHPRL	Api88	18	Gu: N,N,N',N' tetramethylguanidino	Amidation	Linear	L	O denotes L-ornithine	Apidaecin analog	Antibacterial	After 10, 20, 30, 60, or90 min animals (n = 7)	20 mg/kg	11.1	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	MIC = Api88 > Api137
6027	28373972	2017	ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O denotes L-ornithine	Apidaecin analog	Antimicrobial	After 10, 20, 30, 60, or90 min animals (n = 7)	5 mg/kg	33.8	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	The minimum inhibitory concentration (MIC) value for Api137 against E. coli ATCC 25922 is 4 µg/mL.
6028	28373972	2017	ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O denotes L-ornithine	Apidaecin analog	Antimicrobial	After 10, 20, 30, 60, or90 min animals (n = 7)	20 mg/kg	16.9	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	The minimum inhibitory concentration (MIC) value for Api137 against E. coli ATCC 25922 is 4 µg/mL.
6039	28138743	2017	ILKKWPWWPWRRK	CP-11	13	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	A plasma aliquot was withdrawn at each time-point(0, 0.16, 0.5, 1, 2, 4 h)	10 μM	0.21	Mouse plasma protease	LC-HRMS.	Mouse plasma	In Vitro	None	None	N.A.
6040	28138743	2017	ILRWPWWPWRRK	Omiganan	13	Free	Amidation	Linear	L	None	Analogue of indolicidin	Antimicrobial	A plasma aliquot was withdrawn at each time-point(0, 0.16, 0.5, 1, 2, 4 h)	10 μM	0.83	Mouse plasma protease	LC-HRMS.	Mouse plasma	In Vitro	None	None	N.A.
6041	28138743	2017	ILPWKWPWWPWRR	Indolicidin	13	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	A plasma aliquot was withdrawn at each time-point(0, 0.16, 0.5, 1, 2, 4 h)	10 μM	1.53	Mouse plasma protease	LC-HRMS.	Mouse plasma	In Vitro	None	None	N.A.
6066	27815337	2017	pGlu-RPRLSHKGPMPF	pE13F	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	7.2	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 300 ± 182
6067	27815337	2017	RPRlS-Aib-Ka-ProNle-PF	P26	12	Acetylation	Pro(4-Br)Phe substituition	Linear	Mix	Aib, DLeu,ProNle, D-Ala	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	86	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 138 ± 30
6068	27815337	2017	KFRRQRPRLSHKGPMPF	K17F	17	Free	Free	Linear	L	None	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	4.6	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 15 ± 3.6
6069	27815337	2017	KFaRqRPRlS-Aib-Ka-ProNle-PF	P92	17	Acetylation	Pro(4-Br)Phe substituition	Linear	Mix	Aib, DLeu,DGln, ProNle, D-Arg at position 3	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	24	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 4 ± 2.4
6070	27815337	2017	KFRRQRPRLSHKGPMPF	LIT01-196	18	CF3(CF2)7(CH2)2C(O)	Free	Linear	L	None	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	1440	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 16 ± 5.6
6094	28714475	2017	ACRWPARCVHQDLCG	PK128	15	Free	Free	Bicyclic (C2-C8,C8-C14 Disulfide Bond In Pk128)	L	None	Synthetic	Inhibit plasma kallikrein	Probes were taken at different time points (5 min, 0.5, 1, 2, 4, 8, 24 and 48 h) at 37 C , diluted to 3 mM (urokinase inhibitor) or 0.75 mM (plasma kallikrein inhibitor) with assay buffer (10 mM TrisCl, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM CaCl2, 0.01% v/v Tween-20, and 0.1% (w/v) casein)	20 microM	1.8 ± 0.3 (Activity Half Life)	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	Albumin binding (Kd) (nM) = 720±90 for rat albumin for tagPK128
6112	27558296	2016	pGlu-RPRLSHKGPMPF	Compound 1	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	0.025	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 2.6 ± 1.0
6113	27558296	2016	pGlu-RPRLSHKGP-Nle-PF	Compound 2	13	pGlu = Pyroglutamate	Free	Linear	L	Nle = Norleucine at position 11	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	0.13	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 2.0 ± 0.3
6114	27558296	2016	pGlu-CRPRLCHKGP-Nle-PF	Compound 26	14	pGlu = Pyroglutamate	Free	Cyclic (C2-C7 Disulfide Linkage)	L	Nle = Norleucine at position 12	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	0.1	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) > 1000
6115	27558296	2016	QRPRLSHKGP-Nle-Aib-F	Compound 31	13	Palmitic acid conjugation	Free	Linear	L	Nle= Nor-leucine at position 11, Aib = 2-Aminoisobutyric acid at position 12	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	29	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 21.6 ± 4.5 for compound 31
6116	27558296	2016	QRPRLSHKKP-Nle-Aib-F	Compound 31	13	Palmitic acid conjugation	Free	Linear	L	Gly9 was exchanged with Lys, TAMRA = 5,6-carboxytetramethylrhodamine at Lys9 modification at Lysine , Nle= Nor-leucine at position 11, Aib = 2-Aminoisobutyric acid at position 12	compound 31 analogues	Inotropic Agent	37 C	0.00001 M	~4	Porcine liver homogenate protease	HPLC using a fluorescence detector	Porcine liver homogenate	In Vitro	None	None	EC50(nM) = 21.6 ± 4.5 for compound 31
6117	27558296	2016	QRPRLSHKKP-Nle-Aib-F	Compound 31	13	Palmitic acid conjugation	Free	Linear	L	Gly9 was exchanged with Lys, TAMRA = 5,6-carboxytetramethylrhodamine at Lys9 modification at Lysine , Nle= Nor-leucine at position 11, Aib = 2-Aminoisobutyric acid at position 12	compound 31 analogues	Inotropic Agent	37 C	0.00001 M	0.36	Wistar rats plasma protease	HPLC	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 21.6 ± 4.5 for compound 31
6121	27337048	2016	CKASAPPSCYDGDD	SFTI-a	14	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	Sunflower trypsin inhibitor derivative	Immunomodulatory inhibitors of the CD2:CD58 protein–protein interaction	37 °C at various time points from 0 min to 24 h	2 mg/ml	<=24	Human serum protease	HPLC, MS	Human serum	In Vitro	None	None	Cell adhesion inhibition IC50 (µM) = 0.043 ± 0.025 in T cell OVCAR-3
6122	27243004	2016	OWOWORPVYOPRPRPPHPRL	Api793	20	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O = L-ornithine, (WO)2 repititive motifs substituited	Analogs of Api137	Antimicrobial	After 0, 1, 2, 3, and 6 h aliquots (95 μL) were precipitated with aqueous TCA (25 μL, 15% w/v)	70 mg/L	246	Mouse serum protease	N.A.	Mouse serum	In Vitro	None	None	IC50(g/L) = 0.64 ± 0.05 in HEK293
6124	27243004	2016	OIOIORPVYOPRPRPPHPRL	Api795	20	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O = L-ornithine, (IO)2 repititive motifs substituited	Analogs of Api137	Antimicrobial	After 0, 1, 2, 3, and 6 h aliquots (95 μL) were precipitated with aqueous TCA (25 μL, 15% w/v)	70 mg/L	354	Mouse serum protease	N.A.	Mouse serum	In Vitro	None	None	IC50(g/l) > 0.6 in HEK293
6140	27157666	2016	KSLSRHDHIHHH	cMBP2-PEG-Stp/NIS Polyplex	12	Free	PEG-Stp = succinoyl-tetraethylene pentamine/NIS gene	Linear	L	123I labeling	Synthetic	Antitumor	48 hours after polyplex administration, mice received an intraperitoneal injection of 18.5 MBq 123I	18.5 MBq 123I	3	Huh7 subcutaneous mice xenografts protease	Gamma counter	Huh7 subcutaneous mice xenografts	In Vivo	https://sci-hub.st/10.1016/j.nucmedbio.2009.01.005	None	N.A.
6144	27058430	2016	KIKIPWGKVKDFLVGGMKAV	Bicarinalin	20	Free	Amidation	Linear	L	None	Ant venom peptide	Antimicrobial	37 ◦C until 48 h	N.A.	15	Human serum protease	LC-MS	Human serum	In Vitro	None	None	Bicarinalin displayed no cytotoxicity against human lymphocytes in concentrations ranging from 0.066 to 8.5 mol L−1 and its LC50 value was 67.8 mol L−1
6145	27058430	2016	KIKIPWGKVKDFLVGGMKAV	Bicarinalin	20	Free	Amidation	Linear	L	None	Ant venom peptide	Antimicrobial	37 ◦C until 48 h	N.A.	15	Human serum protease	LC-MS	Human serum	In Vitro	None	None	MIC [micromole/L] = 24.4, 5.8, 12.2, 8.7, 5.4 for E.coli, C.sakazakii, P.aeruginosa CIP 82118, P.aeruginosa [R]ATCC 15442, S.enterica respectively.
6146	27058430	2016	KIKIPWGKVKDFLVGGMKAV	Bicarinalin	20	Free	Amidation	Linear	L	None	Ant venom peptide	Antimicrobial	37 ◦C until 48 h	N.A.	15	Human serum protease	LC-MS	Human serum	In Vitro	None	None	MIC [micromole/L] = 12.2, 3, 8.7, 0.45, 24.4 for E.hirae, S.aureus, MRSA, S.xylosus, B.subtilis respectively
6147	27058430	2016	KIKIPWGKVKDFLVGGMKAV	Bicarinalin	20	Free	Amidation	Linear	L	None	Ant venom peptide	Antimicrobial	37 ◦C until 48 h	N.A.	15	Human serum protease	LC-MS	Human serum	In Vitro	None	None	MIC [micromole/L] = 0.75, 17.3, 17.3, 97.5, 6.1 for A.niger, C.albicans, C.albicans[R], G.candidum, S.cerevisiae and MIC[micromole/L] = 1.5 for L.infantum
6166	26808199	2016	LRHWLNLLTRQRW	PYY24–36	13	Free	Amidation	Linear	L	None	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	<0.5	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6167	26808199	2016	LRHYLNLLTRQRY	PYY24–36-Leu31 conjugates 8	13	R8( structure given in paper) at NH terminal	Amidation	Linear	L	Leu31 substituitions	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	24	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6168	26808199	2016	LRHYLNLLTRQRY	PYY24–36-Leu31 conjugates 2	13	R2( structure given in paper) at NH terminal	Amidation	Linear	L	Leu31 substituitions	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	>20	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6169	26808199	2016	LRHYLNLLTRQRY	PYY24–36-Leu31 conjugates 5	13	R5( structure given in paper) at NH terminal	Amidation	Linear	L	Leu31 substituitions	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	>12	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6170	26808199	2016	LRHYLNLLTRQRY	PYY24–36-Leu31 conjugates 7	13	R7( structure given in paper) at NH terminal	Amidation	Linear	L	Leu31 substituitions	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	>12	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6171	26808199	2016	LRHYLNLLTRQRY	PYY24–36-Leu31 conjugates 9	13	R9( structure given in paper) at NH terminal	Amidation	Linear	L	Leu31 substituitions	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	>12	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6227	26565554	2016	SarLys-RPPGFSPf	NG29-TFacetate	10	SarLys = N-methyl glycine and Lysine	TFacetate = Trifluoroacetate addition at C terminal	Linear	Mix	D-Phenyalanine substituitions for L-Phenylanine and Arg9 removal from C terminal	BK analogue	Role in Neurological and Ischemic Cardiovascular diseases and brain cancer	N.A.	75 mg/kg	2.28 (Elimination Half Life)	Wistar Han rats plasma protease	LC-MS/MS	Wistar Han rats plasma	In Vivo	https://sci-hub.st/10.1139/y02-053	None	IC50(nM) = 0.3 for SarLys[dPhe8]desArg9BK ( for hB1R )
6228	26565554	2016	SarLys-RPPGFSPf	NG29-acetate	10	SarLys = N-methyl glycine and Lysine	Acetate addition at C terminal	Linear	Mix	(f) D-Phenyalanine substituitions for L-Phenylanine (F) and Arg9 removal from C terminal	BK analogue	Role in Neurological and Ischemic Cardiovascular diseases and brain cancer	N.A.	75 mg/kg	2.38 (Elimination Half Life)	Wistar Han rats plasma protease	LC-MS/MS	Wistar Han rats plasma	In Vivo	None	None	IC50(nM) = 0.3 for SarLys[dPhe8]desArg9BK ( for hB1R )
6231	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 3 min, 5 min, 10 min, 15 min, 30 min, 1 h, 4 h, 1 d, 2 d, 7 d, 28 d	3.3 mg/kg	59 (Terminal Half Life)	Mouse plasma protease	TLC	Mouse plasma	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6232	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 10 min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 1 d, 2 d, 7 d, 28 d	10 mg/kg	62 (Terminal Half Life)	Mouse plasma protease	TLC	Mouse plasma	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6233	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 10 min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 1 d, 2 d, 7 d, 28 d	10 mg/kg	60 (Terminal Half Life)	Mouse plasma protease	TLC	Mouse plasma	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6234	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 18 h, 1 d, 2 d, 3 d, 7 d, 28 d	10 mg/kg	58 (Terminal Half Life)	Mouse plasma protease	TLC	Mouse plasma	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6235	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 3 min, 5 min, 10 min, 15 min, 30 min, 1 h, 4 h, 1 d, 2 d, 7 d, 28 d	3.3 mg/kg	60 (Terminal Half Life)	Mouse brain homogenate protease	TLC	Mouse brain homogenate	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6236	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 10 min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 1 d, 2 d, 7 d, 28 d	10 mg/kg	61 (Terminal Half Life)	Mouse brain homogenate protease	TLC	Mouse brain homogenate	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6237	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 10 min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 1 d, 2 d, 7 d, 28 d	10 mg/kg	94 (Terminal Half Life)	Mouse brain homogenate protease	TLC	Mouse brain homogenate	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6238	26381279	2016	ptlhthnrrrrr	3H-RD2	12	3H labelled	Amidation	Linear	D	All D-amino acid substituitions	D3 derivative	Therapeutically active against toxic Β-Amyloid oligomers	Time points: 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 18 h, 1 d, 2 d, 3 d, 7 d, 28 d	10 mg/kg	73 (Terminal Half Life)	Mouse brain homogenate protease	TLC	Mouse brain homogenate	In Vivo	DB id: DB09045	None	Fraction unbound to AGP (fu) at a RD2 concentration of 0.23 μM: 12.3%
6239	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	20 mg	5.9	Human serum protease	HPLC–MS/MS	Human serum (Japanese)	In Vivo	Pubchem id: 86278343	None	N.A.
6240	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	80 mg	13.7	Human serum protease	HPLC–MS/MS	Human serum (Japanese)	In Vivo	Pubchem id: 86278343	None	N.A.
6241	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	240 mg	23.5	Human serum protease	HPLC–MS/MS	Human serum (Japanese)	In Vivo	Pubchem id: 86278343	None	N.A.
6242	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	20 mg	6.9	Human serum protease	HPLC–MS/MS	Human serum ( Caucasians)	In Vivo	Pubchem id: 86278343	None	N.A.
6243	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	80 mg	14.4	Human serum protease	HPLC–MS/MS	Human serum ( Caucasians)	In Vivo	Pubchem id: 86278343	None	N.A.
6244	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	240 mg	26.1	Human serum protease	HPLC–MS/MS	Human serum ( Caucasians)	In Vivo	Pubchem id: 86278343	None	N.A.
6269	136-103-666-814-603	2016	MGWSLILLFLVAVATRVLS	bi-specific fusion protein	19	Free	Free	Linear	L	None	NA	non-immunogenic protein	NA	NA	between 2 hours and 24 hours, greater than 24 hours, or greater than one week	NA	ELISA		in vivo	https://www.lens.org/lens/patent/136-103-666-814-603	US 9238080 B2	N.A.